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Introduction
Background
Prostate cancer is predominantly a disease of the elderly. A diagnosis of prostate cancer is
hardly made during the first four decades of life. After age 50, however, a steep increase of
prostate cancer incidence with age is apparent (1). In the Netherlands, age-specific
incidence rates per 100,000 person years in 1995 were 26.8 at ages 50-54, 185.8 at ages
60-64, 628.8 at ages 70-74, and 1028.0 at ages 80-84 (2). Standardized to the world
population, the age-adjusted incidence rate for prostate cancer per 100,000 is 39.6 in the
Netherlands (3) and prostate cancer is the second most common cancer among men (2). In
general, the incidence rates in Europe vary between 20 up to 50 per 100,000 (3). In the
United States, prostate cancer is already the most frequently diagnosed type of cancer
among men (4, 5). Age-standardized to the world population, the incidence rates in the
United States per 100,000 vary between 60 and 110 for whites and between 80 up to 140
for blacks (3). Worldwide, the lowest incidence rates of prostate cancer have been reported
from Asian countries. For example, the age-standardized incidence rates from China vary
between 0.5 and 2.3 per 100,000 and in Japan the rates vary between 6.7 and 10.9 (3).
The large geographical variation in incidence rates of prostate cancer is a remarkable
characteristic of the disease. In its latent form, prostate cancer prevalence does not appear
to show much international variation, as has been observed from autopsy studies (6-8).
Despite the high incidence rates of prostate cancer in Western countries, the etiology is still
largely unknown. The only established risk factors are age and race (9) and also some
familial clustering of prostate cancer is likely (9, 10). Furthermore, environmental factors are
thought to be important in prostate cancer etiology. The marked international variation in
incidence rates and the observation of equivalent prevalence of latent prostate tumors in
low- and high-risk populations support a role for environmental factors (5, 7, 11). Also,
among migrants from low-risk to high-risk populations increases in incidence are observed
(4, 5, 7). The observations of marked differences in clinical prostate cancer rates worldwide
but similar prevalence of latent cancer might implicate that the initiation rate of prostate
cancer is similar in low- and high-risk populations, but that the rate of promotion or
progression to clinically evident prostate cancer differs between these areas (8, 11). One
potentially important environmental factor involved in prostate cancer occurrence is diet.
Nevertheless, no dietary risk factor for prostate cancer has been clearly identified thus far.
Aims of the study
In this thesis, associations between several dietary factors, consumption of alcoholic
beverages, anthropometry, family history of prostate cancer and sodoeconomic status and
the incidence of prostate cancer are tested. Broadly stated, the hypotheses underlying
these investigations are as follows: 1) environmental factors, specifically dietary factors, are
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associated with prostate cancer risk, and 2) these factors are more strongly related to
nonlatent or advanced prostate tumors than to latent tumors. The analyses regarding the
associations between the abovementioned potential risk factors and prostate cancer
incidence were carried out within the context of the Netherlands Cohort Study on diet and
cancer.
Several nondietary potential risk factors for prostate cancer are not addressed in this
thesis. For an overview of the association between vasectomy (12-15), occupation (16-19),
physical activity (20, 21), and smoking (22-24) the reader is referred to other reviews.
Results on endogenous hormones as risk factors for prostate cancer have also been
reviewed before (11, 25-27).
The Netherlands Cohort Study
In 1986 a large-scale prospective cohort study, the Netherlands Cohort Study on diet and
cancer (28), was initiated among 58,279 men (and 62,573 women) aged 55-69 years. The
subjects originated from 204 municipal registries throughout the country. All subjects
completed a self-administered questionnaire on diet and other potential risk factors for
cancer. Incident prostate cancer cases were detected through record linkage with all
regional cancer registries in the Netherlands and with a national pathology register. For the
analyses presented in this thesis, all incident prostate cancer cases detected during a
follow-up period of 6.3 years (September 1986- December 1992) were included (n=704).
The case-cohort approach (29, 30) was used to analyse the relationships between the
potential risk factors and prostate cancer risk.
Outline of the thesis
Results from a literature study on prospective studies investigating dietary and
anthropometric risk factors for prostate cancer are described first (chapter 1). Thereafter,
our findings regarding possible associations between incidence of prostate cancer and
intake of vegetables and fruit (chapter 2), retinol, vitamins C, E and carotenoids (chapter 3),
animal products, calcium and protein (chapter 4), energy, fat and fatty acids (chapter 5),
alcohol (chapter 6), anthropometry (chapter 7), family history of prostate cancer (chapter 8),
and socioeconomic status (chapter 9) are presented. Finally, the findings described in this
thesis are discussed, as well as implications for future research regarding risk factors for
prostate cancer.
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Chapter 1
Prospective epidemiological studies on
dietary risk factors for prostate cancer:
a review
Agnes G. SchuurmarV
Piet A. van den Brandt'
R. Alexandra Goldbohm^
Abstract
Prostate cancer is one of the most frequent cancer sites in Western societies. Dietary
factors are among the potential risk factors for this disease. In this overview prospective
epidemiological studies published between 1966 and July 1998 on potential dietary risk
factors for prostate cancer are reviewed. Factors included in this review are vegetables,
fruit, meat, fish, milk, dairy products, eggs, coffee, tea, vitamins, fat, fatty acids, selenium
and alcohol. In addition, results on anthropometric measures are also included. Almost
without exception, results on potential risk factors are inconclusive. Drawbacks of the
reviewed studies include limited exposure data, a small number of prostate cancer cases,
and no or limited control for potential confounding factors. Furthermore, only a few studies
investigated potential risk factors separately for latent and nonlatent or advanced prostate
tumors. Whether there are different etiologic factors for latent and nonlatent prostate
tumors remains therefore unknown. Future studies on dietary risk factors for prostate
cancer need a comprehensive dietary assessment, information on several other potential
confounding factors, and a large number of cases, offering the ability to also evaluate
tumor subgroups.
' Dept. of Epidemiology, Maastricht University, Maastricht
* Dept. of Consumer Research & Epidemiology, TNO Nutrition and Research Institute, Zeist
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Introduction
Prostatic cancer is presently one of the most frequently occurring forms of cancer in
Western countries. In Europe, as well as in the United States (US) and Canada, the age-
adjusted incidence is increasing (1). Annual age-adjusted clinical prostate cancer incidence
rates of approximately 1 per 100,000 are found in China while in the US for blacks rates up
to 102 per 100,000 are found. Rates for whites in the US vary from about 45 up to 65 per
100,000. In Western Europe most incidence rates are around 20-30 per 100,000 although
also some variation exists (2). Mortality rates have not changed markedly during this
century (1). In contrast to clinical prostate cancer incidence which shows a noteworthy
geographical variation, latent prostate carcinomas seem to be equally distributed across
areas with high and low total prostate cancer incidence rates (3-5).
Age and race are established risk factors for prostate cancer (6). Whether prostate cancer
is familial has not been dissolved completely, but several studies noted familial aggregation
of prostate cancer and therefore Carter et al. (7, 8) conclude that there is evidence for
familial risk factors for prostate cancer. Besides age, race and familial risk factors,
environmental factors are thought to play a role in prostate cancer etiology because of the
substantial variation in incidence rates worldwide. Environmental and genetic factors could
also explain some of the differences in incidence rates between blacks and whites, but also
hormonal factors might play a role (9, 10).
Dietary factors are among the environmental factors which may be important in prostate
cancer etiology. Since 1980 a large number of reviews on prostate cancer have been
published in which also dietary factors were described (4, 5, 9, 11-20). However, in the
majority of these reviews potential dietary risk factors were only briefly addressed, not all
published studies on a specific risk factor were included, or a small selection of potential
dietary risk factors was evaluated (4, 5, 9, 11, 13, 16-18, 20). Therefore, from these
reviews no strong conclusions with respect to any of the investigated dietary risk factors
could be drawn. There were only four reviews in which dietary factors were more
extensively addressed (12, 14, 15, 19). One of these reviews was published some 10 years
ago and, therefore, cannot be regarded as reviewing the state of the knowledge on dietary
risk factors for prostate cancer (19). The other three reviews did not specifically address
methodological aspects of the different studies included in the review and also only broad
categories of different dietary foods were evaluated. Therefore, our review will both discuss
methodological qualities of the different studies and results on several individual foods or
nutrients. Because of the availability of a large number of prospective epidemiological
studies and because prospective studies are less prone to bias compared with case-control
studies, only these type of studies are included.
TaWe f. Descr/pf/Ve c/iaracter/sffcs ofpuW/s/ied prospecffve /nfervenffon sfud/es on dfetery nsfr factors for prosfate cancer, ordered accord/ng to year of
base//ne measuremenr.
Country (ref)
Year of
publication
USA (21)
1996
USA (22)
1998
Finland (23)
1998
USA (24)
1996
Baseline
1982
1983
1985-1988
1988
Cohort size
(age range)'
22,071
(40-84)
974
(63)'
29,133
(50-69)
18,314
(58)'
Years of
follow-up
12
6.5
5-8
4
Number of
cases
(I or D)'
1047 (I&D)
48 (I)
246(1)
300(1)
Design
two-by-two
factorial design
block
randomization by
time & clinic
two-by-two
factorial design
partly two-by-two
factorial design;
partly 1:1
Intervention
ß-carotene: 50 mg
on alternate days
selenium 0.2 g daily
ct-tocopherol: 50 mg daily
ß-carotene: 20 mg daily
ß-carotene 30 mg in
combination with 25 000
IU vitamin A daily
Placebo
yes
yes
yes
yes
Notes
physicians
patients with
previous skin
cancer
smokers
subjects at
high risk for
lung cancer
' Age range of the study population; * I are incident cases, D are deceased cases;' Mean age.
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Methods
The literature for this review was sought with MEDLINE, the computerized database from
the Index Medicus. The keywords used were EPIDEMIOLOGY, ETIOLOGY, DIET, RISK
FACTOR, COHORT, and STUDY, all in combination with PROSTATIC NEOPLASMS.
Furthermore, references in the selected publications were checked to find other relevant
publications not included in the MEDLINE search. Studies included in this review are
prospective analytical epidemiological studies published between 1966, the earliest year
covered by MEDLINE, and July 1998. Only those studies in which dietary intake was
measured by blood samples or questionnaires or interviews, are included. Dietary factors
that are described include vegetables, fruit, meat, fish, milk and dairy products, eggs,
coffee, tea, vitamins, fat, fatty acids, selenium and alcohol. In addition, prospective studies
on anthropometric measures are also reviewed. All individual dietary items with their
original names as mentioned in the reports or measures of anthropometry that were
investigated in the studies are listed in the tables. Items were considered to be associated
with a decrease or increase in prostate cancer risk when the relative risk estimate for the
highest vs lowest exposure category was below 0.8 (decrease) or above 1.2 (increase).
Furthermore, all statistically significant findings are indicated in the tables by means of an
asterix (*). All RRs in the tables refer to the highest vs lowest exposure category as
mentioned in the cited study, unless otherwise indicated. After reviewing and discussing the
results, implications for future research on dietary risk factors in relation to prostate cancer
risk will be discussed.
Results
A total of four intervention studies (21-24) were identified and their descriptive
characteristics are displayed in table 1. All trials were randomized and placebo-controlled;
one trial was conducted in Finland (23) and the other three in the USA (21, 22, 24).
A total of 34 cohort studies were found; 15 of these cohort studies (25-47) made use of
blood samples to measure certain dietary factors (table 2) and 19 studies used
questionnaires or interviews (48-69) to measure dietary risk factors (table 3). In general, the
baseline measurement in most of the cohort studies was before 1980. The range in cohort
size is very large, varying from 974 (22) to 450,279 men (65). There are several studies
with a total number of prostate cancer cases less than 60 (22, 25, 32-35, 37, 38, 40, 42,
58). The largest number of cases to date is a total of 1,748 (65). Endpoints used in
different studies were both incidence and mortality. The majority of studies that used a
questionnaire to measure dietary factors, did not mention whether the questionnaire was
validated or not. Only in the Health Professionals Follow-Up Study (66-69), in the cohort-
based part of the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study (ATBC Study)
(47) and in a Norwegian study (61) it is mentioned that the utilized questionnaire was
fabte 2: Descr/pfrVe characterisfcs or"pub//sned prospecftVe cohort s/ud/es on prostete cancer and d/efary and an(hropomeWc risk factors measured by bfcxxf
samp/es on// or /n comb/'natfon wW) guesfonna/res/fnteAv/eivs, ordered accord/ng to year of base/Zne measurement
Country (ref)
Year of
publication
USA (25)
1981
USA (26, 27)
1993-1995
USA (28-31)
1988-1997
USA (32)
1984
Finland (33,34)
1988-1990
Switzerland (35)
1996
USA (36)
1990
USA (37)
1988
USA (38)
1991
Baseline
measurement
1960-1962
1964-1971
1965-1968
1967-1969
1968-1972
1971-1973
1971-1975
1972-1976
1972-1976
Cohort size
(age range)'
3,102
(>40)
250,000'
(38-81)
7,999
(>65)
?
(?)
36,265'
(15-99)
2,974
(20-79)
2,440
(>50)
6,167
(?)
8,825
(>30)
Years of
follow-up
12-14
1-23
21-23
10-12
6-10
17
10
0-10
8.5
Number of
cases
(I or D)'
8(I&D)
181 (I)
174-306" (I)
14 (I&D)
32 (I)
30 (D)
84 (I&D)
13(1)
6(D)
Exposure
measurement
blood sample
blood sample
blood sample;
FFQ* (interview);
24-h recall
blood sample
blood sample;
questionnaire
blood sample;
questionnaire
blood sample;
questionnaire;
examination
blood sample
blood sample;
interview
Investigated exposure
variables
vitamins
vitamins
vegetables, fruits, meat,
fish, milk, eggs,
coffee, alcohol,
vitamins, anthropometry
vitamins
vitamins
vitamins
vitamins
vitamins, selenium
vitamins, selenium
Number of Validation
items on diet dietary
(alcohol) questionnaire
-
-
FFQ*: 23 unknown
-
NDQ'
NDQ?*
NDQ
(unknown)
-
NDQ*
fab/e 2 confriued
Country (ref)
Year of
publication
Sweden (39)
1994
USA (40)
1984
Norway (41)
1997
USA (42,43)
1990-1996
USA (44-46)
1994-1997
Finland (47)
1998
Baseline
measurement
1972-1978
1973-1974
1973-1994
1974
1982
1985-1993
Cohort size
(age range)'
53,242
(20-55)
4,480
(30-69)
?
(50)
25,802
(?)
22,071
(40-84)
29,133
(50-69)
Years of
follow-up
16.3
5
0.4-19.2
12?
6-12
7
Number of
cases
(I or D)'
220 (I)
11(1)
141 (I)
43-103(1)
120-1,047*(l)
317(1)
Exposure
measurement
blood sample;
questionnaire;
examination
blood sample
blood sample
blood sample
blood sample;
questionnaire
blood sample;
FFQ*
Investigated exposure
variables
fatty acids, anthropometry
vitamins
fat, fatty acids
vitamins, fatty acids
meat, dairy, vitamins,
fatty acids, anthropometry
vitamins, selenium
Number of
items on diet
(alcohol)
NDQ*
-
-
-
(unknown)
(unknown)
203
Validation
dietary
questionnaire
-
-
-
-
unknown
yes 1
' Age range of the study population;' I are incident cases, D are deceased cases; * Only a total of men and women is given; * Number of cases depending on
exposure under study; * FFCNood frequency questionnaire, NDQ=no dietary questionnaire.
7ab/e 3: Descr/pftVe c/jaractensft'cs of puMsned prospecfrVe cohort s/ud/es on d/etery ris/c factors measured by quesfonna/res or /nferv/eivs and on anf/iropomeWc
nsA factors for prostete cancer, ordered accord/ng to year of base//ne measurement.
Country (ref)
Year of
publication
USA (48)
1974
USA (49)
1985
Denmark (50)
1994
USA (51)
1996
USA (52)
1986
USA (53)
1984
Japan (54)
1990
USA (55)
1990
Sweden (56)
1996
Baseline
measurement
1880-1916
1916-1950
1954-1987
1957-1958
1959
1960
1965
1966
1967-1970
Cohort size
(age range)'
18,000
(college
attendents)
51,477
(college
attendents)
15,214
(?)
1,899
(40-55)
336,442
(?)
6,763
(>60)
122,261
(>40)
17,633
(>35)
9,152
(42-81)
Years of
follow-up
?
16-50
12.9
30
12
21
17
20
22
Number of
cases
(I or D)'
268 (D)
243 (I&D)
91(1)
132 (I&D)
?(D)
99 (D)
183 (D)
149 (D)
406 (?)
Exposure
measurement
measurement
questionnaire;
examination
interview
interview;
questionnaire;
dietary history
questionnaire
questionnaire
interview
mailed
questionnaire
questionnaire
Investigated exposure
variables
anthropometry
alcohol,
anthropometry
alcohol
vitamins
anthropometry
vegetables, fruits, meat,
milk, eggs, anthropometry
vegetables, meat, milk,
eggs, alcohol
vegetables, fruits, meat,
milk, fish, eggs, coffee,
alcohol
vegetables, fruits, meat,
fish, milk, eggs, coffee,
alcohol
Number of items
on diet
(alcohol)
-
(unknown)
195
-
14?
7
(2)
35
(2?)
10
(4)
Validation
dietary
questionnaire
-
unknown
unknown
-
unknown
unknown
unknown
unknown
faMe 3 conffm/ed
Country (ref)
Year of
publication
Sweden (57)
1997
USA (58)
1989
USA (59)
1994
USA (60)
1989
Norway (61)
1997
USA (62)
1994
USA (63)
1992
USA (64)
1997
USA (65)
1997
USA (66-69)
1993-1998
Baseline
measurement
1971-1975
1972-1974
1975-1980
1976
1977-1983
1978-1985
1981-1985
1982
1982
1986
Cohort size
(age range)'
135,006
(<30->60)
1,776
(50-84)
20,316
(>45)
14,000
(>25)
25,708
(16-56)
43,432
(>30)
11,577
(>60)
1,050
(>65)
450,279
(>30)
51,529
(40-75)
Years of
follow-up
20
14
14
6
12.4
4.6
8
11
9
6-8
Number of
cases
(I or D)'
2,368 (I&D)
54 (I)
198(1)
180(1)
72(1)
238(1)
208 (1)
71(1)
1,748 (D)
300-1369*
(I&D)
Exposure
measurement
questionnaire;
measurement
interview;
examination
interview;
questionnaire
questionnaire
FFQ*
questionnaire
questionnaire
interview
questionnaire
FFQ*
Investigated exposure
variables
anthropometry
milk, eggs,
anthropometry
vegetables, fruits, meat,
fish, milk, eggs, coffee,
alcohol, anthropometry
vegetables, fruits, alcohol,
meats, milk, fish, eggs
meat, fish, milk, eggs,
fat, anthropometry
alcohol
vegetables, fruits,
vitamins
alcohol, anthropometry
vegetables
vegetables, fruits, meat,
milk, eggs, fat, fatty acids,
vitamins, anthropometry
Number of items
on diet
(alcohol)
-
2
13
unknown
80
(unknown)*
59
(unknown)
unknown
131
Validation
dietary
questionnaire
-
unknown
no
unknown
yes
unknown'
unknown
unknown
unknown
yes
' Age range of the study population;' I are incident cases, D are deceased cases;' FFQ=food frequency questionnaire;' Data compared closely to data from
7-day recall; * Questions on current and past consumption, number of drinks consumed per day, and the type of alcoholic beverage; * Number of cases
depending on exposure under study.
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validated. These studies also had the most extensive questionnaires on diet. Other studies
used questionnaires more limited in size.
In tables 4-7 results from intervention studies and cohort studies on dietary risk factors for
prostate cancer are displayed. Table 4 shows results from the four trials on ß-carotene,
retinol, vitamin E and selenium. In the ATBC Study (23) and the Physicians' Health Study
(21) no effect of supplementation with /^-carotene was observed and in the Beta-Carotene
and Retinol Efficacy Trial (CARET) no effect of supplementation with ß-carotene and retinol
was found (24). Significant decreased risks were found for supplementation with wfam/n £
in the ATBC Study (23) and for se/en/um in the Nutritional Prevention of Cancer Trial (22).
7ab/e 4: Resu/fs on nufrrenfc /n re/afon to ris/c of pros/ate cancer from prospective /nterventfon sfucfes.
Exposure
Vitamins
Selenium
Effect estimate <0.8
Item
vitamin E (suppl.)
selenium (suppl.)
Effect estimate
0.64* (23)
0.37* (22)
(ref)'
Effect estimate 0.8-1
Item
ß-carotene (suppl.)
ß-carotene + retinol
(suppl.)
.2
Effect estimate
1.20(23), NS'
1.01 (24)
(ref)'
(21)
' Effect estimates for highest versus lowest exposure category, asterix (*) denotes statistically significant finding;
' NS=not significant
Results on vitamins and selenium from cohort studies using blood samples (table 5) or
questionnaires (table 6) were mostly inconsistent. From the studies shown in table 5, some
found decreased risks for serum levels of wfam/n / I (36) or refrno/ (38, 43), some found no
association for levels of retinol (32) or carotenes (35, 43) and some found increased risks
for serum retinol levels (33, 35, 37, 40) or carotene levels (33, 40). In questionnaire-based
studies mostly null associations were found for vitamin A (55, 65), retinol (55) or carotenes
(51, 55, 63, 68). In one study a significant increase in risk was observed for intake of retinol
(68). In two cohort studies investigating serum levels of v/ram/n £ decreased associations
were indicated (34, 40) and in two other studies no associations were observed (43, 47).
Vitamin E intake based on questionnaire measurement also showed no association with
prostate cancer risk in two studies (63, 68). Serum levels of se/en/um were associated with
a decreased prostate cancer risk in two cohort studies (37, 38) and in one cohort study no
association was observed (47).
Other carotenoids or vitamins investigated in cohort studies include lycopene, and vitamins
C and D. Lycopene showed an inverse association with prostate cancer risk in both a
serum-based (43) and a questionnaire-based (68) study. For wtem/n C serum levels no
Tabfe 5: Resu/fe on nufrienfe /n re/afion to risfc of prosfate cancer from prospecffve conorf sfud/es us/ng Wood samptes for exposure measurement
Exposure Effect estimate <0.8
Item
Vitamins vitamin A
retinol
lycopene
vitamin D(1,25-D)
vitamin E
Selenium selenium
Fat n-6 pufa
stearic acid
linoleic acid
arachidic acid
docosanoic acid
docosapentaenoic
acid
tetracosanoic acid
tetracosenoic acid
Effect estimate (ref)'
0.4* (36)
0.40 (43), CL' (38)
0.50 (43)
CL*' (27)
0.60 (34), CL* (40)
CL' (38), 0.3 (37)
0.7(41)
0.35 (46)
0.62 (46)
0.7(41)
0.7(41)
0.7(41)
0.5*(41)
0.7 (41)
Effect estimate 0.8-1.2
Item
retinol
carotenes
ß-carotene
vitamin C
vitamin D (25-D)
vitamin D(1,25-D)
vitamin E
vitamin E (suppl.)
selenium
total fat
total fatty acids
saturated fat
unsaturated fat
polyunsaturated fat
n-6 fatty acids
n-3 fatty acids
n-3 pufa
linoleic acid
palmitic acid
eicosapentaenoic add
eicosenoic acid
eicosadienoic acid
dihomo-Y-linoleic acid
arachidonic acid
eicosapentaenoic acid
docosahexaenoic acid
Effect estimate (ref)'
NS* (32)
0.92 (35)
1.08(43)
0.93 (35)
0.92 (45), CS' (27)
0.88 (45)
NS' (47), 1.00(43)
NS' (47)
NS' (47)
0.87 (30)
1.1(41), 1.05'(39)
1.00(30)
1.09(30)
1.1(41)
NA* (42)
NA' (42)
1.1 (41)
0.9(41)
0.90 (46)
0.87 (46)
1.2(41)
1.0(41)
1.1 (41)
0.8(41)
1.2(41)
1.0(41)
Effect estimate >1.2
Item
retinol
carotenoids
ß-carotene
saturated fat
monounsaturated fat
a-linolenic acid
oleic acid
arachidonic acid
myristic acid
palmitic acid
palmitoleic acid
stearic acid
Effect estimate (ref)'
1.48(35), 1.4(33),
3.0 (37), CH* (40)
CH' (40)
5.0* (33)
1.6(41)
1.3(41)
2.0* (41), 2.14 (46)
1.8* (41), 1.50(46)
1.36(46)
1.8*(41)
2.3*(41)
2.8* (41)
1.3(41)
o
' Effect estimates for highest versus lowest exposure category, asterix (*) denotes statistically significant finding; * CL=cases lower level than controls, NS=not
significantly associated, CS=cases similar level than controls, CH=cases higher level than controls, NA=not associated;' Triglycerides per mmol/liter.
TaWe 6: f?esi//fs on nufrren/s /n re/affon fo r/s/c of prostete cancer from prospecfiVe cohort sftvd/es us/ng quesfionna/res or tnterWews for exposure
measuremenf.
Exposure Effect estimate <0.8
Item Effect estimate (ref)'
Vitamins lycopene 0.79* (68)
Fat saturated fat 0.7(61)
Effect estimate 0.8-
Item
vitamin A
vitamin A (suppl.)
retinol
a-carotene
ß-carotene
ß-cryptoxanthin
lutein
vitamin C
vitamin C (suppl.)
vitamin E
vitamin E (suppl.)
saturated fat
linoleic acid
1.2
Effect estimate (ref)'
1.13(68), 1.1(55)
1.13(63)
1.2(55)
1.09(68)
1.05(68), 1.04(51),
1.09 (63), 0.9 (55)
0.94 (68)
1.10(68)
1.09 (68), 0.96 (63)
1.00(63)
0.94 (68)
1.00(63)
0.84 (69)
0.88 (69)
Effect estimate > 1.2
Item
retinol
vitamin C
total fat
monounsaturated fat
polyunsaturated fat
animal fat
a-linolenic acid
Effect estimate (ref)'
1.32* (68)
1.30(51)
1.32(69), 1.3(61)
1.4(61), 1.86(69)
1.4(61)
1.35(60)
1.25(69)
q
5'
sr
3.(A
01
<
I
' Effect estimates for highest versus lowest exposure category, asterix (*) denotes statistically significant finding.
22 Chapter 1
association was observed (35) and in two studies using questionnaires also no
associations were found (63, 68). In one study an increased association was indicated (51).
W/am/n D metabolite levels (1,25-D) measured in blood samples showed either an inverse
association (27) or no association (45). For levels of 25-D no associations were apparent
(27, 45).
Results on fat and fatty acids are also shown in tables 5 and 6. Tofa/ fef or tote/ tetfy adds
were not associated with risk of prostate cancer in serum-based studies (30, 39, 41) but
from questionnaire-based studies positive associations were suggested (61, 69). Safurated
fef showed one null association (30) and one positive association (41) from serum-based
studies and an inverse (61), and a null association (69) from questionnaire-based studies.
For different categorizations of unsaftyrated fef mostly null associatons were observed in
serum-based studies (30, 41, 42), nevertheless, an inverse association was found for n-6
pufa (41) and a positive association was observed for monounsaturated fat (41). In two
questionnaire-based studies increased risks were indicated for intake of monounsaturated
fat (61, 69) and polyunsaturated fat (61). Linoleic acid and a-linolenic acid are two fatty
acids which have most frequently been investigated with respect to risk of prostate cancer.
For //no/e/'c ac/d an inverse (46) and a null association (41) from serum-based studies have
been reported and from questionnaire-based studies a null association was observed (69).
L/no/en/c ac/d showed increased prostate cancer risks from both serum-based (41, 46) and
questionnaire-based studies (69). In two serum-based studies several other fatty acids
were investigated (41, 46) but consistent associations were not observed.
Table 7 summarizes results on foods and alcohol; exposure measurement in all studies is
based on questionnaires or interviews. Consumption of total vegeteb/es showed inverse
associations (55, 65) as well as null associations (63, 68). Furthermore, inverse
associations were observed for consumption of green salads (60), tomatoes (60, 68) and
beans, lentils and peas combined (60) and positive associations were observed for
consumption of cruciferous vegetables (55), fried vegetables (30), cooked and raw spinach
(68). Several other (grouped) vegetables were investigated for which no associations with
prostate cancer risk were indicated. Overall consumption of frurf showed mostly a null
association with risk of prostate cancer (53, 55, 60, 63, 68), but in one study an increased
risk was observed (30). For other items on fruit mostly no associations were observed, only
for consumption of raisins, dates and other dried fruit a decreased prostate cancer risk was
suggested (60).
In two studies overall meaf consumption was not related to prostate cancer risk (30, 55) but
in one study an increased risk was observed (54) and in another study a decreased risk
was observed (61). For consumption of several types of meat either no association or
positive associations were observed. Consumption of fo/i was positively associated with
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prostate cancer risk in two cohort studies (30, 60), inversely in one study (54) and not
associated in four other prospective studies (55, 56, 59, 61).
Consumption of m/Wc or otfier da/>y producfs was either not associated with risk of prostate
cancer or positively associated Positive associations were suggested for consumption of
milk (53, 59), skim milk (61), cheese (53), butter, margarine and cheese combined (30), and
icecream (30). In six cohort studies consumption of eggs was not significantly related to
prostate cancer risk (55, 56, 58, 59, 61, 68). A positive association, nevertheless, was
suggested in two cohort studies (30, 53) and an inverse association in one cohort study
(60).
Coffee consumption was investigated in four cohort studies (30, 55, 56, 59) but only in one
study an association with risk of prostate cancer was observed, which was positive (56). In
one study no association was found for b/ac/c tea and for green tea a borderline significant
increase in risk was noted (30). Exclusion of latent cases in one of the studies did not
change the results.
Nine cohort studies were identified in which a/cofto/ consumpf/on in relation to risk of
prostate cancer was investigated. Overall consumption of alcohol was mostly not
associated with risk of prostate cancer (30, 56, 59, 62, 64) but in one study a decreased
risk was observed (60) and in two cohort studies increased risks were noted (50, 54).
Specific types of alcolic beverages were mostly not associated with risk of prostate cancer
(54, 55, 56) but for consumption of spirits (56) and shochu (54) decreased and increased
associations, respectively, were observed.
Table 8 presents results from prospective cohort studies on anthropometric variables in
relation to risk of prostate cancer. In four studies a significant positive association between
he/gW and prostate cancer risk was observed (44, 57, 59, 67). In five other studies there
was no association (39, 48, 49, 62, 64). l/Ve/gM showed either null associations (48, 59, 62)
or positive associations (29, 52, 53, 57, 64). Body mass /ndex (BMI) has been investigated
most frequently. Although several studies showed no association between BMI and
prostate cancer risk (57, 58, 60, 62, 70), positive associations were found in about an equal
number of studies (31, 39, 56, 61, 64). Some other measures of body fat distribution were
investigated with equivocal findings. Studies on BMI at earlier ages are too few to draw
conclusions yet (49, 64, 70).
Only a few of all prospective studies investigated latent and nonlatent or advanced prostate
tumors separately (27, 30, 41, 46, 59, 64, 67-69, 71). Although for some risk factors, e.g.
vitamin D (27), total fat, monounsaturated fat and a-linolenic acid (69), and BMI (64)
associations were reported to be stronger for advanced or aggressive prostate tumors, for
labte 7: Resu/fe on foods and a/cono/ /n re/affon to risfr of prostete cancer from prospecfcVe epftfemfofogfca/ sfud/es us/ng guesfronna/res or /nterWetvs for
exposure measurement
Exposure Effect estimate <0.8
Item
Vegetables vegetables
green salads
tomatoes
beans/lentils/peas
Fruit fresh winter fruit
raisins/dates/dried
fruit
Meat meat
beef
Effect estimate (ref)'
0.79* (65), 0.7 (55)
0.68 (60)
0.74* (68), 0.60* (60)
0.53* (60)
0.73(60)
0.62 (60)
0.4 (61)
0.58 (56)
Effect estimate a 0.8-:
Item
vegetables
dark green veg.
mixed vegetables
green-yellow veg.
yellow vegetables
raw vegetables
carrots
broccoli
fruits & vegetables
fruit
fresh fruits
fresh citrus fruit
canned/frozen fruit
oranges
strawberries
meat
poultry
beef hamburger
beef steak
ham/bacon/sausage
sausage
frankfurter/sausage
pork
processed meats
;1.2
Effect estimate (ref)'
1.04(68), 1.04(63)
1.19(63)
0.96 (68)
1.03(54)
0.96 (63)
1.1 (59)
1.06(68)
1.05(68)
1.15(56), 1.10(63)
0.84(68), 1.04(63),
0.9(55)1.07(60),
NA' (53)
1.0(59)
0.88 (60)
0.82 (60)
0.94 (68)
0.80 (68)
0.95 (30), 0.8 (55)
1.1 (59), 0.9 (55)
1.07(60)
0.81 (60)
1.11(30)
0.82 (56)
NA'(61)
1.15(56), 1.1(59)
1.2(59)
Effect estimate >1.2
Item
cruciferous veg.
fried vegetables
cooked spinach
raw spinach
fruit
meat
red meat
meat or poultry
poultry
meat/poultry/fish
beef/pork/lamb
beef
hamburger/meatball
fat animal products
liver
Effect estimate (ref)'
1.3(55)
1.40(30)
1.22(68)
1.31 (68)
1.57(30)
1.45(54)
2.5 (46)
1.3(53)
1.34(60)
1.41 (60)
2.51 (46)
1.6* (59), 1.21 (80)
3.1* (61)
1.6(59)
1.28(68)
o
SI
I
labte 7 confenued
dairy
Exposure
Fish
Effect estimate <0.8
Item
fish
Effect estimate (ref)'
0.54 (54)
Effect estimate sO
Item
fish
.8-51.2
Effect estimate (ref)'
0.99 (56), NA* (61),
1.2 (59), 0.8 (55)
Effect estimate >1.2
Item
fish
Effect estimate (ref)'
1.22(30), 1.57(60)
Alcohol alcohol
spirits
0.71 (60)
0.78(56)
milk
whole milk
dairy
NA'(68), 1.00(30),
0.84(56), 1.08(54)
0.80 (60), 0.9* (58)
NA'(46), 1.0(55)
milk
skim vs whole milk
cheese
butter/margarin/
1.4(59), 1.5(53)
2.2* (61)
1.4(53)
Eggs
Coffee,
tea
eggs 0.76 (60) eggs
coffee
black tea
NA'(61, 68), 0.85 (56),
1.1 (59), 0.9 (55),
1.0* (58)
0.92(30), 1.1(59),
1.0(55)
0.83 (30)
cheese
icecream
eggs
coffee
green tea
1.47(30)
1.31(30)
1.57(30), 1.3(53)
1.91 (56)
1.47* (30)
alcohol
lifetime ethanol
beer
wine
liquor
1.0(64), 1.09(30),
0.89(56), 1.0(62)
1.1 (59)
0.84 (56), 0.94 (54),
1.2(55)
1.18(56)
1.0(55)
alcohol
alcohol abusers
shochu
1.38(54)
1.4* (50)
2.34* (54)
' Effect estimates for highest versus lowest exposure category, asterix (*) denotes statistically significant finding;' NA = not associated;' Per cup per day;' Per
egg per week.
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other risk factors like carotenoids (68), fried vegetables and fruit (30), beef and high-fat
animal products (59), and milk and eggs (30) associations in subgroups based on tumor
characterization were reported to be similar.
Discussion
From earlier reviews it is concluded that results from case-control studies on risk factors for
prostate cancer are inconclusive (12, 14). In this review, only prospective studies on risk
factors for prostate cancer have been summarized, and data from these studies also lead
to the conclusion of inconsistent results. At most, we can state that there is some evidence
that certain dietary factors could be protective (e.g. vitamin E, selenium) or are associated
with an increase in prostate cancer risk (e.g. height), but convincing evidence is lacking.
Chance variation might be one of the reasons for the largely inconsistent findings.
Furthermore, we used only published literature in the English language. If certain risk
factors were evaluated in different studies but not published because no association was
observed, this could have influenced our results. However, results that were mentioned in
the results or discussion section of articles without giving effect estimates, were also
included in this review. Furthermore, given the high incidence of prostate cancer and the
largely unknown etiology of the disease, any findings on possible risk factors are likely to
result in publication. The chance of missing published papers seems very small, because
we not only used different keywords, but also checked the references within the reports we
found through Medline.
Methodological drawbacks are also important in explaining the largely inconsistent findings.
A major methodological shortcoming in the majority of the cited studies is the very limited
measurement of dietary exposure. Crude dietary exposure information gathered with
questionnaires or interviews could have resulted in misclassification and, consequently, in
biased results. Furthermore, only in the reports of Hartman et al. (47) and Giovannucci et
al. (68, 69) the validation of the questionnaire has been described. In one other study it is
mentioned that the questionnaire was not validated (59). In all other questionnaire or
interview based studies the validity of the measures that were used to estimate dietary
intake has not been described. Several studies used blood samples to measure nutrients
and these studies were summarized separately. Certainly, random misclassification of
exposure could also have resulted in an underestimation of effect in these studies.
Another consequence of the limited exposure measurement in the majority of studies is
that several possible risk factors have only briefly been investigated. For example, different
types of individual vegetables and fruit have not been investigated thus far. Also, data on
individual types of alcoholic beverages is lacking. Furthermore, if individual dietary foods or
nutrients have been addressed, this has mostly been done by a limited number of studies.
Tafcte Ö: Resute from prospecffve ep/ctem/o/og/ca/ sfud/es on anf/iropomefty /n re/afon to risfc of pros/ate cancer
Exposure Effect estimate <0.8 Effect estimate a0.8-: Effect estimate >1.2
Item Effect estimate (ref)' Item
height
height when sitting
skinfold thickness left
triceps
weight
waist circumference
hip circumference
BMI
Ponderal Index
BMI at age 21
change in BMI during
life
LBM
Effect estimate (ref)'
1.14* (57), 1.1(64),
0.99* (39),
NA' (48,49,62)
0.94(31)
0.94(31)
1.16* (57), 0.9 (59)
NA' (48,62)
0.99 (67)
0.85 (67)
0.90(67)1.13(57)
NA'(62) 1.17 (60)
1.1' (58)
NA' (48)
0.87 (67)
NA* (49)
1.17* (57)
Item
height
leg length
weight
girth left upper arm
skinfold thickness left
scapula
biacromial diameter
BMI
BMI at age 25
BMI at age 50
change in BMI from
age 50 to >65
Effect estimate (ref)'
1.37* (67),
1.27* (44), 1.8* (59)
1.24(31)
1.6(64), 1.52* (29),
1.29 (52), 2.4* (53)
1.49(31)
1.27(31)
1.22(31)
1.5(64), 1.33(31),
2.2* (61), 1.8* (56),
1.25* (39)
1.4(64)
1.3(64)
1.3(64)
Height, BMI 0.7 (59)
weight, change in BMI from
body mass age 25 to >65 0.7 (64)
index
in'
D)
o
3
2
' Effect estimates for highest versus lowest exposure category, asterix (*) denotes statistically significant finding; * Per 10 cm;' NA=not associated;' Per 2.92 kg/nf
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Therefore, consistency in results is hardly evaluable and findings need replication from
other well-designed prospective studies.
Another important drawback which must also be considered in interpreting results from
earlier studies is that there are only a few studies in which a reasonable number of prostate
cancer cases could be investigated. For example, only a few prospective studies included
more than 400 cases (44, 57, 65, 67, 68) and there were various studies in which less than
35 cases were included (25, 32-35, 37, 38, 40). Additionally, in some studies prostate
cancer incidence was used as an endpoint while in other studies prostate cancer mortality
or a combination of both incidence and mortality was the endpoint of study. In general,
incidence is a more appropriate endpoint. If prognosis is related to a certain exposure
factor, selection bias might have been present in studies with mortality as an endpoint.
Bias by confounding is another possibility that may explain the diverse results from
previous studies. As was concluded from Table 1, almost none of the prospective studies
had an extensive dietary assessment. Therefore, controlling for potential confounding by
other than the investigated dietary factor was mostly not possible and also information on
nondietary potential risk factors was often not available.
Finally, the hypothesis that latent and clinically apparent or advanced or aggressive
prostate tumors might have a different etiology has not been investigated in the majority of
earlier prospective epidemiological studies. Therefore, it is too early to draw conclusions.
This issue also deserves attention in future epidemiological studies on prostate cancer
etiology.
In summary, several potential risk factors for prostate cancer have already been
investigated in prospective epidemiological studies but there is hardly any consistency in
results. These inconsistencies can largely be explained by limited exposure data, a small
number of prostate cancer cases, and no or limited control for potential confounding
factors. Future research on dietary risk factors for prostate cancer should be based on an
extensive exposure measurement which also includes information on nondietary risk
factors, making control for confounding from dietary as well as nondietary risk factors
possible. Furthermore, a reasonable number of cases should be available so that also
subgroup analyses can be performed.
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Abstract
The association between 21 vegetables and eight fruits and prostate cancer risk was
assessed in the Netherlands Cohort Study among 58,279 men aged 55-69 years at
baseline in 1986. After 6.3 years of follow-up 610 cases with complete vegetable data and
642 cases with complete fruit data were available for analysis. In multivariate case-cohort
analyses, the following Rate Ratios [RRs] (95% Confidence Interval [95% Cl]) for vegetable
consumption were found (comparing highest vs lowest quintile): total vegetables, 0.80
(0.57-1.12); prepared vegetables, 0.85 (0.61-1.19); raw vegetables, 0.96 (0.69-1.34). For
vegetables categorized in botanical groups no associations were found except for
consumption of pulses (RR=0.71 (0.51-0.98), test for trend p-value 0.01). The RRs for total
fruit and citrus fruit were 1.31 (0.96-1.79) and 1.27 (0.93-1.73), respectively; the
corresponding p-values for the trend tests were 0.02 and 0.01, respectively. In a continuous
model, no association for total fruit was observed. Individual vegetables and fruits were
evaluated as continuous variables (g/day). Nonsignificant inverse associations (RRs per
increment of 25 g/day) were found for consumption of kale (RR=0.74), raw endive
(RR=0.72), mandarins (RR=0.75) and raisins or other dried fruit (RR=0.49). Observed
positive associations were significant for consumption of leek (RR=1.38) and oranges
(RR=1.07) and nonsignificant for sweet peppers (RR=1.60) and mushrooms (RR=1.49).
Results in subgroups of cases were more or less consistent with the overall results. From
our study we cannot conclude that vegetable consumption is important in prostate cancer
etiology, but for certain vegetables or fruits an association can neither be excluded.
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Introduction
Although prostate cancer is one of the types of cancer with a high incidence in Western
countries, the etiology is largely unknown. In a recent review (1) it was concluded that
environmental risk factors, including diet, may play an important role in the etiology of this
disease. Among dietary factors, not only meat consumption and fat intake have been
evaluated frequently but also vegetable and fruit consumption. Vegetable and fruit
consumption may be protective against cancer because of the anticarcinogenic agents in
these foods. Some potentially anticarcinogenic substances are carotenoids, vitamins C and
E, selenium, glucosinolates and indoles, flavonoids, protease inhibitors, and allium
compounds and some possible mechanisms of action are induction of detoxification
enzymes, inhibition of nitrosamine formation, alteration of hormone metabolism, and
antioxidant effects (2, 3). Up to 1998, we identified ten cohort studies (4-13) and 13 case-
control studies (14-26) in which consumption of vegetables or fruit in relation to prostate
cancer risk was evaluated. Many different vegetable groups or individual vegetables have
been investigated, but thus far results are not conclusive. In the majority of these earlier
studies no extensive measurement of vegetable and fruit consumption was made and no or
only limited adjustment for potential confounding factors was employed. Therefore, we
further explored the possible association between vegetable and fruit consumption and
prostate cancer risk in the Netherlands Cohort Study (NLCS) which was specifically
designed to investigate the relationship between diet and cancer. Besides the extensive
assessment of the usual diet, information on other risk factors for cancer is also available,
offering a possibility to control for dietary as well as nondietary factors in multivanate
analyses. Moreover, also subgroup analyses on tumor differentiation grade and tumor size
could be performed to investigate the hypothesis (1) that clinically apparent tumors might
have a different etiology than latent tumors.
Methods
Tfte cohort sfi/dy
The study design has been described elsewhere (27). In brief, the NLCS was initiated in
September 1986. The male cohort consists of 58,279 men who completed a questionnaire
on usual diet, lifestyle, personal and family history of cancer, other risk factors for cancer,
and demographic data. The study population originated from 204 municipal population
registries throughout the country. For reasons of efficiency in data processing and analysis,
the case-cohort approach (28, 29) was used. In a case-cohort approach, cases are derived
from the entire cohort (providing numerator information for calculation of cancer incidence
rates), while accumulated person years at risk in the total cohort are estimated from a
random sample (subcohort) from the cohort (providing denominator information for the
rates). In contrast to nested case-control sampling, this subcohort can be used for multiple
disease endpoints. The subcohort (n=1688) was sampled directly after identification of all
cohort members and has been followed up biennially for vital status information. Follow-up
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for incidence of prostate cancer was established by computerized record linkage with all
nine cancer registries in The Netherlands, and with the Dutch national data base of
pathology reports (PALGA) (30). No subcohort members were lost to follow-up and
completeness of follow-up of cancer was at least 96 percent (31). After a follow-up period of
6.3 years (September 1986-December 1992), 704 incident, microscopically or histologically
confirmed, primary prostate cancer cases were detected.
Tfte guestfonna/re
The self-administered questionnaire has been described elsewhere (32). Usual
consumption of food and beverages during the year preceding the start of the study was
assessed with a 150-item semiquantitative food frequency questionnaire. Participants were
asked to report their frequency of consumption of 12 prepared vegetables, five raw
vegetables and eight fruits (see also Table 1). Categories ranged from 'never or less than
once per month' to '3-7 times per week' (vegetables) or '6-7 times per week' (fruits). For
onions, tomatoes, sweet peppers, and mushrooms participants were asked to report the
number they usually ate per week (onions, tomatoes) or month (sweet peppers, mushrooms
[in boxes of 250 g]). Frequency of vegetable consumption was asked separately for
summer and winter, from which a combined consumption frequency was calculated. For
string beans and endive, portion sizes were asked which were used as indicators to
calculate portion sizes of the other vegetables, according to a vegetable-specific algorithm.
For fruits, subjects were asked to indicate how many pieces they ate each time. Frequency
of consumption and portion size of tomato juice and processed orange/grapefruit juice was
also asked. Mean daily vegetable and fruit consumption (in g/day) was calculated by
multiplying consumption frequency, number of portions per occasion and portion size.
Standard sizes were assumed for each fruit. The questionnaire has been validated against
a 9-day diet record; the Spearman correlation coefficient for total vegetable consumption
was 0.4 and for total fruit consumption this estimate was 0.6 (32).
Date ana/ys/s
Questionnaire data were key-entered twice and processed for all incident cases in the
cohort and for all subcohort members in a manner blinded with respect to case/subcohort
status. This was done in order to minimize observer bias in coding and interpretation of the
data. Subjects who reported a history of cancer other than skin cancer at baseline, were
excluded. Furthermore, according to criteria published before (32), subjects with incomplete
or inconsistent dietary data were excluded; 642 men with prostate cancer and 1525 male
subcohort members remained for analysis on fruit consumption. In addition, for vegetables
we computed an error index based on the consistency of responses on vegetable
questions. When this error index exceeded a certain value, i.e., more than three errors,
subjects were excluded for all analyses regarding consumption of vegetables. Therefore,
data analysis regarding consumption of vegetables was based on 610 cases and 1456
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fab/e): Description of da//y vegeteb/e and fru/f consumption /n prostete cancer cases and subcohort members,
A/e/her/ands Cohort S/udy (?986-?992J.
Vegetable/fruit consumption (g/day)
Vegeteb/es
Total vegetables
Prepared vegetables
Raw vegetables
Pulses'
String/french beans
Broad beans
Brassicas
Cauliflower
Cabbage (white/green)
Kale
Brussels sprouts
Leafy vegetables prepared
Endive prepared
Spinach
Leafy vegetables raw
Endive raw
Lettuce
Alliums
Leek
Onions
Other vegetables
Carrots prepared
Carrots raw
Sauerkraut
Red beets
Sweet peppers
Mushrooms
Tomatoes
Tomato juice
Gherkins
Rhubarb
fru/f
Total fruit
Citrus fruit
Oranges
Mandarins
Grapefruit
Processed orange/grapefruit juice
Grapes
Apples & pears
Bananas
Strawberries
Raisins/other dried fruit
Cases
mean
n=610
183.3
147.0
36.2
33.0
20.0
4.5
31.5
14.3
6.7
3.1
7.4
21.6
12.0
9.5
9.7
2.1
7.5
27.6
9.2
18.4
8.4
2.2
5.8
7.5
2.5
3.2
19.7
2.8
1.7
2.1
n=642
165.6
72.7
49.8
3.3
7.8
11.8
4.2
68.0
13.1
6.8
0.6
SD
69.6
59.8
28.7
22.7
15.3
7.0
19.7
10.3
9.1
3.3
6.7
15.2
10.2
8.7
8.3
4.1
6.5
24.4
13.6
17.2
7.0
9.4
5.8
7.2
4.3
3.9
20.7
16.0
4.7
4.9
112.6
74.1
56.3
6.6
26.4
30.9
8.6
70.7
27.9
8.3
2.3
Subcohort
mean
n=)456
187.1
150.8
36.2
34.7
20.5
4.7
32.7
14.6
7.2
3.3
7.7
21.6
12.0
9.6
9.9
2.4
7.6
28.5
8.5
20.1
9.0
2.1
5.9
7.7
2.5
3.2
19.5
1.9
1.9
2.2
n=)525
154.4
64.8
40.6
18
6.6
118
3.9
67.4
12.9
6.8
0.7
SD
76.3
63.1
29.0
23.0
15.3
7.2
20.3
11.1
8.2
3.4
6.7
16.0
10.8
8.9
9.2
4.9
6.7
24.2
10.9
19.0
8.9
7.8
5.5
a7
4.0
3.9
20.1
13.5
8.1
5.7
111.8
69.8
51.5
7.2
21.7
38.2
8.5
74.6
25.0
7.8
3.2
' Dried seeds were also included.
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subcohort members. •
Mean intake levels (g/day) of vegetables and fruits and other characteristics were compared
between prostate cancer cases and male subcohort members. Furthermore, the mean
intakes of total vegetable and total fruit were compared in categories of potential
confounding factors and tested with analysis of variance. Variables that were considered as
potential confounders were age, a family history of prostate cancer, socioeconomic status,
fruit consumption (for analyses regarding vegetables) and vegetable consumption (for
analyses regarding fruits). Total energy and total fat intake were not considered as potential
confounding factors because no association with prostate cancer risk was observed (data
not shown). Rate Ratios (RRs) and 95% confidence intervals (95% Cl) were computed
using the GLIM statistical package (33). Exponentially distributed survival times were
assumed in the follow-up period. Since standard software was not available, specific
macros were developed in GLIM to account for the additional variance introduced by using
the subcohort instead of the entire cohort (34). Tests for trend were based on likelihood
ratio tests and two-sided P-values are used throughout this report. We first evaluated
combined vegetable and fruit consumption, total vegetables, prepared and raw vegetables,
vegetables categorized in botanical groups, total fruit, and citrus fruit, after categorizing
subjects into quintile levels of consumption. Age-adjusted as well as multivariate-adjusted
analyses were done. In addition, cases detected during the first and the first two years of
follow-up were excluded from analyses to evaluate whether preclinical symptoms might
have influenced results. Second, vegetables and fruits were evaluated as continuous
variables (g/day) and multivariate RRs were expressed per increment of 25 g/day,
corresponding to a consumption frequency of a vegetable of approximately once per week.
In order to assess the independent contribution of each specific vegetable or fruit on
prostate cancer risk, total vegetable or total fruit consumption was added to the multivariate
model. Analyses were also done for continuous variables in subgroups of cases, based on
differentiation grade and size of the tumor, and for latent and nonlatent tumors. The
differentiation grade and tumor size were unknown for 8.7% and 22.8% of all cases,
respectively. Latent and nonlatent prostate tumors were defined based on information from
pathology reports that have been obtained from PALGA. Prostate cancer cases detected
incidentally during transurethral prostate resections were coded latent. Cases detected
during surgical procedures used in case of suspected prostate cancer (biopsy, radical
prostatectomy) were coded nonlatent (35). If available, more than one pathology report per
subject was used. 38.8% of all cases could not be grouped according to latency.
Results
In Table 1 mean daily consumption of total vegetables, vegetables combined into botanical
groups, total fruit, citrus fruit and all individual vegetables and fruits is presented for cases
and subcohort members. Total and prepared vegetable consumption was slightly lower
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among cases compared to subcohort members. Onion consumption was slightly lower and
leek consumption was higher among cases compared to subcohort members. For the other
vegetable groups or individual vegetables no large differences in mean daily consumption
were observed. Total fruit, citrus fruit, orange and grapefruit consumption was higher for
cases than for subcohort members. No large differences in consumption of other fruit items
between cases and subcohort members were found. Comparison of the distribution of
potential confounding factors showed that cases were somewhat older and more highly
educated than subcohort members and more often had a positive family history of prostate
cancer (data not shown).
Mean vegetable and fruit consumption was also compared across categories of potential
confounding factors. Total vegetable consumption was significantly lower for subjects with a
positive family history of prostate cancer and significantly higher for subjects with the
highest fruit consumption. Total fruit consumption varied slightly over categories of
socioeconomic status but increased with age. A significantly increased total fruit
consumption was found for subjects with a positive family history of prostate cancer, and for
subjects with the highest vegetable consumption (data not shown).
RRs for categories of grouped of vegetables and fruit are presented in Table 2. Overall,
age-adjusted and multivanate adjusted RRs were similar. Vegetable and fruit consumption
combined showed no association with prostate cancer risk. The RR for the highest versus
the lowest quintile of consumption was 1.05 (95% Cl: 0.76-1.45). Total vegetable
consumption was neither associated with prostate cancer risk (RR=0.80, 95% Cl: 0.57-1.12
for the highest vs the lowest quintile of consumption). Also for prepared and raw vegetables
no associations were found (RRs of 0.85 and 0.96, respectively, for the same contrast).
When the botanical groups were evaluated, RRs for pulses and brassicas were below unity
but only for pulses there was a significantly decreasing trend in risk with increasing
consumption (p=0.01). Only the RR in the highest quintile of consumption of pulses was
significant (RR=0.71, 95% Cl: 0.51-0.98). In the other botanical groups no clear
associations were seen. For both total fruit consumption and citrus fruit consumption a
significant positive trend in risk was found (p-values of 0.02 and 0.01, respectively). The RR
for total fruit consumption (highest vs the lowest quintile) was 1.31 (95% Cl: 0.96-1.79) and
for citrus fruit the estimate was 1.27 (95% Cl: 0.93-1.73). Exclusion of the first or the first
two years of follow-up did not essentially change the results (data not shown).
Expressed as an increment of 25 g/day, the RR (95% Cl) for vegetables and fruit combined
was 1.00 (0.98-1.02) (Table 3). For total vegetable consumption the estimate was 0.98
(0.95-1.02). In contrast to the findings for total fruit evaluated as a categorized variable, fruit
evaluated as a continuous variable showed no association with prostate cancer risk
(RR=1.01, 95% Cl: 0.99-1.04). Also displayed in Table 3 are RRs (per 25 g increment) for
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fab/e 2: Rate Ratios (RRJ and 95% Confidence /nterva/s fC/J for pros/ate cancer accord/ng to vegeteb/e and
fru/f consumption, A/efner/ands Conorf S/udy (f 986-f 992J.
Vegetable/fruit
(g/day in quintiles)
Vegetables & fruit
combined
1 (low)
2
3
4
5 (high)
Total vegetables
1 (low)
2
3
4
5 (high)
Prepared vegetables
1 (low)
2
3
4
5 (high)
Raw vegetables
1 (low)
2
3
4
5 (high)
Pulses
1 (low)
2
3
4
5 (high)
Brassicas
1 (low)
2
3
4
5 (high)
Median
intake in
subcohort
177.7
257.1
319.0
392.9
519.0
100.0
144.0
175.0
214.0
285.0
79.0
115.0
143.0
174.0
234.0
7.0
19.0
30.0
44.0
73.0
11.0
22.0
30.0
40.0
62.3
10.7
21.0
29.0
4O.0
58.3
Age-adjusted
No of cases/
Person years
in subcohort
107/1756
123/1696
121/1784
136/1731
123/1748
117/1725
126/1765
127/1743
145/1777
95/1705
118/1757
127/1739
139/1756
123/1765
103/1699
125/1861
108/1673
118/1752
144/1722
115/1707
149/1769
140/1918
100/1655
121/1646
100/1727
146/1936
130/1682
102/1620
129/1809
103/1669
RR (95% Cl)
1.00
1.10(0.80-1.53)
1.08(0.78-1.50)
1.19(0.86-1.64)
1.05(0.76-1.45)
P-trend 0.56
1.00
1.07(0.78-1.46)
1.12(0.82-1.54)
1.27(0.93-1.74)
0.82(0.59-1.14)
P-trend 0.61
1.00
1.04(0.76-1.42)
1.19(0.87-1.62)
1.11 (0.81-1.53)
0.85(0.61-1.18)
P-trend 0.40
1.00
0.94(0.68-1.29)
1.03(0.75-1.41)
1.19(0.88-1.62)
1.04(0.76-1.42)
P-trend 0.26
1.00
0.90(0.67-1.21)
0.75(0.55-1.04)
0.92(0.67-1.25)
0.69(0.51-0.95)
P-trend 0.01
1.00
0.97(0.72-1.31)
0.81(0.59-1.11)
0.88(0.65-1.19)
0.80(0.58-1.10)
P-trend 0.06
Multivariate adjusted
No of cases/
Person years
in subcohort
107/1744
120/1674
121/1772
135/1725
123/1741
116/1719
125/1749
126/1730
145/1764
94/1693
117/1753
126/1720
138/1743
123/1740
102/1699
125/1848
107/1661
117/1740
142/1722
115/1685
147/1750
139/1900
100/1639
121/1639
99/1727
145/1936
130/1669
101/1598
127/1796
103/1656
RR (95% Cl)
1.00"
1.08(0.78-1.50)
1.07(0.77-1.48)
1.16 (0.84-1.60)
1.05(0.76-1.45)
P-trend 0.58
1.00'-'
1.06(0.77-1.46)
1.08(0.78-1.49)
1.28(0.94-1.75)
0.80(0.57-1.12)
P-trend 0.51
1.00'-'
1.03(0.74-1.41)
1.19(0.87-1.64)
1.13(0.82-1.56)
0.85(0.61-1.19)
P-trend 0.46
1.00"
0.89(0.64-1.23)
0.97(0.71-1.34)
1.11(0.81-1.51)
0.96(0.69-1.34)
P-trend 0.61
1.00''
0.92(0.68-1.24)
0.77(0.55-1.06)
0.93(0.68-1.27)
0.71 (0.51-0.98)
P-trend 0.01
1.00"
0.98(0.72-1.32)
0.81 (0.59-1 12)
0.87 (0.64-1.18)
0.82(0.59-1.12)
P-trend 0.06
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faWe 3. Rate Rafos (RRj and 95% Confidence /nferva/s CC/J forprostefe cancer for confinuous variaWes of
yegeteWe and fti//f consumpftbn, Nefher/ands Cohort Sfudy (•J986-J992J.
Vegetable/fruit (g/day)
Vegetables and fruit combined
Total vegetables
Total fruit
/nd/V/dua/ vege/aWe /'terns
String/french beans
Broad beans
Cauliflower
Cabbage (white/green)
Kale
Brussels sprouts
Endive prepared
Spinach
Endive raw
Lettuce
L66K
Onions
Carrots prepared
Carrots raw
Sauerkraut
Red beets
Sweet peppers
Mushrooms prepared
Tomatoes
Tomato juice
Gherkins
Rhubarb
/nd/V/dua/fri/// /terns
Oranges
Mandarins
Grapefruit
Processed orange/grapefruit juice
Grapes
Apples & pears
Bananas
Strawberries
Raisins/other dried fruit
RR'(95%CI)
per 25 g
1.00(0.98-1.02)^
0.98(0.95-1.02)
1.01 (0.99-1.04)
0.94(0.80-1.12)
0.90(0.63-1.30)
0.90(0.71-1.14)
0.88(0.64-1.21)
0.67(0.31-1.42)
0.81(0.55-1.21)
0.89(0.71-1.12)
1.03(0.78-1.36)
0.69(0.40-1.18)
0.99(0.67-1.46)
1.23(0.99-1.54)
0.92(0.80-1.05)
0.83(0.60-1.13)
1.04(0.76-1.42)
1.01 (0.64-1.59)
0.89(0.65-1.23)
1.35(0.72-2.56)
1.33(0.67-2.62)
1.00(0.88-1.14)
1.11(0.96-1.29)
0.89(0.61-1.28)
0.90(0.55-1.47)
1.06(1.02-1.11)
0.79(0.54-1.17)
1.03(0.93-1.15)
0.96(0.89-1.03)
1.10(0.83-1.44)
0.99(0.96-1.03)
1.02(0.92-1.12)
0.94(0.69-1.29)
0.52(0.20-1.39)
RR' (95% Cl)
per 25 g
0.98(0.81-1.20)
0.95(0.65-1.38)
0.94(0.73-1.23)
0.94(0.66-1.35)
0.74(0.33-1.64)
0.87(0.56-1.36)
0.93(0.72-1.13)
1.12(0.82-1.52)
0.72 (0.41-1.25)
1.06(0.71-1.59)
1.38(1.08-1.76)
0.93(0.79-1.10)
0.87(0.61-1.23)
1.08(0.78-1.49)
1.15(0.69-1.91)
0.95(0.67-1.35)
1.60(0.82-3.12)
1.49(0.74-3.01)
1.05(0.90-1.22)
1.12(0.96-1.29)
0.92(0.64-1.32)
0.92(0.56-1.51)
1.07(1.01-1.14)
0.75(0.50-1.11)
1.01 (0.90-1.13)
0.96(0.89-1.03)
1.04(0.78-1.39)
0.95 (0.90-0.99)
1.00(0.91-1.11)
0.89(0.65-1.24)
0.49(0.18-1.32)
' Adjusted for age, family history of prostate cancer, socioeconomic status, and total fruit consumption (for
vegetable items) or total vegetable consumption (for fruit items);' Adjusted for age, family history of prostate
cancer, socioeconomic status, total fruit and total vegetable consumption;' Adjusted for age, family history of
prostate cancer, and socioeconomic status.
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Furthermore, we excluded subjects who appeared not to have correctly understood how to
fill in the questions on vegetable consumption; those subjects were defined by an extreme
score on an error index. In the NLCS validation study, the correlation coefficient for total
vegetable consumption was 0.4 (32), which is quite low, but comparable to the figure
reported for other prospective studies (37-39). One possible reason for the low correlation
may be the relative lack of true contrast in the frequency of total vegetable consumption in
the NLCS. Most subjects are accustomed to a diet including one hot meal per day, which
almost always includes vegetables. Due to individual preferences, however, contrast in
consumption frequency of many specific vegetables is much higher. As can be seen in
Table 3, the median intake in the highest quintile of, for example, pulses, is more than five
times higher than the median intake in the lowest quintile. Also for Brassicas there is about
a fivefold difference between the median intake in the highest and lowest consumption
quintile. For individual vegetables the range in consumption is even higher because very
often subjects in the lowest consumption quintile are nonconsumers of the specific
vegetable. Therefore a smaller measurement error and a higher correlation is to be
expected for specific vegetable items. It was not possible to assess the validity for specific
vegetables in the NLCS validation study, since 9 days of dietary record are not sufficient to
estimate consumption frequency of specific vegetables. In our validation study, the
correlation coefficient for fruit consumption was 0.60 which may implicate that there is less
measurement error regarding fruit consumption in the NLCS. For total fruit consumption, the
range of difference between highest and lowest consumption quintile is about 252 grams,
which is not low, and, as for vegetables, the range in consumption of specific fruits is
determined by individual preferences and should therefore also be large enough.
Misclassification of both vegetable and fruit consumption is likely to be nondifferential, thus
leading to an underestimation of the strength of association.
Another explanation that has to be considered in the interpretation of our results is that
unmeasured or unknown factors may have caused residual confounding. We considered,
however, most of the factors that have been implied in prostate cancer etiology and factors
showing an association with prostate cancer risk in our study were included into the
multivariate model. Thus, total energy and fat intake were not included into the multivariate
model. When we performed some analyses with these factors additionally in the
multivariate model, risk estimates did not change. Therefore, factors other than energy or
fat intake could be responsible for residual confounding. Preclinical symptoms are not likely
to have influenced our results because after exclusion of cases detected in the first and in
the first two years of follow-up results were similar to results including all cases. Finally,
chance will have played a role in our findings, in particular because of the multiple
comparisons that were made.
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TaWe 4: Rate Rafos (Rfis) and 95% Confidence /ntenrafe fC/J of pros(ate cancer for conffnuous variabtes of
vegefab/e and fru/f consumption /n subgroups on d/'/ferentiafon grade, Wetfier/ands Conorf Sfudy
Vegetable/fruit
Vegetables and fruit combined'
Total vegetables^
Prepared vegetables
Raw vegetables
Pulses
Brassicas
Leafy vegetables prepared
Leafy vegetables raw
Alliums
Total fruit'
Citrus fruit
Well differentiated
(n=181)
RR'(95%CI)
per 25 g
1.00(0.97-1.03)
0.99(0.93-1.04)
0.89(0.75-1.06)
1.12(0.94-1.34)
0.93(0.76-1.15)
0.95(0.73-1.24)
0.88(0.65-1.19)
1.23(0.81-1.87)
0.92(0.75-1.15)
1.00(0.97-1.04)
1.01 (0.94-1.07)
Moderately
differentiated
(n=217)
RR' (95% Cl)
per 25 g
1.00(0.98-1.02)
0.96(0.91-1.01)
0.97(0.82-1.15)
1.03(0.87-1.22)
0.88(0.72-1.08)
0.88(0.68-1.13)
1.11(0.85-1.46)
0.78(0.49-1.23)
1.06(0.87-1.29)
n=229
1.03(1.00-1.06)
1.02(0.96-1.08)
Poorly or
undifferentiated
(n=153)
RR' (95% Cl)
per 25 g
1.00(0.98-1.03)
0.99(0.94-1.05)
1.08(0.89-1.31)
0.93(0.76-1.13)
1.07(0.87-1.32)
0.99(0.75-1.30)
1.13(0.83-1.52)
0.89(0.54-1.47)
1.11(0.89-1.37)
n=J60
1.02(0.99-1.06)
1.02(0.96-1.09)
' Adjusted for age, family history of prostate cancer, socioeconomic status, total fruit consumption and total
vegetable consumption;' Not adjusted for total vegetable and total fruit consumption;' Not adjusted for total
vegetable consumption;' Not adjusted for total fruit consumption.
There were only four other cohort studies on prostate cancer in which total vegetable
consumption was investigated. In three studies, as in our study, no clear associations were
observed (8, 9, 11) and in the other cohort study a decreased risk was found (13). In one
case-control study total vegetables showed no association (20) and in three case-control
studies in which 'vegetables' were investigated also no clear associations were noted (19,
22, 25). We found no association for prepared vegetables but in one case-control study a
decreased risk was noted (26). As in our study, raw vegetables showed no association in
one cohort study (10). For consumption of pulses, we found a statistically significant inverse
trend in risk. Beans, lentils and peas combined were also negatively associated with
prostate cancer risk in another cohort study (5) and two case-control studies (14, 26), but
this was not supported by another case-control study reporting no association (24). All the
estimates for vegetables of the brassica genus were below unity in our study, but not
significant, and there was no clear trend in risk. In three other studies cruciferous
vegetables showed no clear associations with prostate cancer risk (8, 15, 20), but in two
case-control studies cabbage was inversely associated with prostate cancer risk (14, 21).
For prepared and raw leafy vegetables and alliums we found no increase or decrease in
risk. For individual vegetables, evaluated as continuous variables, inverse associations
were found for consumption of kale and raw endive, and positive associations were noted
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for consumption of leek, sweet peppers and mushrooms. Only the RR for leek was
statistically significant. In other studies different (groups of) vegetables have been
evaluated and no associations were shown for consumption of green or yellow vegetables
(7, 9), dark green (leafy) vegetables (9, 20, 26), 'other" vegetables (4), 'mixed' vegetables
(11), tomatoes (20, 26), carrots (11, 20, 22-24), onions (26), spinach (11, 18), broccoli (11),
cauliflower (14), bracken fern (19) and rutabaga (14). In some studies positive associations
were noted for consumption of fried vegetables (6) and mushrooms (19), and protective
associations were noted for consumption of dark green vegetables for men aged less than
70 years (20), leafy green vegetables (24), tomatoes (5, 11, 14), carrots (14, 18, 21, 26),
and spinach (19, 21).
Because so many different vegetables were evaluated, and studies were carried out in
various populations with different eating habits, the interpretation of results from these
studies are hampered. In addition, studies differ in the level and range of exposure, thus
leading to results that are not directly comparable. These drawbacks not only apply to
studies on prostate cancer risk in relation to vegetable consumption but also in relation to
fruit consumption (discussed below). Other drawbacks are that endpoints in previous
studies were either incidence or mortality and, as a consequence, consistency in results is
difficult to evaluate. Also, several epidemiological studies are hampered by the fact that no
extensive measurement of consumption of vegetables and fruit was made. Therefore, no
complete evaluation of vegetables and fruit was possible and for those vegetables and fruit
that were included, a random misclassification bias may have occurred which led to an
underestimation of effect. Another drawback is that because in several studies only limited
adjustment was employed, results in these studies might have been influenced by
confounding. Finally, in none of the previous studies the independent effect of individual
vegetables or fruits was assessed by including total vegetable or total fruit consumption into
the multivariate model.
When quintiles of total fruit and citrus fruit consumption were evaluated in our cohort study,
we observed significant positive trends in risk, but in a continuous model no association with
total fruit consumption was found. In most other cohort studies no clear associations were
found for total fruit (4, 5, 8, 9, 11) and fresh citrus fruit (5). Total fruit consumption was
positively associated with prostate cancer in one cohort study (6) and one case-control
study (25) and also for citrus fruit a positive association was noted in a case-control study
(26). Null associations have been reported for consumption of canned or frozen fruit (5),
fresh winter fruit (5), noncitrus fruit (26) or 'other" fresh fruit (5, 10). In one case-control
study fresh fruit consumption was negatively associated with prostate cancer risk, but only
for men aged 70 years and older (22). Except for mandarins and raisins, which were
inversely associated with prostate cancer risk in the NLCS, no strong associations for
individual fruits were found. There is only one other study in which consumption of raisins
46 Chapter 2
and other dried fruit was evaluated and in this cohort study also an inverse association was
observed (5). Other individual fruits that have been evaluated are oranges (11),
strawberries (11), pumpkin or mangoes and papaya (20). Only for papaya a positive
association with prostate cancer risk was observed in men aged 70 years and older. In two
cohort studies consumption of vegetables and fruit combined showed no associations with
prostate cancer risk (9, 12), and this was confirmed in our study.
It has been suggested before that latent and nonlatent or aggressive prostate tumors might
have a different etiology (1). The RRs for groups of vegetables and fruits did not differ to a
large extent between the different subgroups in our study. In one other study in which only
carrots were evaluated it was mentioned that a distinction in localized and advanced
prostate tumors displayed results similar to overall results (23). Thus far, there have been
no other studies regarding vegetable and fruit consumption and prostate cancer risk in
which subgroup analyses based on tumor characterization were conducted.
In conclusion, for most vegetables thus far no consistent associations with prostate cancer
risk have been observed. Moreover, in most studies, including the present one, vegetable
consumption seemed not to be associated with prostate cancer risk. However, different
vegetables have been evaluated in different studies which makes a comparison between
studies difficult. We found some indication of a protective effect of consumption of pulses,
kale and raw endive and of a positive association between consumption of leek, sweet
peppers and mushrooms and prostate cancer risk. These results, however, need to be
confirmed in other studies. For fruit, similar conclusions can be drawn. We found a positive
trend in risk for total fruit consumption and citrus fruit consumption, but this has mostly not
been reported from other studies. In a continuous model, fruit consumption showed no
association with prostate cancer risk. Results from our study regarding individual fruits were
not very convincing. Nevertheless, there was a tendency for a protective effect of
consumption of raisins and other dried fruit. Because this effect was also reported in
another study, more studies on a possible effect of raisins are warranted. Our results
indicate no different association for latent and nonlatent or more advanced prostate tumors.
Acknowledgements
We are indebted to the participants of this study and further wish to thank the regional
cancer registries (IKA, IKL, IKMN, IKN, IKO, IKR, IKST, IKW, IKZ), and the Dutch national
data base of pathology (PALGA); A. Volovics for statistical advice; S. van de Crommert, J.
Nelissen, H. Brants, M. Moll, W. van Dijk, C. Sloot, P. Florax and A. Pisters for assistance;
and H. van Montfort, R. Schmeitz, T. van Montfort, and M. de Leeuw for programming and
statistical assistance.
Vegetables, fruit and prostate cancer 47
References
1. Kolonel LN. Nutrition and prostate cancer. Cancer Causes Control 1996;7:83-94.
2. Steinmetz KA, Potter JD. Vegetables, fruit, and cancer. II. Mechanisms. Cancer Causes Control
1991;2:427-42.
3. Steinmetz KA, Potter JD. Vegetables, fruit, and cancer prevention: a review. J Am Diet Assoc
1996;96:1027-39.
4. Snowdon DA, Phillips RL, Choi W. Diet, obesity, and risk of fatal prostate cancer. Am J
Epidemiol 1984;120:244-50.
5. Mills PK, Beeson WL, Phillips RL, et al. Cohort study of diet, lifestyle, and prostate cancer in
Adventist men. Cancer 1989;64:598-604. ' '-
6. Severson RK, Nomura AM, Grove JS, et al. A prospective study of demographics, diet, and
prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res 1989:49:1857-60.
7. Hirayama T. Life-style and mortality. A large-scale census-based cohort study in Japan. Basel:
Karger, 1990.
8. Hsing AW, McLaughlin JK, Schuman LM, et al. Diet, tobacco use, and fatal prostate cancer
results from the Lutheran Brotherhood Cohort Study. Cancer Res 1990:50:6836-40.
9. Shibata A, Paganini Hill A, Ross RK, et al. Intake of vegetables, fruits, beta-carotene, vitamin C
and vitamin supplements and cancer incidence among the elderly: a prospective study. Br J
Cancer 1992:66:673-9.
10. Le Marchand L, Kolonel LN, Wilkens LR, et al. Animal fat consumption and prostate cancer: a
prospective study in Hawaii. Epidemiology 1994;5:276-82.
11. Giovannucci E, Ascherio A, Rimm EB, et al. Intake of carotenoids and retinol in relation to risk of
prostate cancer. J Natl Cancer Inst 1995:87:1767-76.
12. Gronberg H, Damber L, Damber JE. Total food consumption and body mass index in relation to
prostate cancer risk: a case-control study in Sweden with prospectively collected exposure data.
JUrol 1996;155:969-74.
13. Rodriguez C, Tatham LM, Thun MJ, et al. Smoking and fatal prostate cancer in a large cohort of
adult men. Am J Epidemiol 1997;145:466-75.
14. Schuman LM, Mandel JS, Radke A, et al. Some selected features of the epidemiology of
prostatic cancer: Minneapolis-St. Paul, Minnesota case-control study, 1976-1979. In: Magnus K,
ed. Trends in cancer incidence: causes and practical implications. Washington: Hemisphere
Publishiong corporation, 1982:345-54.
15. Graham S, Haughey B, Marshall J, et al. Diet in the epidemiology of carcinoma of the prostate
gland. J Natl Cancer Inst 1983;70:687-92.
16. Mishina T, Watanabe H, Araki H, et al. Epidemiological study of prostatic cancer by matched-pair
analysis. Prostate 1985:6:423-36.
17. Talamini R, La Vecchia C, Decarli A, et al. Nutrition, social factors and prostatic cancer in a
Northern Italian population. Br J Cancer 1986:53:817-21.
18 Ross RK, Shimizu H, Paganini Hill A, et al. Case-control studies of prostate cancer in blacks and
whites in southern California. J Natl Cancer Inst 1987;78:869-74.
19. Oishi K, Okada K, Yoshida O, et al. A case-control study of prostatic cancer with reference to
dietary habits. Prostate 1988:12:179-90.
20. Le Marchand L, Hankin JH, Kolonel LN, et al. Vegetable and fruit consumption in relation to
prostate cancer risk in Hawaii: a reevaluation of the effect of dietary beta-carotene. Am J
Epidemiol 1991 ;133:215-9.
21. Walker AR, Walker BF, Tsotetsi NG, et al. Case-control study of prostate cancer in black patients
in Soweto, South Africa. Br J Cancer 1992:65:438-41.
22. Talamini R, Franceschi S, La Vecchia C, et al. Diet and prostatic cancer: a case-control study in
northern Italy. Nutr Cancer 1992:18:277-86.
23. Andersson SO, Baron J, Wölk A, et al. Early life risk factors for prostate cancer: a population-
based case-control study in Sweden. Cancer Epidemiol Biomarkers Prev 1995:4:187-92.
24. Ewings P, Bowie C. A case-control study of cancer of the prostate in Somerset and east Devon.
BrJ Cancer 1996;74:661-6.
25. De Stefani E, Fierro L, Barrios E, et al. Tobacco, alcohol, diet and risk of prostate cancer. Tumori
1995:81:315-20.
26. Key TJ, Silcocks PB, Davey GK, et al. A case-control study of diet and prostate cancer. Br J
Cancer 1997:76:678-87.
48 Chapter 2
27. Van den Brandt PA, Goldbohm RA, Van 't Veer P, et al. A large-scale prospective cohort study
on diet and cancer in The Netherlands. J Clin Epidemiol 1990;43:285-95.
28. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials.
Biometrika 1986;73:1-11.
29. Self SG, Prentice RL. Asymptotic distribution theory and efficiency results for case-cohort
studies. Ann Stat 1988:16:64-81.
30. Van den Brandt PA, Schouten LJ, Goldbohm RA, et al. Development of a record linkage protocol
for use in the Dutch Cancer Registry for Epidemiological Research. Int J Epidemiol 1990:19:553-
8.
31. Goldbohm RA, Van den Brandt PA, Dorant E. Estimation of the coverage of Dutch municipalities
by cancer registries and PALGA based on hospital discharge data. Tijdschr Soc Gezondheidsz
1994:72:80-4.
32. Goldbohm RA, Van den Brandt PA, Brants HAM, et al. Validation of a dietary questionnaire used
in a large-scale prospective cohort study on diet and cancer. Eur J Clin Nutr 1994:48:253-65.
33. Baker J. GLIM 3.77 Reference Manual. Oxford: Numerical Algorithms Group, 1985.
34. Volovics A, van den Brandt PA. Methods for the analyses of case-cohort studies. Biom J • ••:
1997:2:195-214.
35. Boyle P, Maisonneuve P, Napalkov P. Geographical and temporal patterns of incidence and
mortality from prostate cancer. Urology 1995;46:47-55.
36. Van den Brandt PA, Van 't Veer P, Goldbohm RA, et al. A prospective cohort study on dietary fat
and the risk of postmenopausal breast cancer. Cancer Res 1993:53:75-82.
37. Ocke MC, Bueno de Mesquita HB, Goddijn HE, et al. The Dutch EPIC food frequency
questionnaire. I. Description of the questionnaire, and relative validity and reproducibility for food
groups. Int J Epidemiol 1997;26 Supplement:S37-S48.
38. Nes M, Frost Andersen L, Solvoll K, et al. Accuracy of a quantitative food frequency
questionnaire applied in elderly Norwegian women. Eur J Clin Nutr 1992:46:809-21.
39. Hankin JH, Wilkens LR, Kolonel LN, et al. Validation of a quantitative diet history method in
Hawaii. Am J Epidemiol 1991:133:616-28.
Chapter 3
A prospective cohort study on retinol,
vitamins C and E, and carotenoids and
prostate cancer risk'
Agnes G. Schuurman'
R. Alexandra Goldbohm*
Henny A.M. Brants'
Piet A. van den Brandt
• " / *
Abstract
The association between retinol, vitamins C and E, and carotenoids and prostate cancer
risk was investigated in the Netherlands Cohort Study among 58,279 men aged 55-69
years at baseline in 1986. Information on diet was assessed with a 150-item semi-
quantitative food frequency questionnaire. After 6.3 years of follow-up 642 cases were
available for analyses. Multivariate analyses were adjusted for age, family history of
prostate cancer, socioeconomic status and alcohol intake. A positive association was
observed for intake of ß-cryptoxanthin. RRs in increasing quintiles were 1.00 (ref), 0.94,
1.01, 1.16, 1.41; p-trend <0.01. For intake of retinol, vitamins C and E and other
carotenoids (a-carotene, ß-carotene, lycopene and lutein/zeaxanthin) no effect on overall
prostate cancer risk was found. RRs for vitamin supplement use were decreased, but not
significantly. Nutrients were also evaluated in subgroups of nondrinkers and drinkers.
Among nondrinkers, nonsignificant inverse associations were observed for intake of retinol,
a-carotene, and ß-carotene. RRs in the highest vs lowest intake quintile were 0.23, 0 60,
and 0.76, respectively. Among drinkers, ß-cryptoxanthin showed a positive association (RR
highest vs lowest quintile=1.40). In conclusion, from our study an interaction between
vitamins and alcohol consumption is suggested, which needs confirmation.
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Introduction
Vitamins are thought to play a potentially important role in the prevention of cancer. For
example, vitamin A may inhibit tumor promotion, carotenoids and vitamins C and E may be
protective because of antioxidant effects, and vitamin C may prevent the formation of
carcinogens from precursor compounds (1). In fact, for different types of cancer (e.g.
cancers of the stomach, esophagus, lung, oral cavity and pharynx, endometrium, and
pancreas) the evidence for a protective effect of consumption of vegetables and fruit is
considered to be consistent. However, for prostate cancer the evidence is questionable (2).
For several nutrients, results from trials with prostate cancer as one of the endpoints have
become available recently. The Finnish Alpha-Tocopherol, Beta-Carotene Cancer
Prevention Study (ATBC study), a large chemoprevention trial among male smokers,
indicated an adverse effect of ß-carotene on prostate cancer risk. Among nondrinkers,
however, ß-carotene supplementation appeared to decrease the risk of prostate cancer. In
this same trial, a protective effect of a-tocopherol supplementation was observed. Subjects
receiving a-tocopherol plus ß-carotene had a slight nonsignificant decrease in prostate
cancer incidence compared with the placebo group (3). In the Physicians' Health Study
among US male physicians ß-carotene supplementation showed no statistically significant
effect on prostate cancer risk (4) and in the US Beta-Carotene and Retinol Efficacy Trial
among subjects at high risk of developing lung cancer, no effect on prostate cancer
incidence of supplementation with ß-carotene or retinol was observed (5). Besides these
trials, several observational epidemiological studies have been conducted. Especially
retinol and ß-carotene have been investigated for many years now, but results for these
and other nutrients are still mostly inconsistent (6). Few studies to date have investigated
specific carotenoids besides ß-carotene in prostate cancer etiology (6, 7). Nevertheless,
prospective studies indicated a decreased association with intake of lycopene (8) and an
increased association for serum ß-cryptoxanthin (9) and in one case-control study an
increased risk was observed for intake of papaya and it was suggested that ß-
cryptoxanthin, a common carotenoid in papaya, may be responsible for this observed
association (10).
To further explore a possible association between intake of vitamins and carotenoids and
prostate cancer risk, we investigated this within the Netherlands Cohort Study (NLCS) on
diet and cancer.
Materials and methods
The cohort sfudy
We will only briefly outline the study design because this has been reported in detail
elsewhere (11). The NLCS was initiated in September 1986 and includes 58,279 men aged
55-69 years at the beginning of the study. The study population originated from 204
municipal registries throughout the country. All cohort members completed a mailed, self-
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administered questionnaire on dietary habits and other risk factors for cancer. For reasons
of efficiency in data processing and analysis, the case-cohort approach (12, 13) was used.
In a case-cohort approach, cases are derived from the entire cohort (providing numerator
information for calculation of cancer incidence rates), while accumulated person years at
risk in the total cohort are estimated using a random subcohort sample (providing
denominator information for the rates). In contrast to nested case-control sampling, this
subcohort can be used for multiple disease endpoints. The subcohort (n= 1,688) was
sampled directly after identification of all cohort members and has been followed up
biennially for vital status information. Follow-up for incidence of prostate cancer was
established by computerized record linkage with all nine cancer registries in the
Netherlands and with the Dutch national data base of pathology reports (PALGA) (14). No
subcohort members were lost to follow-up and completeness of follow-up of cancer has
been estimated to be at least 96 percent (15). After a follow-up period of 6.3 years
(September 1986-December 1992), 704 incident, microscopically or histologically
confirmed, primary prostate cancer cases were detected.
The guestfonna/re
The self-administered questionnaire has also been described in detail elsewhere (16). The
dietary section of the questionnaire, a 150-item semiquantitative food frequency
questionnaire, concentrated on habitual consumption of food and beverages during the
year preceding the start of the study. Questionnaire data were key-entered twice and
processed for all incident cases in the cohort and for all subcohort members in a
standardized manner blinded with respect to case/subcohort status. This was done in order
to minimize observer bias in coding and interpretation of the data. Mean daily vitamin
intakes were calculated using the computerized Dutch food composition table (17). For
carotenoids, a recently developed food composition database was used. Regularly eaten
vegetables were comprehensively sampled and analyzed for their carotenoid content and
the database was completed with data from the recent literature and information from food
manufacturers (18). Information on dietary supplement use was collected using an open-
ended question with space for adding a maximum of four different supplements.
Participants were asked whether they used vitamin tablets, drops or other preparations
during five years before baseline. Subjects were categorized in users or nonusers of
supplements and supplements containing vitamin A, C or E. The questionnaire was
validated against a 9-day diet record. The energy and sex-adjusted Pearson correlation
coefficients between the 9-day record and the questionnaire were 0.48 for total vitamin A,
and 0.55 for vitamin C (16).
Date ana/ys/s
In the subcohort prevalent cancer cases at baseline other than skin cancer were excluded,
leaving 1,630 subcohort members for analysis. Furthermore, according to criteria published
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before (16), subjects with incomplete or inconsistent dietary data were excluded; 642 men
with prostate cancer and 1,525 male subcohort members remained for analysis.
The distribution of dietary factors and other characteristics was compared between cases
and subcohort members. Furthermore, mean intakes of vitamins and carotenoids were
compared across categories of potential confounding variables. Variables that were
considered as potential confounders were age (continuous), a family history of prostate
cancer (no, yes), socioeconomic status (low, medium, high) and alcohol intake from
white/fortified wine (<15 g/day, >15 g/day) because in previous analyses these factors were
associated with prostate cancer risk in the NLCS (data not shown). Total energy and total
fat intake were not considered as potential confounding factors because no association
with prostate cancer risk was observed (data not shown). The same applies to vegetable
and fruit consumption (19). Subjects were categorized according to quintile levels of
nutrients, or according to their use of vitamin supplements. Vitamin C intake was
categorized into three categories because the validation study showed that quintiles two
and three and quintiles four and five of vitamin C intake could not be distinguished (16).
Rate ratios (RRs) and 95 percent confidence intervals (95 percent Cl) were computed using
the GLIM statistical package (20). Exponentially distributed survival times were assumed in
the follow-up period. Since standard software was not available, specific macros were
developed to account for the additional variance introduced by using the subcohort instead
of the entire cohort (21). Tests for trend were based on likelihood ratio tests and two-sided
p-values are used throughout this report. Age-adjusted as well as multivanate adjusted
analyses were done. Advanced prostate cancer cases (T3-4, MO; TO-4, M1) were evaluated
separately to test the hypothesis that diet may be more strongly related to advanced
prostate tumors. Furthermore, associations between intake of vitamins and carotenoids and
supplement use and risk of prostate cancer were also investigated in subgroups of
nondrinkers and drinkers of alcoholic beverages because in the ATBC trial an interaction
between ß-carotene supplementation and alcohol consumption was shown. To evaluate
whether preclinical disease might have influenced results, cases detected in the first two
years of follow-up were exluded in additional analyses.
Results
The mean daily intake of vitamins is shown in table 1. Mostly, no large differences in intake
between cases and subcohort members were observed although vitamin C intake was
somewhat higher among cases. Overall, use of any vitamin supplement was similar
between cases and subcohort members. However, use of supplements containing vitamin
A, C, or E among cases (3.7, 7.2, and 3.7 percent, respectively) was lower compared to
subcohort members (5.2, 8.2, and 4.8 percent, respectively). Also shown in this table is the
distribution of potential confounding factors. Compared to subcohort members, cases are
older (63.9 vs 61.4 years), more often have a family history of prostate cancer (4.4 vs 2.7
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percent) and are more often of a higher socioeconomic status (20.2 vs 17.8 percent).
7ab/e 7: Descr/pf/on of mean da//y /n/ate of w'fam/ns, caroteno/cte and wtem/n supp/emenf use and d/slribufion
ofpotenöa/confound/ng factors, Netfier/ands Cohort Sfudy ft986-t992/
Characterises
Exposure var/abfes
Retinol (mg)
Vitamin C (mg/day)
Vitamin E (mg/day)
a-carotene (mg/day)
ß-carotene (mg/day)
ß-cryptoxanthin (mg/day)
Lycopene (mg/day)
Lutein/zeaxanthin (mg/day)
Any vitamin supplement use (% yes)
Use of supplements containing vitamin A (% yes)
Use of supplements containing vitamin C (% yes)
Use of supplements containing vitamin E (% yes)
Pofentfa/ confound/ng factora
Age (years)
Family history (% yes)
Socioeconomic status (% high)
Alcohol from white/fortified wines (g/day)'
Cases (n=642)
mean
0.6
102.2
14.4
0.6
2.9
0.2
1.1
2.5
22.9
3.7
7.2
3.7
63.9
4.4
20.2
3.0
SD
0.3
43.4
6.4
0.5
1.3
0.2
2.3
1.1
3.8
6.6
Subcohort
mean
0.6
98.1
14.7
0.7
3.0
0.2
1.0
2.6
22.4
5.2
8.2
4.8
61.4
2.7
17.8
2.3
(n=1,525)
SD
0.3
41.7
6.6
0.6
1.6
0.2
1.6
1.1
4.2
5.3
' Nondrinking cases (n=101) and nondrinking subcohort members (n=231) not included.
Furthermore, among drinking cases alcohol intake from white wine and fortified wines was
higher than among drinking subcohort members (3.0 vs 2.3 g/day). When we evaluated the
intake of vitamins across categories of potential confounding factors, the mean intakes of
retinol, vitamin E, a-carotene, ß-carotene, and lutein and zeaxanthin did not differ between
categories of age, socioeconomic status, family history of prostate cancer and alcohol
intake. The intake of vitamin C and ß-cryptoxanthin increased with age and the intake of
vitamin C and lycopene increased with socioeconomic status. Finally, subjects with the
lowest socioeconomic status had the lowest intake of ß-cryptoxanthin, and subjects in the
medium category had the highest intake (data not shown).
RRs for intake of retinol, vitamins C and E, and carotenoids are shown in table 2, for all
cases as well as for advanced cases separately. No associations were observed between
intake of retinol, and vitamins C and E and overall risk of prostate cancer. Also for
advanced cases no clear associations were observed. For intake of a-carotene, all
estimated RRs were below unity. The RR for the highest versus lowest quintile of intake
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was 0.85 (95 percent Cl 0.62-1.17), but no trend in risk was noted for overall prostate
cancer risk (p-trend=0.29). When advanced cases were evaluated separately, the RR for
the same contrast was 0.64 (95 percent Cl 0.39-1.06) and the trend test was of borderline
significance (p=0.07). For ß-cryptoxanthin, a positive trend in risk was observed (p<0.01).
Only in the highest quintile of intake a significant increased risk was found (RR=1.41, 95
percent Cl 1.03-1.92). For advanced cases only, the positive trend in risk was still
significant (p-trend=0.01) and the estimate in the highest intake quintile was of borderline
significance (RR=1.56, 95 percent Cl 0.99-2.44). For other individual carotenoids no
associations were noted.
fabte 2: Rate raftos and 95% confidence /nterva/s for prostete cancer accord/ng to gu/nfttes of /ntefce o/Yefrno/,
w'(am/ns C and £, and caroteno/ds, Ne//)er/ands Co/iorf Sfudy ("7986-7992j.
Exposure
Retinol (mg/day)'
Cases/person years
RR (95% Cl)'
RR (95% Cl)'
Advanced cases (nf
RR (95% Cl)'
Vitamin C (mg/day)'
Cases/person years
RR (95% Cl)'
RR (95% Cl)'
Advanced cases (n)'
RR (95% Cl)'
Vitamin E (mg/day)'
Cases/person years
RR (95% Cl)'
RR (95% Cl)'
Advanced cases (nf
RR (95% Cl)'
a-carotene (mg/day)'
Cases/person years
RR (95% Cl)'
RR (95% Cl)'
Advanced cases (n)*
RR (95% Cl)'
ß-carotene (mg/day)'
Cases/person years
RR (95% Cl)'
RR (95% Cl)'
Advanced cases (n)'
RR (95% Cl)'
QV
0.3
138/1807
1.00
1.00
46
1.00
52.5
109/1816
1.00
1.00
33
100
7.1
128/1769
1.00
1.00
48
1.00
0.2
134/1800
1.00
1.00
44
1.00
1.5
119/1801
1.00
1.00
36
1.00
Q2
0.4
147/1841
1.06(0.78-1.42)
1.08(0.80-1.46)
53
1.16(0.75-1.79)
82.3
245/3645
1.10(0.83-1.45)
1.06(0.80-140)
84
1.19(0.77-1.84)
10.4
126/1854
1.05(0.77-1.43)
1.05(0.77-1.44)
43
0.96(0.61-1.51)
0.4
136/1839
0.95(0.70-1.29)
0.95(0.69-1.29)
49
1.04(0.67-1.63)
2.1
148/1840
1.19 (0.88-1.62)
1.19(0.87-1.62)
51
1.34(0.84-2.14)
Q3
0.6
115/1831
0.89(0.65-1.22)
0.86(0.62-1.18)
34
0.76(0.47-1.23)
128.3
288/3662
1.22 (0.93-1.61)
1.15(0.87-1 52)
93
1.24(0.81-1.91)
13.5
149/1845
1.20(0.88-1.62)
1.14(0.84-1.54)
37
0.77(0.49-1.23)
0.6
126/1819
0.92(0.67-1.25)
0.91 (0.67-1.25)
44
0.96(0.61-1.52)
2.7
130/1819
1.12 (0.82-1.54)
111 (0 81-1.53)
47
1.30 (0.81-2.09)
Q4
0.7
123/1821
0.98(0.72-1.33)
0.98(0.72-1.34)
42
0.99(0.63-1.57)
17.3
126/1820
0.99(0.72-1.34)
0.94(0.69-1.29)
39
0.81 (0.51-1.29)
0.8
132/1830
0.97(0.71-1.31)
0.96(0.71-1.31)
44
0.94(0.60-1.49)
3.4
120/1818
0.97 (0.71-1.33)
0.95(0.69-1.31)
41
1.07 (0.66-1.74)
Q5
1.0
119/1821
0.93(0.69-1.27)
0.96(0.70-1.32)
35
0.86(0.53-1.38)
23.6
113/1835
0 95(0.69-1.31)
0.94(0.68-1.29)
43
0.96(0.61-1.50)
1.3
114/1834
0.85(0.62-1.16)
0.85(0.62-1.17)
29
0.64(0.39-1.06)
4.7
125/1844
1.07(0.78-1.47)
1.09 (0.79-1.49)
35
0.97(0.59-1.60)
Pfor
trend
0.44
0.49
0.33
0.06
0.19
0.32
0.60
0.42
0.57
0.29
0.29
0.07
0.77
0.79
0.54
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Exposure
ß-cryptoxanthin
(mg/day)'
Cases/person years
RR (95% Cl)'
RR (95% Cl)'
Advanced cases (n)'
RR(95%CI)'
Lycopene (mg/day)'
Cases/person years
RR (95% Cl)'
RR (95% Cl)'
Advanced cases (n)'
RR (95% Cl)'
Lutein/zeaxanthin
(mg/day)'
Cases/person years
RR (95% Cl)'
RR (95% Cl)'
Advanced cases (n)*
RR (95% Cl)'
01'
0.012
112/1826
1.00
1.00
36
1.00
0.1
128/1825
1.00
1.00
42
1.00
1.4
138/1812
1.00
100
40
1.00
02
0.045
105/1833
0.96 (0.70-1
0.94 (0.68-1
32
0.87 (0.52-1
0.4
104/1841
0.81 (0.59-1
0.79 (0.57-1
35
0.80 (0.49-1
1.9
123/1800
0.95 (0.70-1
0.91 (0.67-1
40
1.01 (0.63-1
Tafc/e 2 continued
.34)
.32)
.45)
.11)
.09)
.31)
.30)
.25)
.63)
03
0.1
115/1830
1.02(0.74-1.41)
1.01 (0.73-1.40)
35
0.91 (0.55-1.51)
0.7
150/1824
1.15(0.85-1.55)
1.08(0.80-1.47)
49
1.09 (0.69-1.71)
24
123/1843
0.86 (0.63-1.17)
0.86(0.63-1.17)
35
0.84(0.51-1.37)
0.2
136/1810
1.18(0.86-1.61)
1.16(0.85-1.60)
44
1.15(0.71-1.85)
1.1
134/1822
1.02(0.75-1.38)
0.99(0.72-1.36)
43
0.94(0.59-1.50)
29
139/1843
1.07(0.79-1.44)
1.05(0.77-1.43)
52
1 34(0.85-2 11)
05
04
174/1824
1.45(1.07-1.96)
1.41 (1.03-1.92)
63
1.56(0.99-2.44)
2.0
126/1810
1.03(0.76-1.40)
0.98(0 71-1.34)
41
0.92(0.57-1.47)
3.9
119/1824
0.91 (0.67-1.24)
0.91 (0.66-1.24)
43
1.16(0.73-1.85)
Pfor
trend
<0.01
<0.01
0.01
0.33
0.58
0.96
0.79
0.85
0.22
' Reference category;' Median intake (subcohort) in category;' Adjusted for age;' Adjusted for age, family
history of prostate cancer, socioeconomic status, and alcohol from white or fortified wine; * T3-4, M0, T0-4, M1.
Table 3 shows the results for vitamin supplement use. For use of supplements containing
vitamin A, vitamin C or supplements containing vitamin E, all estimated RRs were below
unity, although not statistically significant. The RRs (95 percent Cl) for users versus
nonusers were 0.65 (0.40-1.07), 0.80 (0.55-1.17) and 0.70 (0.42-1.15), respectively. The
estimates in the subgroup of advanced cases were similar to the estimated RRs for overall
prostate cancer risk. After exclusion of cases detected in the first two years of follow-up risk
estimates were similar to those presented in tables 2 and 3 (data not shown).
We also evaluated vitamin intake among nondrinkers and drinkers separately (table 4).
Among nondrinkers, a decreased risk was observed for intake of retinol. The estimate for
the highest vs lowest intake quintile was 0.23 with a 95 percent Cl of 0.08 to 0.61 and the
p-value for the trend test was <0.001. Also for intake of cx-carotene and ß-carotene inverse
associatons were observed among nondrinking subjects. Risk estimates (95 percent Cl) for
the same contrast were 0.60 (0.28-1.26) and 0.76 (0.36-1.61), respectively. Lycopene
intake showed decreased RRs in quintiles 2-4, but in the fifth quintile a RR of 0.90 was
observed. No clear associations were found for intake of vitamins C and E, ß-cryptoxanthin,
and lutein and zeaxanthin among nondrinkers. Among drinking subjects, mostly no
associations with prostate cancer risk were observed. Only for intake of ß-cryptoxanthin a
56 Chapter 3
significant positive association was noted (RR highest vs lowest intake quintile was 1.43,
95 percent Cl 1.01-2.01), and the trend test was also statistically significant (p-value <0.01).
Vitamin supplement use did not show clearly different associations with prostate cancer risk
among drinkers and nondrinkers. As for the overall analyses, inverse associations were
indicated.
fab/e 3: Rate rafros and 95% confidence /nterva/s for prosfate cancer accorrf/ng to gu/nfc'tes of/nte/ce of
supptemente, A/efter/ands Cohort Sfudy (J986-J992J.
Exposure
Any vitamin supplement
Cases/person years
RR (95% Cl)*
RR (95% Cl)'
Advanced cases (n)'
RR (95% Cl)'
Vitamin A supplement
Cases/person years
RR (95% Cl)'
RR (95% Cl)'
Advanced cases (n)*
RR (95% Cl)'
Vitamin C supplement
Cases/person years
RR (95% Cl)'
RR (95% Cl)'
Advanced cases (n)'
RR (95% Cl)'
Vitamin E supplement
Cases/person years
RR (95% Cl)'
RR(95%CI)'
Advanced cases (n)'
RR (95% Cl)'
No'
495/7085
1.00
1.00
167
1.00
618/8642
1.00
1.00
202
1.00
596/8381
1.00
1.00
197
1.00
618/8688
1.00
1.00
202
1.00
Yes
147/2037
0.95(0.75-1.20)
0.93(0.73-1.18)
43
0.79(0.55-1.14)
24/480
0.65(0.40-1.07)
0.65(0.40-1.07)
8
0.62(0.29-1.32)
46/741
0.83(0.57-1.20)
0.80(0.55-1.17)
13
0.64(0.35-1.18)
24/434
0.71 (0.43-1.16)
0.70(0.42-1.15)
8
0.70(0.33-1.49)
' Reference category;' Adjusted for age;' Adjusted for age, family history of prostate cancer, socioeconomic
status, and alcohol from white or fortified wine;' T3-4, M0, TO-4, M1.
Discussion
Among nondrinking subjects, we found inverse associations for intake of retinol, a -
carotene, and ß-carotene in relation to risk of prostate cancer. Among drinkers, intake of ß-
cryptoxanthin was positively associated with prostate cancer risk. In the total group of
prostate cancers a positive association was also noted for intake of ß-cryptoxanthin but for
the total group of cases few other associations were observed. Users of vitamin A, C and E
containing supplements showed nonsignificantly decreased risks, also in subgroups of
Vitamins, carotenoids and prostate cancer 67
drinkers and nondrinkers, for users of any vitamin supplements this was less clear. We
found no indication that vitamins or carotenoids are more strongly related to advanced
prostate tumors.
One important strength of the NLCS and other prospective studies is that exposure was
assessed before the diagnosis of cancer. Therefore, recall bias is not likely to have
influenced our results. Furthermore, selection bias is also unlikely because of the high
completeness of follow-up of cases and subcohort members (15, 22). Another strength is
that the consumption of vegetables and fruits, which contribute most to the intake of
vitamins, was extensively measured in the NLCS, using a validated semi-quantitative food
frequency questionnaire. Furthermore, also the assessment of intake of vitamin
supplements was shown to be reasonably well in our study (23). The large number of
prostate cancer cases in the NLCS is also an important strength. Besides overall analyses
with relatively high power, we were also able to investigate different subgroups based on
tumor characterization (advanced cases) or other characteristics of our study population
(nondrinkers vs drinkers). There are also some limitations to our study. For example,
misclassification of exposure might have occurred. However, from our validation study it
was concluded that the questionnaire could satisfactorily rank subjects according to the
intake of a number of macro- and micronutrients (16). If misclassification has occurred, we
expect this to be nondifferential and risk estimates are most likely biased towards the null
value. Another potential limitation is that we cannot exclude that residual confounding has
influenced our results. Finally, also chance may have played a role in our findings.
The ATBC Study, a randomized placebo-controlled trial among 29,000 male Finnish
smokers, was the first in which was reported that vitamin intake in relation to prostate
cancer risk differed between drinking and nondrinking subjects. In this trial supplementation
with ß-carotene decreased the risk of prostate cancer by 32 percent among nondrinkers.
Among drinkers, divided in tertiles, risk was increased by 25, 42 and 40 percent,
respectively (3). In our study, also inverse associations were observed among nondrinkers
whereas among drinkers mostly no associations were noted. Thus far, for several vitamins
and carotenoids inconsistencies in results from several studies exist (discussed below). If
an interaction between vitamin or carotenoid intake and alcohol consumption exists,
different proportions of drinkers and nondrinkers in previous studies may explain the
inconsistent results observed thus far. In the NLCS, a lower intake of several nutrients
among drinkers of alcoholic beverages compared to nondrinkers could not explain our
findings (data not shown). We do, however, not have an obvious biological explanation for
a potential interaction effect between vitamins or carotenoids and alcohol in prostate
cancer etiology. Therefore, mechanistic research is warranted in addition to epidemiologies!
studies.
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TaWe 4: Rate ratios fRR) and 95% confidence /nterva/s CCy for prosfafe cancer accord/ng to /nfa/ce of wfam/ns,
caroteno/ds and wfam/n supp/emenf use, /n subgroups of nondrinters and drinkers, Wefher/ands
Cohort Sfudy(?986-f992J.
Exposure
Retinol
1 (low)'
2
3
4
5 (high)
Vitamin C
1 (low)'
2
3 (high)
Vitamin E
1 (low)'
2
3
4
5 (high)
a-carotene
1 (low)'
2
3
4
5 (high)
ß-carotene
1 (low)'
2
3
4
5 (high)
ß-cryptoxanthin
1 (low)'
2
3
4
5 (high)
Nondrinkers
Cases/ Person
years in
subcohort
30/283
31/256
17/292
16/258
6/254
17/282
35/513
48/548
22/332
17/256
21/271
21/269
19/215
28/301
23/264
17/249
14/232
18/297
28/339
23/251
18/228
14/247
17/278
22/312
17/221
13/294
22/246
26/270
RR' (95% Cl)
1.00
1.37(0.68-2.73)
0.65(0.31-1.38)
0.69(0.32-1.50)
0.23(0.08-0.61)
P-trend <0.001
1.00
1.05(0.52-2.13)
1.36(0.69-2.68)
P-trend 0.21
1.00
0.88(0.40-1.92)
1.18(0.56-2.49)
1.27(0.60-2.65)
1.31 (0.60-2.83)
P-trend 0.22
1.00
0.78(0.38-1.60)
0.71 (0.34-1.50)
0.66(0.30-1.46)
0.60(0.28-1.26)
P-trend 0.08
1.00
1.03(0.51-2.11)
0.97 (0.46-2.07)
0.65(0.29-1.42)
0.76(0.36-1.61)
P-trend 0.17
1.00
1.17(0.52-2.62)
0.66(0.29-1.48)
1.11(0.52-2.35)
1.40(0.68-2.91)
P-trend 0.31
Drinkers
Cases/Person
years in
subcohort
108/1499
115/1561
95/1508
105/1534
109/1520
91/1493
207/3049
234/3080
106/1401
108/1560
123/1547
102/1544
93/1569
103/1458
110/1542
108/1526
117/1579
94/1517
89/1427
124/1549
109/1560
103/1540
107/1545
86/1457
87/1581
101/1506
112/1537
146/1541
RR'(95%CI) '
1.00
0.98(0.70-1.37)
0.89 (0.63-1.26)
1.02(0.73-1.43)
1.11(0.79-1.56)
P-trend 0.41
1.00
1.06(0.78-1.45)
1.13(0.83-1.53)
P-trend 0.31
1.00
1.11(0.79-1.56)
1.14(0.82-1.60)
0.91 (0.65-1.29)
0.91 (0.64-1.29)
P-trend 0.23
1.00
0.99(0.70-1.39)
0.97(0.69-1.37)
1.02(0.72-1.42)
0.91 (0.64-1.29)
P-trend 0.62
1.00
1.25(0.89-1.77)
1.13(0.79-1.60)
1.02(0.71-1.45)
1.15(0.81-1.63)
P-trend 0.93
1.00
0.94(0.65-1.35)
1.09(0.76-1.57)
1.20(0.84-1.71)
1.43(1.01-2.01)
P-trend <0.01
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Exposure
Lycopene
1 (low)'
2
3
4
5 (high)
Lutein/zeaxanthin
1 flow)'
2
3
4
5 (high)
Any vitamin supplement
No'
Yes
Vitamin A supplement use
No'
Yes
Vitamin C supplement use
No'
Yes
Vitamin E supplement use
No'
Yes
Nondrinkers
Cases/ Person
years in
subcohort
39/366
13/289
18/201
12/279
18/208
26/331
22/296
13/295
22/214
17/208
75/990
25/353
96/1248
4/94
92/1227
8/116
97/1259
3/84
fab/e 4 continued
RR' (95% Cl)
1.00
0.36 (0.17-0.77)
0.68(0.32-1.43)
0.28(0.12-0.65)
0.90(0.43-1.89)
P-trend 0.14
1.00
0.99 (0.48-2.03)
0.58(0.26-1.29)
1.31 (0.62-2.78)
1.13(0.52-2.44)
P-trend 0.53
1.00
0.79(0.45-1.40)
1.00
0.49(0.15-1.58)
1.00
0.86(0.35-2.14)
1.00
0.46(0.13-1.70)
-- - •. . - ...
Drinkers
Cases/Person
years in
subcohort
88/1389
88/1526
128/1617
121/1515
107/1575
110/1453
99/1485
110/1509
114/1585
99/1590
410/5957
122/1665
512/7248
20/373
494/7015
38/606
511/7284
21/337
RR' (95% Cl)
1.00
0.95(0.66-1.37)
1.25(0.88-1.76)
1.24(0.87-1.76)
1.05 (0.74-1.51)
P-trend 0.28
1.00
0.92(0.65-1.31)
0.94(0.67-1.32)
1.02(0.73-1.43)
0.88(0.63-1.24)
P-trend 0.63
1.00
0.98(0.76-1.28)
1.00
0.68(0.39-1.18)
1.00
0.79(0.52-1.19)
1.00
0.77(0.45-1.32)
' Adjusted for age, family history of prostate cancer, and socioeconomic status;' Reference category.
Vitamin A is involved in cell differentiation and since lack of differentiation is a feature of
cancer cells, a protective effect vitamin A on cancer development may be expected (1).
Retinol is the physiologically active form of vitamin A, and retinoids may act as suppressing
agents retarding neoplasia development, or as inhibitors of tumor promotion (1). In our
study, protective effects of supplements containing vitamin A were suggestive. In three
previous prospective studies no association for vitamin A intake (8, 24) or vitamin A
supplements (25) was shown. In one cohort study protective effects were indicated for
serum levels of vitamin A (26). Case-control studies on vitamin A in relation to prostate
cancer risk have also shown equivocal findings (10, 27-37). In our study we found no
association between intake of retinol and overall prostate cancer risk but among
nondrinkers a strong inverse association was observed. Other cohort studies found no
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association for intake (24) or serum levels (9, 38), but several cohort studies indicated a
positive association for both intake (8) and serum levels (39-41) of retinol and for serum
levels in two cohort studies also a protective effect was observed (42, 43). Case-control
studies on retinol were equally diverse in results. In two case-control studies increased
associations for intake levels were only observed for cases aged 70 years or older (44, 45),
and in two other case-control studies inverse associations were indicated for intake (29)
and serum levels (46).
Vitamin C is mostly known for its antioxidant capacity (1, 47). For prostate cancer, however,
mostly no effect of vitamin C intake levels (8, 25), serum levels (39), or vitamin C
supplements (25) was observed, and also in the NLCS no association was apparent. Only
for supplements containing vitamin C a slight nonsignificant decrease in risk was observed.
One cohort study indicated an increased risk only in the highest quartile of intake, no trend
in risk was observed (48). Most case-control studies reported null associations for vitamin C
in relation to risk of prostate cancer (28, 29, 31, 35, 36, 44, 49-52). In two case-control
studies, estimated risks suggested a positive association between vitamin C intake and
prostate cancer risk (30, 37).
The antioxidative property of vitamin E might be a mechanism by which (prostate) cancer
incidence is reduced (3, 53). Also, an enhancement of immune functions might be a
pathway (3). In the ATBC-trial, a 32 percent decrease (95 percent Cl -47 to -12 percent) in
prostate cancer incidence was observed for subjects receiving a-tocopherol compared with
those not receiving it (3). In the NLCS, however, no effect of dietary intake of vitamin E was
found but subjects taking supplements containing vitamin E showed nonsignificant
decreased risks. No associations were shown in other cohort studies using intake (8, 25) or
serum levels (9, 42, 54, 55) or vitamin E supplements (25). Also in a cohort analysis of the
ATBC Study between baseline vitamin E from the diet and serum vitamin E (a-tocopherol)
and prostate cancer risk no associations were apparent (53). In two case-control studies an
inverse association has been shown for vitamin E, but only in the highest category of intake
(50) or serum level (46). In other case-control studies no clear alteration in risk was noted
(29, 49, 56).
Beta-carotene has long been known for its antioxidative properties and is the most
investigated carotenoid in prostate cancer etiology. Also, via its conversion to vitamin A or
via an enhancement of immunologic function a protective effect of this carotenoid may be
explained (1). In the NLCS, no clear associations emerged for intake of ß-carotene and
overall prostate cancer risk. In one out of the three chemopreventive trials, an adverse
effect of ß-carotene was observed (3), in the other two trials ß-carotene showed no effect
on prostate cancer risk (4, 5). In five other cohort studies, intake (8, 24, 25, 48) or serum
levels (42) of ß-carotene were also not associated with risk of prostate cancer. In two cohort
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studies an increased risk was observed for serum levels (9, 40). Case-control studies were
also inconsistent, varying from no association (29, 33, 45) to inverse associations (32, 57),
also for serum levels (46), and positive associations only for men aged 70 years (44, 45) or
68 years (30) and older.
Few studies have evaluated specific carotenoids besides ß-carotene in relation to prostate
cancer occurrence. For intake of ß-cryptoxanthin a positive association was observed in our
study. In one cohort study, also a positive association was found (for serum levels), but the
trend test was not significant in that study (9) while in another prospective cohort study no
association for intake of ß-cryptoxanthin was noted (8). In a case-control study in Hawaii
(10) a positive association was noted for consumption of papaya, and ß-cryptoxanthin is a
common carotenoid in papaya (7). Further research into this issue is warranted. A
significant inverse trend in risk was observed for intake of lycopene in the Health
Professionals Follow-up Study (8), but in another study no association was observed for
serum levels (9). In two nested case-control studies, serum lycopene levels were also
inversely related to prostate cancer risk, but nonsignificantly and no trend in risk was
observed (42, 54). A role of lycopene in prostate cancer carcinogenesis is not
inconceivable because lycopene is an efficient scavenger of singlet oxygen (8, 58).
Comparable to our results, in two other studies with prospectively collected exposure data,
intake (8) and serum levels (9) of both a-carotene and lutein were found not to be related
to prostate cancer risk.
Inverse associations for users of vitamin supplements were suggestive but statistically
nonsignificant in our study. Since it has been shown that vitamin supplement users have
cancer-related behaviours that are different from non-users of vitamin supplements (59),
confounding might explain some of our findings regarding vitamin supplement use. For
example, in the United States supplement users have been shown to have had a prostate-
specific antigen test twice as likely as nonusers, to take regularly aspirin, more often
exercise, and eat more vegetables and fruit and less fat (59). However, during our follow-
up period prostate-specific antigen testing was not a common screening routine in the
Netherlands and therefore we should not expect a confounding effect of this factor.
Moreover, if supplement users more often had a prostate-specific antigen test an increased
risk of prostate cancer would be expected, while we observed a decrease in risk. In our
study no associations between consumption of vegetables and fruit and risk of prostate
cancer was shown (19) and also for fat intake no clear associations emerged, therefore, we
do not expect a confounding effect of these dietary factors. Furthermore, residual
confounding by aspirin use or physical activity cannot be excluded but since these factors
are not known to be strong risk factors for prostate cancer a large confounding effect is not
suspected.
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In summary, associations between vitamins and carotenoids and risk of overall prostate
cancer were not clearly indicated in our study. Nevertheless, for intake of retinol, a-
carotene and ß-carotene a protective effect was suggested among nondrinking subjects.
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Abstract
Prostate cancer risk in relation to consumption of animal products, and intake of calcium
and protein was investigated in the Netherlands Cohort Study. At baseline in 1986, 58,279
men aged 55-69 years completed a self-administered 150-item food frequency
questionnaire and a questionnaire on other risk factors for cancer. After 6.3 years of follow-
up, 642 prostate cancer cases were available for analysis. In multivariate case-cohort
analyses adjusted for age, family history of prostate cancer and socioeconomic status, no
associations were found for consumption of fresh meat, fish, cheese and eggs. Positive
trends in risk were found for consumption of cured meat and milk products (p-values 0.04
and 0.02, respectively). For calcium and protein intake, no associations were observed. The
hypothesis that dietary factors might be more strongly related to advanced prostate tumors
could not be confirmed in our study. We conclude that, in this study, animal products are
not strongly related to prostate cancer risk.
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Introduction
Remarkable geographic variation exists as regards clinical prostate cancer incidence.
Annual age-adjusted incidence rates of approximately 1 per 100,000 are found in China
while in the US rates up to 102 per 100,000 are found for blacks. Rates for whites in the US
vary from about 45 to 65 per 100,000. In Western Europe most incidence rates are around
20-30 per 100,000 although also some variation exists (1). The prevalence of latent
prostatic carcinomas is estimated to be similar in areas with high and with low total prostate
cancer incidence rates (2, 3). Because of these variations in incidence rates worldwide,
environmental factors, particularly dietary factors, are supposed to be related to risk of
prostate cancer (4). Consumption of animal products like meat, fish, milk, dairy products
and eggs differs between countries with high and low prostate cancer incidence rates and
may, therefore, be an explanation for the observed differences in incidence rates.
Results from several cohort (5-14) and case-control studies (15-28) are available on
consumption of animal products and prostate cancer risk. However, the role of animal
products remains unclear since contradictory results from both types of studies have been
reported.
A potential effect of animal products on prostate cancer risk is often explained by the fat
contained in the product (3, 29-31). Increased fat intake might lead to increased
testosterone levels and this might, eventually, lead to increased cell division and activation
of proto-oncogenes and deactivation of tumor suppressor genes (32). However, there is no
conclusive evidence to the role of fat in prostate cancer etiology (31). Therefore, other
hypotheses on the mechanism of action are also plausible. For example, it has been
proposed that 1,25(OH)2D levels, which is a vitamin D metabolite, are protective against
prostate cancer (33, 34) and intake of calcium, for which dairy products are a major dietary
source, may increase prostate cancer risk by suppressing 1,25(OH)2D levels (35). Finally,
another possibility is that meat may get burned at high temperatures and heterocyclic
amines are produced which are mutagenic and may be carcinogenic (36).
Several authors suggest that dietary factors may play a greater role in accelerating tumor
growth than in initiating cancer (4, 29, 31) but thus far it is not clear whether this is true for
animal products. We further investigated animal products consumption as well as calcium
intake in relation to prostate cancer risk in the Netherlands Cohort Study (NLCS). To
evaluate the effect of a diet containing mostly animal foods or mostly plant-based foods, the
intake of protein (total, animal and vegetable) was also evaluated in this study.
Materials and methods
The cohort
The study design has been described in detail elsewhere (37). In brief, the NLCS was
initiated in September 1986. The male cohort consists of 58,279 men aged 55-69 years
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who completed a self-administered questionnaire on usual diet, and other risk factors for
cancer. The case-cohort approach (38) was used for data processing and analysis. In a
case-cohort approach, cases are derived from the entire cohort (providing numerator
information for calculation of cancer incidence rates), while accumulated person years at
risk in the total cohort are estimated using a random subcohort sample (providing
denominator information for the rates). The male subcohort was sampled directly after
identification of the total cohort and includes 1,688 men. The method of cancer follow-up
has also been described previously (39). In short, incident prostate cancer cases were
detected by computerized record linkage with all nine cancer registries in The Netherlands,
and with the Dutch national data base of pathology reports (PALGA). The subcohort has
been followed up biennially for vital status information. Completeness of cancer follow-up
was at least 96 percent (40) and follow-up of person years in the subcohort was complete.
After a follow-up period of 6.3 years (September 1986-December 1992), 704 incident,
microscopically confirmed, primary prostate cancer cases were detected. During this period,
systematic screening for prostate cancer was not used in the Netherlands.
The questionnaire
Usual consumption of food and beverages during the year preceding the start of the study
was assessed with a 150-item semiquantitative food frequency questionnaire (41).
Participants were asked to report their frequency of consumption of 14 different individual
fresh meat items (several cuts of beef and pork, minced meat, chicken, liver, other meat),
fish, 14 milk and milk items (whole, low-fat and skimmed milk, cream, buttermilk, chocolate
milk, dry curd, whole and skimmed yogurt, other items), and eggs. For fresh meat items,
participants also had to indicate their usual amount of consumption in grams (as bought,
i.e., based on raw meat). For four cured meat items (boiled ham, bacon, lean meat products
including smoked beef, and 'other sliced cold meats') and two cheese items (fat cheese and
low-fat cheese), subjects had to indicate how many slices of bread they ate with the
particular product on it. For other items, subjects had to indicate the consumption amount in
natural or household units (e.g. glass). Mean daily consumption (g/day) of the items was
calculated by multiplying frequency of consumption by amount of consumption with
standard portion sizes for the items that were asked in natural or household units. Calcium
and protein intake were computed using the computerized Dutch food composition table
(42). The questionnaire has been validated against a 9-day diet record. For the exposures
under study the Spearman correlation coefficients betweeen questionnaire and the dietary
record were as follows: fresh meat 0.46, cured meat 0.54; milk and milk products 0.60;
cheese 0.61; fish 0.53; eggs 0.61. The Pearson correlation coefficient (energy and sex-
adjusted) for calcium was 0.62 and for total protein, vegetable protein and animal protein
the estimates were 0.59, 0.68 and 0.64, respectively (41).
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Data analysis
In the subcohort, prevalent cases other than skin cancer were excluded, leaving 1630 ^
subcohort members for analysis. Furthermore, according to criteria published before (41),
subjects with incomplete or inconsistent dietary data were excluded; 642 men with prostate
cancer and 1525 male subcohort members remained for analysis.
Intake of calcium and protein was adjusted for energy by regression analysis (43). Mean
intake levels of the different exposure variables and other characteristics were compared
between prostate cancer cases and male subcohort members. Furthermore, mean intakes
of fresh meat, fish, cured meat, milk and milk products, cheese, eggs, calcium and protein
were compared in categories of potential confounders. Variables that were considered as
potential confounders were age, a family history of prostate cancer, and socioeconomic
status. Total energy and total fat intake were not considered as potential confounding
factors because no association with prostate cancer risk was observed in our study (data
not shown). The same applies to vegetable and fruit consumption (44). Energy was,
however, included in the analyses for calcium and protein, whereas total protein was
included in the analyses of animal and vegetable protein to assess the substitution effects
of the two sources of protein. Rate ratios (RRs) and 95% confidence intervals (95% Cl)
were computed for quintiles or categories of exposure variables, as well as for continuous
variables, using the GLIM statistical package (45). Exponentially distributed survival times
were assumed in the follow-up period. Since standard software was not available, specific
macros were developed to account for the additional variance introduced by using the
subcohort instead of the entire cohort (46). Tests for trend were based on likelihood ratio
tests. Throughout this report two-sided P-values are used. Age-adjusted and multivariate
analyses were conducted. In order to evaluate the independent contribution of each specific
type of fresh meat, cured meat, and dairy items analyses were done with the inclusion of
total fresh meat, total cured meat, and total dairy consumption, respectively, in the
multivariate models. Furthermore, analyses were done for localized (TO-2, MO) and
advanced (T3-4, MO; TO-4, M1) prostate cancer cases separately. This classification is
based on the TNM staging system. To evaluate whether preclinical symptoms may have
influenced results, additional analyses with exclusion of cases detected during the first two
years of follow-up were conducted.
Results
The mean intake of fresh meat, fish, cured meat, milk and milk products, cheese, eggs,
calcium and protein among cases and subcohort members is shown in Table 1. Mean
intake of none of these food products differed markedly between cases and subcohort
members. The distribution of potential confounding factors is also shown in this table.
Cases are older than subcohort members and more often have a positive family history of
prostate cancer. Furthermore, cases more often have a high socioeconomic status
Animal products, calcium, protein and prostate cancer 69
compared to subcohort members. Consumption of cured meat was highest among the
youngest men and protein intake was highest among men aged 60-64 years. Men in the
lowest category of socioeconomic status consumed more fresh meat, cured meat and eggs,
and less cheese. Men with a positive family history of prostate cancer consumed more
calcium than men without such a family history. Mean consumption of animal products or
protein intake differed not between subjects with and without a family history of prostate
cancer (data not shown). *
Tab/e ): Description of mean da/7y /ntefce of an/ma/ products, profe/n and ca/c/um and ofher characteristics /n
pros/ate cancer cases and subcohort members, /vetherfands Cohort S/t/dy ff 986-7992).
Characteristics
Exposure vanab/es (c/dayj
Fresh meat and poultry'
Fish
Cured meat'
Milk and milk products'
Cheese*
Eggs
Calcium (mg/day)*
Total protein*
Vegetable protein'
Animal protein'
Potenf/a/ con/bund/r/g; variab/es
Age (years)
Family history of prostate cancer (%yes)
Highest educational level (%)"
low
medium
high
Cases (n=642)
mean
102.9
15.0
15.2
307.1
23.0
16.5
951.7
75.3
27.6
48.2
63.9
4.4
44.4
34.6
20.2
SD
39.6
17.2
15.0
190.1
18.7
12.1
274.7
10.9
6.0
11.1
3.8
Subcohort
(n=1525)
mean
105.2
14.2
15.7
308.0
22.8
17.1
943.7
75.4
27.9
48.1
61.4
2.7
46.8
34.8
17.8
SD
43.1
16.0
17.3
215.0
19.4
12.5
292.4
11.4
6.0
11.8
4.2
' This includes beef, pork, minced meat (beef & pork), poultry, liver, and 'other meaf (raw weight);' This includes
boiled ham, bacon, lean meat products (including smoked beef), and 'other sliced cold meats' (several types of
sausages);' This includes fermented milk products, and nonfermented milk products; * This includes fat cheese,
and low-fat cheese;' Energy-adjusted; * There was missing information for 0.8% (cases) and 0.7% (subcohort
members); low is defined as primary school with/without lower level vocational education, medium as secondary
school or medium level vocational education, high as university or higher level vocational education.
RRs for quintile or categorized variables for clusters of food items are shown in Table 2. For
total fresh meat and fish consumption no associations with prostate cancer were observed.
For both total cured meat and milk and milk products a positive trend in risk was observed
(p-values for trend test were 0.04 and 0.02, respectively). The RRs (95% Cl) were 1.37
(1.00-1.89) for cured meat and 1.12 (0.81-1.56) for milk and milk products for the highest vs
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lowest quintile of consumption. Only the RR in the fourth quintile of consumption of milk and
milk products was significantly increased (RR=1.63, 95% Cl: 1.20-2.20). In the age-adjusted
analysis, consumption of cheese showed a positive trend in risk (p=0.04), this p-value was
0.09 in the multivariate analysis. The RR for the highest vs the lowest category of
consumption was 1.21 (95% Cl: 0.87-1.70). Egg consumption showed no association with
prostate cancer risk. After exclusion of cases diagnosed in the first two years of follow-up,
RRs were virtually the same. •- •*••:<
Taofe 2: Rafe rafos (RRsJ and 95% confidence mterva/s (95% C/j forprosfafe cancer accord/ng to gu/nWes or
categories or consumpfion of mea/, fen, processed mea/, m///( and da/>y, cheese, and eggs,
Nefher/ands Cohort Sfudy (J986-J992J.
Exposure
Fresh meat and poultry
Median intake'
Cases/Person years
RR (95% Cl)'
RR (95% Cl)'
Fish
Median intake"
Cases/Person years
RR (95% Cl)'
RR (95% Cl)'
Cured meat
Median intake'
Cases/Person years
RR (95% Cl)'
RR (95% Cl)'
Milk and milk products
Median intake'
Cases/Person years
RR (95% Cl)'
RR (95% Cl)'
Cheese
Median intake'
Cases/Person years
RR (95% Cl)'
RR (95% Cl)'
Eggs
Median intake''
Cases/Person years
RR (95% Cl)'
RR (95% Cl)'
QV
56
128/1820
1.00
1.00
0
162/2238
1.00
1.00
0
118/1849
1.00
1.00
74
114/1860
1.00
1.00
2
140/2261
1.00
1.00
5
197/2530
1.00
1.00
Q2
85
138/1919
1.08(0.80-1
1.08(0.79-1
5
135/2115
0.85 (0.64-1
0.83 (0.62-1
5
137/1907
1.18(0.87-1
1.22(0.90-1
179
112/1835
1.08(0.79-1
1.11 (0.80-1
13
121/1620
1.29(0.95-1
1.27(0.94-1
14
208/3243
0.90 (0.70-1
0.89 (0.69-1
.46)
.47)
.13)
.11)
.61)
.67)
.49)
.53)
.74)
.73)
.15)
.14)
Q3
102
144/1787
1.23(0.91-1.67)
1.27(0.93-1.73)
14
119/1874
0.95(0.70-1.28)
0.95(0.70-1.29)
11
140/1703
1.46(1.07-1.99)
1.50(1.09-2.06)
271
132/1803
1.22(0.89-1.67)
1.25(0.91-1.71)
19
119/1607
1.16(0.86-1.58)
1.15(0.84-1.56)
29
237/3349
0.96 (0.76-1.22)
0.96(0.75-1.22)
Q4
123
121/1766
105(0.77-1.43)
1.12(0.82-1.53)
32
226/2895
106(0.82-1.37)
1.03(0.80-1.34)
19
124/1880
1 14(0.84-1.57)
1 18(0.86-1.62)
376
172/1824
1 60 (1.19-2.17)
1.63(1.20-2.20)
27
175/2371
1.34(1.01-1.77)
1.28(0.97-1.70)
Q5
158
111/1830
1.01 (0.73-1.39
1.07(0.77-1.47)
36
123/1783
1.32(0.96-1.81)
1.37(1.00-1.89)
566
112/1800
1.09(0.79-1.50)
1 12 (0.81-1 56)
43
87/1264
1.26 (0.90-1.76)
1.21 (0.87-1.70)
Pfor
trend
0.98
0.52
0.32
0.41
0.07
0.04
0.03
0.02
0.04
0.09
0.72
0.71
' Reference category;' Median intake (g/day) in subcohort; cutpoints fresh meat and poultry 73,93,108,137; fish
0,10,20; cured meat 2,8,14,25; milk and milk products 139,220,321,460; cheese 7,14,21,37; eggs 7,14; *
Adjusted for age;' Adjusted for age, family history of prostate cancer, and socioeconomic status; * Categories
instead of quintiles.
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Table 3 shows results for animal products evaluated as continuous variables, for all tumors
and separately for localized and advanced prostate tumors. Within the cluster of fresh meat
and poultry items, none of the continuous variables was clearly associated with risk of
prostate cancer. Also in subgroups of localized and advanced prostate tumors mostly no
association existed. Only for consumption of liver an inverse association with advanced
prostate tumors was observed (RR per 5 g increments.79, 95% Cl: 0.63-0.99). An item on
horsemeat, lamb and mutton and an item on consumption of veal were included in the other
meat category. The RR (95% Cl) per 5 g for consumption of horsemeat, lamb and mutton
was 1.11 (1.02-1.21) and 1.07 (0.99-1.15) for consumption of veal (data not shown). Total
fish and total cured meat consumption were not associated with overall prostate cancer risk,
nor with risk of localized and advanced tumors. Evaluated as continuous variables, none of
the individual cured meat items was strongly related to prostate cancer risk. Nevertheless,
in categorized analyses a positive trend in risk was noted for consumption of 'other sliced
cold meats' (p-value trend test=0.02). For the highest vs the lowest consumption category a
RR of 1.37 (95% Cl: 1.03-1.83) was found in the multivariate analysis. This increase in risk
was only found in the subgroup of localized prostate tumors (RR for the same
contrast=1.44, 95% Cl: 0.95-2.20) and not for advanced prostate tumors (data not shown).
Fermented whole milk showed a borderline significant inverse association with overall
prostate cancer risk (RR per 50 g=0.87, 95% Cl: 0.76-1.00), and also for advanced tumors
an inverse association was suggested (RR per 50 g=0.84, 95% Cl: 0.66-1.05). For none of
the individual milk items except consumption of whole yogurt, associations with prostate
cancer risk were observed. In the continuous model, the RR for consumption of whole
yogurt per 50 g increment was 0.88 (95% Cl: 0.76-1.01). Cheese consumption showed no
association with overall prostate cancer risk, but was positively associated with localized
prostate tumors (RR per 20 g=1.20, 95% Cl: 1.06-1.37). Finally, consumption of eggs was
inversely associated with advanced prostate tumors (RR per 20 g=0.70, 95% Cl: 0.53-0.93).
The results for calcium and protein intake are shown in Table 4. For intake of calcium and
total protein no associations with prostate cancer risk were noted. Controlling for total
protein, intake of vegetable protein showed RRs below one in all four categories, but none
of the RRs was statistically significant. All RRs for intake of animal protein were above one.
Only the RR in the fourth quintile of intake was statistically significant (RR=1.52, 95% Cl:
1.01-2.30). For both sources of protein intake, no trend in risk was found. We also
evaluated calcium and protein intake in subgroups of localized and advanced prostate
tumors. As for the animal products, there was no clear tendency for stronger associations
with advanced prostate tumors.
Discussion
Overall consumption of fresh meat and poultry, fish, cheese and eggs showed no
association with prostate cancer risk in the NLCS. The observed positive trend in risk for
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quintiles of total cured meat consumption could be explained by a positive association with
consumption of 'other sliced cold meats'. For most clusters of milk items, or individual milk
items no strong associations were observed, but consumption of whole yogurt might be
associated with a decreased prostate cancer risk. Intake of calcium and protein was not
associated with risk of prostate cancer in our study. Finally, we found no clear evidence for
a stronger association of various products with advanced prostate cancer.
TaWe 3: Rate rafos (RRsJ and 95% confidence /nterva/s f 95% C/j for prostete cancer for conffnuous vanabfes
of consumpfion of an/ma/ producte, for a// cases and separate/y for focafeed (TO-2, MQ) and advanced
(T3-4, MO; FO-4, M?j lumors, Afe(ner/ands Conorf S/udy ff986-f992J.
Exposure
Fresh meat and poultry
beef
pork'
minced meat (beef&pork)'
chicken*
liver'
other meat'
Fish
Cured meat
boiled ham*
bacon*
lean meat products'
other sliced cold meat'
Milk and milk products
whole milk, fermented'
low-fat milk, fermented'
whole milk'
low-fat milk*
Cheese
cheese'
low-fat cheese^
Eggs
Intake in
subcohort
(g/day)
Mean (SD)
105.2 (43.1)
27.4 (23.6)
40.6(31.1)
20.0 (19.0)
13.4(15.0)
2.1 (4.7)
2.8 (6.0)
14.2 (16.0)
15.7 (17.3)
5.4(8.1)
2.0(5.1)
2.4 (5.4)
6.0 (10.2)
308.0(215.0)
15.9(40.1)
68.4 (107.5)
136.0 (164.4)
87.8(139.4)
22.8(19.4)
21.1(18.6)
1.7(7.6)
17.1 (12.5)
Incre-
ment
25
25
25
25
25
5
5
25
15
15
15
15
15
50
50
50
50
50
20
20
20
20
All tumors
(n=642)
RR(95%CI)'
1.00(0.86-1.16)
1.00(0.89-1.12)
1.06(0.96-1.18)
0.86(0.74-1.01)
1.00(0.84-1.18)
0.92(0.82-1.04)
1.06(0.99-1.15)
1.06(0.91-1.22)
1.03(0.94-1.12)
0.94(0.73-1.21)
0.80(0.57-1.13)
0.93(0.68-1.27)
1.18(0.96-1.44)
1.00(0.98-1.03)
0.87(0.76-1.00)
1.01 (0.96-1.07)
1.00(0.96-1.03)
1.01 (0.97-1.05)
1.02 (0.93-1.13)
0.99(0.76-1.30)
1.01 (0.77-1.32)
0.95(0.81-1.11)
Localized
tumors (n=226)
RR (95% Cl)'
0.99(0.91-1.08)
0.95(0.80-1.12)
1.16(1.00-1.34)
0.84(0.66-1.07)
0.89(0.68-1.16)
0.99(0.85-1.17)
1.04(0.93-1.16)
0.91 (0.73-1.15)
1.03(0.91-1.17)
1.00(0.69-1.45)
0.79(0.47-1.33)
0.78(0.48-1.29)
1.22(0.90-1.65)
1.01 (0.98-1.05)
0.96(0.79-1.15)
1.01 (0.94-1.09)
0.97(0.92-1.03)
1.03(0.97-1.09)
1.20 (1.06-1.37)
0.94(0.68-1.29)
1.07(0.78-1.47)
0.99(0.78-1.24)
Advanced
tumors (n=213)
RR (95% Cl)'
1.00(0.91-1.09)
0.92(0.77-1.10)
1.06(0.91-1.23)
0.90(0.71-1.14)
1.11(0.87-1.42)
0.79 (0.63-0.99)
1.09(0.98-1.21)
1.08(0.87-1.33)
1.00(0.88-1.14)
0.95(0.64-1.40)
1.04(0.66-1.65)
1.01(0.63-1.60)
1.01 (0.74-1.39)
0.99(0.95-1.03)
0.84(0.66-1.05)
1.03(0.95-1.11)
1.00(0.95-1.06)
0.99(0.93-1.06)
0.92(0.78-1.08)
1.05(0.66-1.68)
0.95(0.60-1.52)
0.70 (0.53-0.93)
' Adjusted for age, family history of prostate cancer, and socioeconomic status; 'Additional adjustment for
consumption of total fresh meat and poultry;' Additional adjustment for consumption of total cured meat; *
Additional adjustment for consumption of total milk and milk products; * Additional adjustment for consumption of
total cheese.
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Tab/e 4: Rate rafios (RRsJ and 95% confidence /nterva/s (95% C/) forprosfate cancer according to gu/nWes of
/ntefce of energy-adyusted ca/c/um and energy-ad/usted prote/n, for a// cases and separafe/y for
focaftzed f TO-2, MOJ and advanced (73-4, MO; fO-4, MfJ prostete humors, A/efher/ands Cohort Sfudy,
(J986-7992J.
Exposure
Calcium
Median intake mg/da/
Cases/Person years
RR (95% Cl)'
RR (95% Cl)'
Localized tumors (n)
RR(95%CI)'
Advanced tumors (n)
RR (95% Cl)'
Total protein
Median intake; g/day*
Cases/Person years
RR (95% Cl)'
RR (95% Cl)'
Localized tumors (n)
RR (95% Cl)'
Advanced tumors (n)
RR (95% Cl)'
Vegetable protein
Median intake; g/day*
Cases/Person years
RR (95% Cl)'
RR (95% Cl)>
Localized tumors (n)
RR (95% Cl)*
Advanced tumors (n)
RR(95%CI)*
Animal protein
Median intake; g/day*
Cases/Person years
RR (95% Cl)'
RR (95% Clf
Localized tumors (n)
RR (95% Cl)'
Advanced tumors (n)
RR (95% Cl)>
QV
602
120/1821
1.00
1.00
47
1.00
44
1.00
62
128/1839
1.00
1.00
51
1.00
46
1.00
22
143/1827
1.00
1.00
53
1.00
38
1.00
34
112/1825
1.00
1.00
44
1.00
43
1.00
Q2
780
126/1845
1.07(0.79-1.47)
1.10(0.80-1.51)
30
0.69(0.42-1.13)
46
1.08(0.69-1.70)
69
121/1836
1.03(0.75-1.41)
1.04(0.76-1.43)
34
0.76(0.47-1.22)
43
1.04(0.66-1.64)
25
129/1833
0.87(0.64-1.18)
0.86(0.63-1.17)
46
0.86 (0.55-1 33)
43
1.08(0.67-1.74)
42
137/1843
1.21 (0.88-1.65)
1.29 (0.92-1.81)
40
0.94(0 57-1.55)
49
1.21 (0.75-1.95)
Q3
911
127/1840
1.03 (0.75-1.41)
1.04(0.76-1.42)
45
0.96(0.61-1.50)
37
0.79(0.49-1.27)
75
134/1821
1.10(0.81-1.50)
1.12(0.82-1.53)
40
0.87(0.55-1.38)
48
1.08(0.69-1.69)
27
139/1813
0.99(0.74-1.34)
1.00(0.74-1.36)
42
0.85(0.54-1.33)
57
155(0.98-2.44)
47
121/1819
1.11(0.81-1.53)
1.16 (0.80-1.68)
44
1.08(0.64-1.83)
41
0.96(0.56-1.65)
Q4
1064
140/1817
1.20(0.88-1.64)
1.21 (0.89-1.66)
46
1.04(0.67-1.63)
46
1.06(0.67-1.66)
81
135/1792
1.31 (0.96-1.79)
1.35(0.98-1.84)
49
1.27 (0.82-1.96)
38
1.02(0.64-1.64)
30
110/1812
0.83(0.61-1.13)
0.83(0.61-1.14)
35
0.73(0.46-1.17)
30
0.85(0.51-1.43)
53
150/1812
1.42 (1.04-1.93)
1.52(1.01-2.30)
45
1.13(0.62-2.05)
47
1.11 (0.61-2.04)
Q5
1329
129/1800
1.07(0.79-1.47)
1.09(0.79-1.50)
56
1.21 (0.79-1.86)
37
0.83(0.52-1.34)
90
124/1834
1.09(0.80-1.48)
1.10(0.81-1.51)
50
1 13(0.73-1.74)
35
0.83(0.51-1.33)
35
121/1839
0.92(0.67-124)
0.90(0.66-1.23)
48
0.96(0.62-1.48)
42
1.19(0.74-1.92)
64
122/1823
1.16(0 84-159)
1.32(0.76-2.29)
51
1.26(0.58-2.75)
30
0.71 (0.31-1.63)
Pfor
trend
0.36
0.34
0.10
0.45
0.15
0.11
0.13
0.49
043
0.37
063
0.81
0.11
0.09
0.44
0.61
' Reference category; * Median intake in subcohort; cutpoints calcium 709,848,984,1164; total protein 66,72,
77,84; vegetable protein 23,26,29,32; animal protein 38,45,50,58;' Adjusted for age;* Adjusted for age,
family history of prostate cancer, socioeconomic status, and total energy intake; * Adjusted for age, family history
of prostate cancer, socioeconomic status, total energy intake, and total protein intake.
The NLCS is a prospective cohort study specifically designed to evaluate the relation
between diet and cancer. An important strength of prospective studies is that recall bias is
avoided because of the prospective nature of these studies. Selection bias is also not likely
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to have taken place because of the high completeness of follow-up of subcohort members
(40, 47). A 150-item semi-quantitative food frequency questionnaire was used to estimate
the usual consumption of fresh meat and poultry, fish, cured meat, milk and milk products,
cheese and eggs during the year preceding the start of the study. The questionnaire was
validated against a 9-day dietary record. Based on the Spearman correlation coefficients we
conclude that our exposure variables were reasonably well measured. In addition, these
correlation coefficients may be underestimated because many of the record data were
coded as ingredients from recipes or mixed dishes as opposed to the questionnaire data,
which were coded as food product. Consequently, the division between food groups was
not always clear, resulting in lower correlations (41). Misclassification of subjects according
to their exposure status is possible, but expected to be nondifferential. To prevent
substantial misclassification of subjects with respect to exposure status, subjects with
incomplete or inconsistent data were excluded, according to criteria published before (41).
Besides a validation study, five annually repeated measurements of the food frequency
questionnaire were conducted. From the results it was concluded that the single
measurement of diet in the NLCS can characterize dietary habits for a period of at least five
years (48). This is further supported by the fact that our study population consists of older
subjects (aged 55-69 years) with relatively stable dietary habits (37).
Data gathered with our questionnaire allowed us to take other dietary and nondietary risk
factors for prostate cancer into account in multivariate analyses. Although our final
multivariate model was also somewhat restricted, we considered several potential
confounding factors and only those factors associated with prostate cancer risk in our study
were included in the model. Certainly, unmeasured or still unknown other factors may have
caused residual confounding. Results after exclusion of cases detected in the first two
years of follow-up were similar to results including all prostate cancer cases. Therefore,
preclinical disease are not likely to have influenced our results. Finally, chance will have
played a role in our study, in particular because of the multiple associations that were
studied.
Only a minority of previous cohort (5, 13, 49) and case-control studies (21, 24, 25) had a
more or less comprehensive measurement of dietary habits. Therefore, (random)
misclassification of exposure may have affected results in earlier studies. Furthermore,
results from most other studies were based on substantially less cases than the total
number of cases in our study. There were only two cohort studies with more than 400 cases
(13, 14, 49) and only three case-control studies with more than 300 cases (16, 21, 28).
Consistency in results between studies is also hampered by the fact that endpoints in
previous studies were either incidence or mortality. Deceased prostate cancer cases may
not adequately reflect the source population of total prostate cancer cases. Finally, limited
adjustment for confounding factors may have influenced results in different studies.
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Total meat consumption or consumption of specific types of meat were not clearly
associated with prostate cancer risk in several other cohort studies (5-7, 10, 13) and case-
control studies (15, 24, 25, 28). However, positive associations were also observed, in
cohort studies for consumption of meat (9), high fat animal products and beef (12), beef,
pork and lamb (11, 49), and for meat, poultry and fish (6) and in case-control studies for
consumption of meat (17, 18, 23), lamb and pork (22) and meat and fish combined (16). In
other cohort studies inverse associations were suggested for consumption of beef (14), and
bacon or side pork (15), and in case-control studies for consumption of poultry or chicken
(15, 19) and liver (27).
As in our study, intake of fish was overall not associated with prostate cancer risk in cohort
studies (7, 10, 12, 14), but also a positive (6) and an inverse association (9) have been
reported. From case-control studies positive (25), inverse (15, 27, 28) and null associations
(24) have been indicated.
One cohort study reported on processed meats in relation to prostate cancer risk and in this
study no association was found (12). Our data suggested a positive association between
consumption of 'other sliced cold meats' and prostate cancer risk. Although 'other sliced
cold meats' were not defined further in our questionnaire, several types of sausages are
frequently consumed in the Netherlands and these products are most likely to account for
the observed association.
In most cohort studies intake of milk or other dairy products was not clearly associated with
prostate cancer risk (6-10, 12-14), only in one cohort study a positive association was
reported (5). From case-control studies on milk or dairy products, however, positive
associations were more frequently reported (17, 18, 21, 24), although in this type of study
also null associations have been found (15, 25, 26). To our knowledge, an (inverse)
association between fermented milk products and prostate cancer risk has not been
reported elsewhere. Nevertheless, an inverse association has been reported for other
hormone-related cancers (50).
Consumption of cheese (5) and cheese in combination with butter and margarine (7) were
associated with a modest increase in risk in two cohort studies. In two case-control studies
no associations were found (24, 25). Egg consumption was not associated with prostate
cancer risk in all (5, 6, 8, 10, 12-14) but one cohort study, in which a positive association
was indicated (7). Results from case-control studies were more diverse, varying from a
suggestive inverse association (26), and null associations (15, 24, 25) to positive
associations (19, 23).
In some studies the exposure variables were evaluated separately for localized and regional
or distant, or advanced prostate tumors (12, 13, 25). We also evaluated risk factors
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separately for localized and advanced tumors, but in our study some 30 percent of all cases
could not be classified because of missing information on tumor characterization. The
results from our or other studies do not uniformly point at stronger associations between the
exposure variables and advanced prostate tumors. Because the number of studies in which
subgroup analyses based on tumor characterization is low, definite conclusions cannot be
drawn yet.
From the results of the NLCS and from the overview of results from other studies we can
conclude that, thus far, there is no convincing evidence for an important role of the
consumption of fresh meat, fish, cured meat, milk and milk products, cheese and eggs in
prostate cancer etiology. It has to be mentioned, however, that even the lower tail of the
distribution of consumption of animal products in the NLCS and in most of the other studies
represents a higher consumption than the average consumption level in countries with low
prostate cancer incidence rates. Therefore, the possibility that at much lower levels
consumption of animal products is important in prostate cancer etiology cannot be ruled out.
In our study we could not confirm a positive association between calcium intake and
prostate cancer risk, which has recently been proposed (35). Furthermore, also for animal
and vegetable protein associations with prostate cancer risk were not clear. More studies
are needed to investigate the suggested role of calcium intake in prostate cancer etiology.
Other studies should also evaluate whether a diet based on animal foods might be
positively associated with prostate cancer risk and whether plant-based foods might be
protective. In future studies, long follow-up periods with repeated extensive measurements
of diet could be helpful in evaluating whether diet is involved in prostate cancer progression
or whether diet has an effect relatively early in carcinogenesis. Finally, also mechanistic
research is warranted.
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Intake of energy and fat and prostate cancer
risk: results from the Netherlands Cohort
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Abstract
The role of energy and fat intake as risk factors for prostate cancer is still questionable.
Therefore, this was evaluated within the Netherlands Cohort Study. The cohort consists of
58,279 men aged 55-69 years at baseline in 1986; after 6.3 years of follow-up, 642 incident
prostate cancer cases were available for analysis. Intake of energy, fat, and separate fatty
acids were measured by means of a self-administered questionnaire; fat intake was
adjusted for energy by regression analysis. The case-cohort method was used to calculate
rate ratios (RR). Analyses were done for all prostate cancer cases together, and for case
subgroups (latent vs nonlatent; localized vs advanced). No associations were found in
multivariate analyses between prostate cancer and intake of energy, total fat, total
saturated fatty acids, and total frans unsaturated fatty acids (RR highest vs lowest quintile:
0.99, 1.10, 1.19, 0.99, respectively). Oleic acid intake showed a nonsignificant positive
association (RR=1.38, 95% Cl: 0.88-2.19). Also in subgroup analyses positive associations
were observed for intake of oleic acid. Intake of linoleic acid (RR=0.78, 95% Cl: 0.56-1.09)
and linolenic acid (RR=0.76. 95% Cl: 0.66-1.04) showed nonsignificant^ decreased risks;
only for linolenic acid these associations persisted in subgroup analyses. No associations
were found for intake of arachidonic acid, eicosapentaenoic acid and docosahexaenoic
acid. These data suggest that some specific fatty acids might be involved in prostate cancer
occurrence, although chance findings cannot be excluded.
2
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Introduction
Prostate cancer incidence as well as mortality are increasing (1). In many Western
countries, prostate cancer is one of the most frequently occurring types of cancer among
men. Because clinical prostate cancer shows a noteworthy geographical variation in
incidence compared to latent prostate cancer, environmental risk factors, among which are
energy and fat intake, are thought to play an important role in the etiology of clinical
prostate cancer (2-5).
The relationship between fat intake and prostate cancer risk was summarized in several
reviews on (dietary) risk factors for prostate cancer (2-6). From these reviews it is mostly
concluded that fat intake is positively related to prostate cancer risk. However, these
conclusions are not only based on fat intake per se, but also on results regarding
consumption of meat, milk and dairy. In one of the reviews it is concluded that there is no
conclusive evidence to the role of fat in prostate cancer etiology (2). Furthermore, specific
fatty acids have been investigated in few studies (7-14). Nevertheless, in some studies a
positive association between a-linolenic acid (9, 10, 12) and oleic acid (10, 12) and risk of
prostate cancer was shown. It has been proposed that clinically apparent or advanced
prostate tumors might have a different etiology than latent tumors. Only a minority of all
studies on fat and prostate cancer risk examined fat intake for latent and nonlatent or
localized and advanced tumors separately (9, 10, 13, 15-17), with diverse results.
Underlying biological mechanisms explaining a possible effect of fat intake on prostate
cancer risk are not clear but some mechanisms have been proposed. Increased fat intake
might lead to increased testosterone levels and this might, eventually, lead to increased cell
division and activation of proto-oncogenes and deactivation of tumor suppressor genes
(18). A role of specific fatty acids in prostate tumor occurrence is biologically plausible since
essential fatty acids are a source of metabolic energy, and are required for membrane
structure and for the synthesis of intermediate compounds important for cellular metabolism
(19). Linoleic acid and linolenic acid are both precursors for eicosanoid production and
eicosanoids have been shown to be related to tumor development, including cell
proliferation, immune response, invasion, and metastasis (10, 20). In vitro, linoleic acid has
been shown to stimulate growth of some but not all prostate cell lines (19, 20) and the same
counts for linolenic acid (19). For docosahexaenoic acid and eicosapentaenoic acid growth
inhibitory effects have been reported (20) but at low concentrations eicosapentaenoic acid
has also been reported to stimulate tumor promotion (19). Finally, another potential
mechanism to explain an effect of fatty acids may be free radical formation resulting from
oxidation of fatty acids (9, 10).
In this article we present our findings regarding fat intake and prostate cancer risk from the
Netherlands Cohort Study (NLCS) which was specifically designed to examine diet in
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relation to cancer. Findings are also presented with respect to latent and nonlatent, and
localized and advanced prostate tumors.
Methods
The cohort
The study design has been described elsewhere (21). In brief, the NLCS was initiated in
September 1986. The male cohort consists of 58,279 men aged 55-69 years who
completed a self-administered questionnaire on usual diet, and other risk factors for cancer.
Subjects originated from 204 municipal population registries throughout the country. For
reasons of efficiency in data processing and analysis, the case-cohort approach (22) was
used. In a case-cohort approach, cases are derived from the entire cohort (providing
numerator information for calculation of cancer incidence rates), whereas accumulated
person years at risk in the total cohort are estimated using a random male subcohort
sample (providing denominator information for the rates). In contrast to nested case-control
sampling, this subcohort can be used for multiple disease endpoints. The male subcohort
was sampled directly after identification of the total cohort and includes 1,688 men. The
method of cancer follow-up has also been described previously (23). In short, incident
primary prostate cancer cases were detected by computerized record linkage with all nine
cancer registries in the Netherlands, and with the Dutch national data base of pathology
reports (PALGA). The subcohort has been followed up biennially for vital status information.
No subcohort members were lost to follow-up and completeness of follow-up of cancer was
at least 96 percent (24). After a follow-up period of 6.3 years (September 1986-December
1992), 704 incident, microscopically confirmed, primary prostate cancer cases were
detected.
The questionnaire
The self-administered questionnaire has been described elsewhere (25). Usual
consumption of food and beverages during the year preceding the start of the study was
assessed with a 150-item semiquantitative food frequency questionnaire Among the
principal nutrients of interest were energy and fat intake. Questionnaire data were key-
entered twice and processed for all incident cases in the cohort and for all subcohort
members in a manner blinded with respect to case/subcohort status. This was done in order
to minimize observer bias in coding and interpretation of the data. Mean daily nutrient
intakes were calculated using the computerized Dutch food composition table (26). Intake of
specific fatty acids was based on a food compostion database with specific fatty acids,
including frans fatty acids, derived from the TRANSFAIR study (27). For this database, the
hundred foods that contributed most to fat intake in the Dutch dietary pattern were sampled
and analyzed as methyl esters of the fatty acids present in the foods. In the database, total
fat includes triglycerides and other lipids such as phospholipids and sterols. The percentage
of triglycerides in total fat is assumed to be on average 93 percent, but varies across food
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sources. In the database for the NLCS, the concentrations of fatty acids were based on the
concentrations before 1995, when changes in the frans content of manufactured products
such as margarines led to a decrease in intake of frans fatty acids.
Data analysis
In the subcohort prevalent cancer cases at baseline other than skin cancer were excluded,
leaving 1,630 subcohort members for analysis. Furthermore, according to criteria published
before (25), subjects with incomplete or inconsistent dietary data were excluded; 642 men
with prostate cancer and 1525 male subcohort members remained for analysis.
Exposure variables included in the present analysis are intake of total energy, total fat, total
fatty acids, saturated fattty acids, mono and polyunsaturated fatty acids, frans unsaturated
fatty acids, c/'s unsaturated fatty acids, palmitic acid, stearic acid, oleic acid, linoleic acid,
linolenic acid, arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid. Fat
intake was adjusted for energy by regression analysis (28). Mean intake levels of exposure
variables and other characteristics were compared between prostate cancer cases and
male subcohort members. Furthermore, mean intakes of total energy and total fat intake
were compared in categories of potential confounders. Rate ratios (RR) and 95%
confidence intervals (95% Cl) were computed for quintiles of energy and fat intake, as well
as for continuous variables of intake, using the GLIM statistical package (29). Exponentially
distributed survival times were assumed in the follow-up period. Since standard software
was not available, specific macros were developed to account for the additional variance
introduced by using the subcohort instead of the entire cohort (30).Throughout this report
two-sided P-values are used; trend tests for quintile ranks were based on likelihood ratio
tests. Age-adjusted and multivariate analyses were conducted. Variables that were
considered as potential confounders were age, family history of prostate cancer, and
socioeconomic status. For all energy-adjusted variables energy intake was also included
into the multivariate model, in conformity with the method described by Willett (28). In
addition, in order to assess the independent contribution of saturated fatty acids, mono and
polyunsaturated fatty acids and each specific fatty acid, total energy-adjusted fat intake was
also included in the multivariate model. Vegetable and fruit consumption and intake of
vitamin E were not considered as potential confounding factors because no association with
prostate cancer risk was observed (31). In additional analyses, cases detected during the
first two years of follow-up were excluded to evaluate whether preclinical disease may have
influenced results.
Subgroup analyses
Separate analyses were done for latent and nonlatent tumors, for continuous variables of
exposure. The subgroups were constructed based on information about surgical procedures
mentioned in the pathology reports that have been obtained from PALGA. Tumors that were
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detected as a consequence of transurethral prostate resections, usually performed for
problems associated with Benign Prostatic Hyperplasia (BPH), were coded latent. Nonlatent
tumors were those tumors that were detected as a consequence of procedures used in :
case of suspected cancer (biopsy, radical prostatectomy). Cases were excluded from these
subgroup analyses when this additional information was unknown or unclear (38.2%).
Because population screening for prostate cancer was not instituted before 1992 in the
Netherlands, we assumed there were no tumors detected by screening in the 6.3 years of
follow-up. Analyses were also done for localized prostate tumors (TO-2, MO: no evidence of
primary tumor [TO], clinically inapparent tumor [T1], or tumor confined within the prostate
[T2], no distant metastasis [MO]) and advanced prostate tumors (T3-4, MO; TO-4, M1: tumor
faWe 1: Descnpffon ofmea/i energy and energy-ad/usfed far /nfa/ce and d/sfribufion of potenfra/ confound/ng
var/ab/es /n prosfate cancer cases and ma/e subco/iort members, Ne/her/ands Cohort Sfady (7986-
7992J.
Characteristics
Exposure yar/ab/es (g/day)
Energy intake (kcal/day)
Total fat'
Total fatty acids*
Total saturated fatty acids
Total monounsaturated fatty acids
Total polyunsaturated fatty acids
Total frans unsaturated fatty acids
Total c/s unsaturated fatty acids
Palmitic acid
Stearic acid
Oleic acid
Linoleic acid
Linolenic acid
Arachidonic acid
Eicosapentaenoic acid
Docosahexaenoic acid
Pofenfra/ confound/ng variaWes
Age (years)
Family history of prostate cancer (% yes)
Highest educational level (%)'
low
medium
high
Cases (n=642)
mean SD
2115
94.1
87.5
36.9
28.5
20.2
3.3
45.4
18.6
8.3
21.7
18.0
1.3
0.11
0.05
0.09
63.9
4.4
44.7
34.9
20.4
487
13.3
12.8
8.5
5.1
7.7
1.4
9.6
3.7
1.4
4.4
7.7
0.6
0.04
0.06
0.09
3.8
Subcohort(n=1525)
mean
2157
93.6
87.0
36.3
28.3
20.5
3.3
45.6
18.4
8.2
21.6
18.2
1.4
0.11
0.04
0.08
61.4
27
47.1
35.0
17.9
SD
513
14.4
13.8
8.4
5.2
8.2
1.3
10.1
3.8
1.6
4.3
8.1
0.6
0.05
0.05
0.08
4.2
' Includes other lipids such as phospholipids; * Includes about 2 percent unidentified fatty acids;' Low is defined
as primary school with/without lower level vocational education, medium as secondary school or medium level
vocational education, high as university or higher level vocational education.
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extending through prostatic capsule [T3], fixed tumor or tumor invading adjacent structures
other than seminal vesicles [T4], no distant metastasis [MO]; any tumor [TO-4] with distant
metastasis [M1]), based on the TNM classification system (32). Of all cases, 31.6% could
not be categorized in localized or advanced tumors. -
Results
In Table 1 the mean intake of energy and energy-adjusted fat intake among cases and
subcohort members is shown. The mean energy intake was somewhat lower among cases
compared to subcohort members. Overall, mean fat intake did not differ to a large extent
between cases and subcohort members. Also shown in this table is the distribution of
potential confounding factors. Cases are older than subcohort members, they more often
have a positive family history of prostate cancer and are more highly educated than
subcohort members. Comparing total energy and fat intake across categories of potential
confounding factors showed that total energy intake was highest at younger ages and in the
lowest category of socioeconomic status. Total fat intake did not differ across categories of
potential confounding factors (data not shown).
Age-adjusted and multivariate adjusted RRs for prostate cancer according to total energy
and total fat intake, as well as grouped fatty acids are summarized in table 2. Multivariate
adjusted RRs were similar to age-adjusted risk estimates. No associations were observed
for intake of total energy, total fat, total fatty acids, saturated fatty acids and frans
unsaturated fatty acids. A nonsignificant slightly increased risk was noted for intake of
monounsaturated fatty acids (RR highest vs lowest quintile=1.32, 95% Cl: 0.82-2.12).
Nonsignificant inverse associations were indicated for intake of polyunsaturated fatty acids
(RR=0.78, 95% Cl: 0.56-1.10) and intake of c/s unsaturated fatty acids (RR=0.80, 95% Cl:
0.54-1.20). When c/s unsaturated fatty acids were separated in monounsaturated and
polyunsaturated c/s fatty acids, the RR comparing highest vs lowest quintile for c/s
monounsaturated fatty acids was somewhat increased (RR=1.34, 95% Cl: 0.84-2.14), while
the RR for c/s polyunsaturated fatty acids was slightly decreased (RR=0.77, 95% Cl: 0.55-
1.08). However, both estimates were not significant and there was no trend in risk (data not
shown).
In Table 3 the RRs for the intake of specific fatty acids in relation to prostate cancer risk are
shown. Again, age-adjusted and multivariate adjusted RRs were very similar. For most
individual fatty acids no clear associations with prostate cancer were observed. Only for
intake of oleic acid, a nonsignificant slightly increased risk was observed (RR=1.38) but
there was no trend in risk. In the highest intake quintiles, both for intake of linoleic acid and
linolenic acid nonsignificant decreased risks were observed (RRs of 0.78 and 0.76,
respectively) but the trend test was not significant in both instances. Exclusion of cases
detected during the first two years of follow-up did not change the results presented in
tables 2 and 3 (data not shown).
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TaWe 2: Rate rafos (W?J and 95% confidence /nterva/s (95% C/J
/'nfate of energy, and energy-ad/usted far, i
Exposure
Energy intake
Median intake'
Cases/Person years
RR' (95% Cl)
RR' (95% Cl)
Total fat
Median intake*
Cases/Person years
RR' (95% Cl)
RR* (95% Cl)
Total fatty acids
Median intake*
Cases/Person years
RR' (95% Cl)
RR* (95% Cl)
Saturated fatty acids
Median intake*
Cases/Person years
RR' (95% Cl)
RR' (95% Cl)
Monounsaturated fatty
acids
Median intake*
Cases/Person years
RR' (95% Cl)
RR' (95% Cl)
Polyunsaturated fatty
acids
Median intake*
Cases/Person years
RR* (95% Cl)
RR' (95% Cl)
Trans unsaturated fatty
acids
Median intake*
Cases/Person years
RR' (95% Cl)
RR' (95% Cl)
C/s unsaturated fatty
acids
Median intake*
Cases/Person years
RR*(95%CI)
RR' (95% Cl)
Q1'
1541
133/1804
1.00
1.00
76.0
114/1804
1.00
1.00
70.1
110/1804
1.00
1.00
26.4
129/1814
1.00
1.00
22.3
120/1780
1.00
1.00
11.0
135/1807
1.00
1.00
1.9
119/1795
1.00
1.00
34.2
135/1821
1.00
1.00
Q2
1870
141/1803
1.08(0.80-1.46)
1.05(0.78-1.43)
87.2
139/1828
1.24(0.91-1.69)
1.22(0.89-1.67)
80.9
146/1820
1.36(1.00-1.86)
1.32(0.97-1.82)
31.7
115/1822
0.91 (0.67-1.25)
0.88(0.63-1.24)
25.8
133/1846
1.16(0.85-1.59)
1.22(0.87-1.71)
15.9
101/1833
0.71 (0.52-0.98)
0.73(0.53-1.01)
2.6
136/1824
1.22(0.89-1.66)
1.25(0.90-1.72)
40.2
122/1814
0.93(0.69-1.27)
0.90(0.65-1.24)
for pros/ate cancer accord/no; to gu/nfttes of
fVefnerfands Conort Sfudy ff986-^992;.
Q3
2117
129/1831
0.97(0.72-1
0.95(0.70-1
94.0
132/1853
1.12 (0.82-1
1.10 (0.80-1.
87.3
127/1864
1.07(0.78-1.
32)
30)
.54)
51)
.47)
1.04(0.76-1.44)
35.5
128/1812
0.96(0.71-1.31)
0.93(0.65-1
28.2
144/1849
1.26(0.93-1
.32)
.71)
1.30(0.90-1.88)
19.8
150/1819
1.14(0.85-1.54)
1.15(0.84-1.56)
3.2
135/1830
1.18(0.86-1
1.20(0.86-1
45.0
127/1812
1.00(0.74-1
0.94 (0.67-1
.60)
.65)
.37)
.32)
Q4
2377
135/1836
1.08(0.80-1.
1.04(0.77-1.
100.3
132/1806
1.10(0.81-1.
46)
.41)
,51)
1.10(0.80-1.51)
93.5
133/1812
1.14(0.84-1
1.13 (0.82-1
40.0
103/1864
0.75(0.54-1
0.75(0.51-1
30.6
117/1827
1.00(0.73-1
.57)
.56)
03)
08)
.37)
1.07(0.72-1.60)
24.1
142/1843
1.01 (0.75-1.37)
1.00(0.73-1.37)
3.7
136/1829
1.13(0.83-1
1.12(0.80-1
51.1
142/1847
1.03(0.76-1
0.96 (0.68-1
.54)
.55)
.39)
.35)
Q5
2803
104/1848
0.98(0.71-1.36)
0.99(0.72-1.37)
110.4
125/1831
1.11(0.81-1.52)
1.10(0.80-1.52)
103.5
126/1822
1.15(0.84-1.58)
1.14(0.83-1.57)
47.5
167/1809
1.23(0.91-1.65)
1.19(0.80-1.76)
34.3
128/1821
1.22(0.89-1.67)
1.32(0.82-2.12)
31.1
114/1821
0.80(0.58-1.09)
0.78(0.56-1 10)
4.7
116/1844
1.01 (0.73-1.39)
0.99(0.70-1.40)
58.1
116/1829
0.89(0.65-1.22)
0.80(0.54-1.20)
Pfor
trend
0.94
0.93
0.81
0.78
0.77
0.77
0.27
0.43
039
0.48
0.71
0.52
0.87
0.72
0.67
0.34
' Reference category; * Median intake (kcal/day) in subcohort;' Adjusted for age; * Adjusted for age, family history
of prostate cancer, and socioeconomic status; Median intake (g/day) in subcohort; * Adjusted for age, family
history of prostate cancer, socioeconomic status, and total energy intake;' Adjusted for age, family history of
prostate cancer, socioeconomic status, total energy intake, and total energy-adjusted fat intake.
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In Table 4, results from multivariate analyses for continuous variables of energy and fat
intake are presented for all prostate cancer cases, and separately for latent, nonlatent,
localized and advanced tumors. For most exposure variables, no clear associations were
observed in the different subgroups and, overall, associations were mostly similar in
subgroups of latent and nonlatent and localized and advanced tumor subgroups.
Nonsignificant increased risk estimates were found for intake of monounsaturated fatty
acids and latent and nonlatent tumors and for oleic acid in association with all four tumor
subgroups. Inverse associations were observed in subgroups of latent, nonlatent and
localized tumors for intake of linolenic acid.
Discussion
In the NLCS we found no association between intake of energy, total fat, total fatty acids,
saturated fatty acids, and frans unsaturated fatty acids and overall prostate cancer risk. For
specific fatty acids, a positive association with prostate cancer risk was indicated for oleic
acid intake, also in subgroup analyses. An inverse association was indicated for intake of
linoleic acid and linolenic acid. The trend test for linolenic acid intake was significant in the
age-adjusted analysis. Results in subgroups were less clear.
Before discussing the results in relation with other studies, some remarks about the NLCS
are relevant. Loss to follow-up is the primary source of potential selection bias in
prospective cohort studies. Given the high completeness of follow-up of the cases and
subcohort person years in the NLCS (24, 33) selection bias is unlikely. In the case of
prostate cancer, symptoms of prostate cancer (e.g. urethral obstruction) are unlikely to
cause a change in dietary fat intake. Nevertheless, we conducted analyses after exclusion
of cases diagnosed in the first two years of follow-up, and the results were similar to our
overall results.
The questionnaire has been validated against a 9-day diet record. Crude and energy-sex-
adjusted (in parentheses) Pearson correlation coefficients between the dietary record and
the questionnaire were as follows: energy, 0.74; total fat, 0.72 (0.52); saturated fat, 0.73
(0.58); polyunsaturated fat, 0.73 (0.75) (25). From this validation study we conclude that fat
intake was reasonably well measured in our self-administered semiquantitative
questionnaire. The correlation coefficient of 0.52 for total fat intake is most likely a
consequence of the relatively homogeneous dietary fat intake in our study population. For
polyunsaturated fat intake, however, the range in intake is much higher and the correlation
coefficient from our validation study was 0.75. To prevent substantial misclassification, we
excluded subjects with incomplete or inconsistent data. A possible misclassification of fat
intake is likely to be nondifferential, thus leading to a bias towards the null value. Besides a
validation study, five annually repeated measurements of the food frequency questionnaire
were conducted. From the results it was concluded that the single measurement of intake of
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Tab/e 3: Rate raffos (RRJ ancy 95% co/iffdence /nterva/s (95% C/j forprosfate cancer accortf/ng to gu/Mtes of
/n(ate of spec/fc energy-aoyusted feffy ac/ds, Nef/ier/ands Cohort Sfudy f 1986- J992J.
Exposure Q1' Q2 Q3 Q4 Q5 Pfor
trend
16.5 18.3 20.2 23.2
136/1816 128/1834 137/1860 131/1811
1.38(1.01-1.90) 1.14(0.83-1.56) 1.19(0.87-1.63) 1.16(0.85-1.60) 0.62
1.37 (0.98-1.91) 1.14 (0.80-1.62) 1.20(0.83-1.74) 1.14(0.75-1.74) 0.79
7.4 8.2 8.9 10.1
133/1831 140/1810 133/1854 131/1823
1.15(0.84-1.59) 1.28(0.94-1.76) 1.06(0.77-1.45) 1.17 (0.85-1.61) 0.49
1.18(0.84-1.67) 1.35(0.93-1.94) 1.12(0.75-1.66) 1.23(0.78-1.94) 0.57
19.6 21.5 23.4 26.3
152/1829 131/1864 118/1807 128/1827
1.45(1.06-1.97) 1.18(0.86-1.62) 1.10(0.80-1.52) 1.30(0.94-1.78) 0.45
1.47(1.05-2.06) 1.23(0.85-1.79) 1.17(0.78-1.76) 1.38(0.88-2.19) 0.48
13.6 17.1 21.4 28.8
101/1824 144/1824 144/1836 118/1825
0.69(0.50-0.95) 1.05(0.78-1.42) 1.06(0.78-1.43) 0.80(0.58-1.09) 0.89
0.71(0.51-0.98) 1.04(0.77-1.42) 1.05(0.77-1.44) 0.78(0.56-1.09) 0.68
1.1 1.3 1.7 2.1
126/1820 125/1808 123/1838 114/1855
0.80 (0.59-1.08) 0.82(0.61-1.11) 0.80(0.59-1.08) 0.76(0.56-1.03) 0.04
0.76(0.55-1.05) 0.82(0.60-1.13) 0.80(0.59-1.10) 0.76(0.66-1.04) 0.09
0.09 0.11 0.13 0.17
133/1849 151/1879 113/1783 132/1830
1.23(0.90-1.69) 1.38(1.01-1.88) 1.10(0.80-1.53) 1.20(0.87-1.64) 0.40
1.21(0.88-1.66) 1.37 (1.00-1.87) 1.11(0.80-1.54) 1.20(0.87-1.66) 0.30
0.01 0.03 0.05 0.10
102/1853 125/1790 138/1771 142/1790
0.69(0.50-0.95) 0.94(0.69-1.28) 1.06(0.79-1.44) 1.01(0.75-1.37) 0.11
0.66 (0.47-0.91) 0.92(0.67-1.27) 1.05(0.77-1.44) 1.00(0.73-1.35) 0.10
0.03 0.06 0.09 0.18
111/1834 128/1811 139/1836 140/1796
0.82(0.60-1.13) 1.01 (0.74-1.38) 1.07 (0.79-1.46) 1.05 (0.77-1 42) 0.19
0.81(0.58-1.11) 1.00(0.73-1.38) 1.09(0.80-1.49) 1.03(0.75-1.40) 0.19
' Reference category; * Median intake (g/day) in subcohort;' Adjusted for age;' Adjusted for age, family history of
prostate cancer, socioeconomic status, total energy intake and total energy-adjusted fat intake.
Palmitic acid
Median intake*
Cases/Person years
RR' (95% Cl)
RR« (95% Cl)
Stearic acid
Median intake*
Cases/Person years
RR3 (95% Cl)
RR' (95% Cl)
Oleic acid
Median intake*
Cases/Person years
RR* (95% Cl)
RR' (95% Cl)
Linoleic acid
Median intake*
Cases/Person years
RR' (95% Cl)
RR* (95% Cl)
Linolenic acid
Median intake*
Cases/Person years
RR' (95% Cl)
RR' (95% Cl)
Arachidonic acid
Median intake*
Cases/Person years
RR' (95% Cl)
RR< (95% Cl)
Eicosapentaenoic acid
Median intake*
Cases/Person years
RR' (95% Cl)
RR' (95% Cl)
Docosahexaenoic acid
Median intake*
Cases/Person years
RR'(95%CI)
RR'(95%CI)
13.9
110/1802
1.00
1.00
6.4
105/1804
1.00
1.00
16.8
113/1795
1.00
1.00
9.0
135/1813
1.00
1.00
0.7
154/1802
1.00
1.00
0.06
113/1781
1.00
1.00
0.00
135/1918
1.00
1.00
0.01
124/1846
1.00
1.00
r«bte 4: Rate raftos f/?RJ and 95% confidence /nterva/s (95% C/) per 10 g /ncremenf forprosfafe cancer accord/ng to /nte/te of energy and energy-ad/usted rat
for a// cases and/'n subgroups based on fumor c/iaracter/zaftbn, Nerter/ands Conor/ Sfudy (7986-)992J.
CO
00
Exposure
Energy intake
RR" (95% Cl)
Total fat
RR' (95% Cl)
Total fatty acids
RR' (95% Cl)
Saturated fatty acids
RR« (95% Cl)
Monounsaturated fatty acids
RR' (95% Cl)
Polyunsaturated fatty acids
RR'(95%CI)
Frans unsaturated fatty acids
RR«(95%CI)
C/s unsaturated fatty acids
RR' (95% Cl)
Palmitic acid
RR< (95% Cl)
Stearic acid
RR* (95% Cl)
Oleic acid
RR* (95% Cl)
All tumors
(n=642)
1.00(0.98-1.02)
1.02(0.95-1.09)
1.02(0.95-1.10)
1.09(0.92-1.28)
1.25(0.89-1.75)
0.91 (0.80-1.04)
1.06 (0.48-2.33)
0.94(0.82-1.08)
1.17(0.79-1.75)
1.06(0.37-3.01)
1.32(0.90-1.91)
Tumor subgroups
Latent tumors
(n=115)
1.01 (0.97-1.05)
1.07(0.93-1.22)
1.08(0.93-1.24)
1.02(0.72-1.43)
1.45(0.76-2.75)
0.91 (0.70-1.18)
0.99 (0.22-4.55)
0.96(0.74-1.26)
1.34(0.61-2.92)
1.52(0.20-11.62)
1.50(0.75-3.02)
Nonlatent tumors
(n=282)
1.00(0.97-1.02)
1.00(0.91-1.10)
1.00(0.91-1.10)
1.06(0.84-1.33)
1.30(0.84-2.02)
0.94(0.79-1.12)
1.11(0.39-3.14)
0.97(0.81-1.16)
0.99(0.59-1.68)
0.66 (0.17-2.60)
1.43(0.88-2.34)
Tumor subgroups
Localized
(n=226)
1.03(1.00-1.06)
1.03(0.93-1.14)
1.03(0.93-1.15)
1.08(0.86-1.36)
1.12(0.70-1.80)
0.93(0.77-1.12)
0.93 (0.30-2.86)
0.94(0.78-1.14)
1.07(0.61-1.89)
0.74(0.17-3.18)
1.22(0.72-2.08)
Advanced
(n=213)
0.99(0.96-1.02)
1.00(0.90-1.11)
1.01(0.90-1.12)
1.02(0.80-1.31)
1.23(0.74-2.03)
0.98(0.80-1.19)
0.76 (0.21-2.71)
1.02(0.83-1.25)
1.09(0.60-2.00)
0.92(0.19-4.45)
1.43(0.82-2.50)
o
0)
7abte 4 continued
Exposure
Linoleic acid
RR* (95% Cl)
Linolenic acid
RR' (95% Cl)
Arachidonic acid
RR'* (95% Cl)
Eicosapentaenoic acid
RR« (95% Cl)
Docosahexaenoic acid
RR« (95% Cl)
All tumors
(n=642)
0.92(0.81-1.05)
0.22(0.04-1.36)
1.06(0.85-1.32)
1.15(0.96-1.38)
1.08(0.96-1.21)
Tumor subgroups
Latent tumors
(n=115)
0.92(0.71-1.19)
0.26 (0.00-9.20)
0.79 (0.50-1.24)
1.14(0.80-1.62)
1.08(0.86-1.36)
Nonlatent tumors
(n=282)
0.94(0.79-1.12)
0.20 (0.02-2.31)
1.04(0.77-1.39)
1.02(0.80-1.32)
1.00(0.85-1.17)
Tumor subgroups
Localized
(n=226)
0.94(0.78-1.13)
0.14(0.00-1.93)
0.90(0.65-1.25)
0.97(0.73-1.29)
0.95(0.79-1.15)
Advanced
(n=213)
0.98(0.80-1.19)
1.12(0.08-16.18)
1.11(0.80-1.54)
1.11(0.84-1.45)
1.09(0.92-1.29)
' Adjusted for age, family history of prostate cancer, and socioeconomic status;' RR per increment of 100 kcal;' Adjusted for age, family history of
prostate cancer, socioeconomic status, and total energy intake;' Adjusted for age, family history of prostate cancer, socioeconomic status, total energy
intake, and total energy-adjusted fat intake;* RR per increment of 0.1 g.
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diet in the NLCS can characterize dietary habits for a period of at least five years (34).
Furthermore, our study population consists of older subjects (aged 55-69 years) which were
chosen because, in general, they show more stable dietary habits than younger individuals
(21). Nevertheless, if diet in early adulthood might be important in prostate cancer etiology,
our results may not reflect these effects.
Finally, residual confounding cannot be excluded and it is also important to note that
multiple comparisons were made in our study. Therefore, although the power of the NLCS,
based on 642 cases and 1525 subcohort members, was large, chance will have played a
role in our findings and one needs to be stringent in interpreting the data.
Some remarks about other studies on energy and fat intake and prostate cancer risk are
also in place. First, most evidence on fat intake in relation to prostate cancer risk comes
from case-control studies (7, 8, 13-17, 35-45), there are only six cohort studies on the topic
(9-12, 46, 47). In general, case-control studies are more prone to bias than cohort studies.
Second, there were only a few cohort studies (9, 10, 12) and case-control studies (13, 15,
16, 37, 43, 44) that extensively evaluated the role of energy and fat intake. Other studies
had limited exposure information. In addition, there was only a minority of studies in which
energy intake was taken into account in evaluating fat intake (9, 13, 15, 16, 43-45). Third, in
several studies only limited adjustment for other possible confounders was made and
residual confounding may have influenced results. Finally, evidence from earlier studies on
fat in relation to prostate cancer risk is mostly based on a number of cases that was less
than the 642 cases used in our study. To date, the largest cohort study on fat intake in
relation to prostate cancer risk comprised 300 cases (9).
For intake of energy, total fatty acids, saturated fatty acids, and mono- and polyunsaturated
fatty acids, no strong associations with overall risk of prostate cancer were observed in our
study. In several other studies also no associations were reported for energy (44-46), total
fat (9, 12, 13, 15, 17, 37-39, 42, 45, 46), saturated fat (9, 13, 45, 46), unsaturated fat (37,
46), monounsaturated fat (12, 13, 16, 45) and polyunsaturated fat (12, 13, 16, 43, 45).
Nevertheless, also positive associations have been reported for energy (13, 15, 43), total fat
(16, 35, 36, 40, 41), saturated fat (12, 15, 16, 37), monounsaturated (9, 15), and
polyunsaturated fat (15, 44) and inverse association for energy (39), total fat (43, 44),
saturated fat (43, 44), and monounsaturated fat (43, 44).
The principal saturated fatty acids in the diet are palmitic and stearic acid for which we
found no clear associations. In previous studies, for serum levels of palmitic acid, both no
association (10) and a positive association (12) were reported and for serum levels of
stearic acid, both a null association (12) and an inverse association (10) were observed. For
oleic acid, the principal monounsaturated fatty acid in the diet, we observed a positive
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association. Positive associations have been reported before for serum levels of oleic acid
(10, 12), but not for intake levels (7, 8). Our results indicated an inverse association > -;,.,
between prostate cancer risk and intake of linoleic and linolenic acid. The suggested
inverse association between prostate cancer risk and linoleic acid intake gains support from
one other cohort study using serum levels (10), but in some other studies associations were
less clear (9, 12, 13), or even positive (14). From other studies on linolenic acid mostly
increased estimates have been reported (10, 12, 14), sometimes only for advanced tumors
(9) and in one study no association was found (13). Finally, we found no clear associations
for intake of arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid. From
other studies also no clear or strong associations for these fatty acids have been reported
(9, 10, 12, 14).
For none of our exposure variables of interest, except for intake of oleic acid, we found a
stronger association with nonlatent or advanced prostate tumors. Our results, however,
need to be interpreted carefully, because a considerable proportion of cases could not be
classified into tumor subgroups. In two case-control studies also no evidence was found
that fat intake is more strongly related to risk of advanced tumors than to overall prostate
cancer risk (12, 13). Furthermore, in some other studies it was found that excluding focal
microscopic cancers (10), or diffuse latent cancers (17) did not change results. However, in
one cohort study total fat intake and intake of a-linolenic acid were positively associated
with advanced tumors, and not with all tumors (9). In one case-control study only saturated
fat intake showed a stronger positive association with advanced tumors than with all
prostate tumors (16), and in another case-control study fat intake was consistently stronger
associated with aggressive prostate tumors, only for men aged 68 years and older (15).
Thus far, conclusions regarding fat intake being particularly associated with advanced or
aggressive prostate tumors seem preliminary.
In conclusion, from our study we found no evidence for a strong association between
energy or fat intake, or intake of a number of specific fatty acids and prostate cancer risk.
However, there was a suggestion for a positive association for intake of oleic acid and an
inverse association for intake of linoleic acid and linolenic acid. Findings from other studies
are very diverse, also with respect to nonlatent or advanced prostate tumors. More studies
with extensive exposure information are needed to clarify the role of specific fatty acids in
prostate cancer etiology.
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Chapter 6
A prospective cohort study on consumption
of alcoholic beverages in relation to prostate
cancer incidence^
Agnes G. Schuurman*
R. Alexandra Goldbohm^
Piet A. van den Brandt*
Abstract
Alcohol consumption in relation to prostate cancer incidence was examined within the
Netherlands Cohort Study. At baseline in 1986, 58,279 men aged 55-69 years completed a
self-administered questionnaire on diet, consumption of alcoholic beverages and other risk
factors for cancer. For data processing and analyses, the case-cohort approach was used.
After 6.3 years of follow-up, 680 incident primary prostate cancer cases were available for
analysis. In multivariate analyses adjusted for age, socioeconomic status and family history
of prostate cancer, no association between total alcohol consumption, alcohol intake from
beer and liquor and prostate cancer risk was found. When different types of wine were
evaluated, increased associations were found for alcohol from white wine and fortified
wines compared to nondrinkers, but not for red wine. The RRs (95% Cl) in the intake
category of >15 g/day were 3.25 (1.15-9.21) and 2.32 (1.16-4.67), respectively, after
additional adjustment for total alcohol intake. There was, however, no significant trend in
risk. Alcohol intake was more strongly related with localized than with advanced prostate
tumors. Our results do not support an important role for alcohol in prostate cancer etiology.
Nevertheless, for specific types of alcoholic beverages, particularly wines, a positive
association was suggested which needs examination in further studies.
^ Prow's/onaWy accepted by Cancer Causes &
* Dept. of Epidemiology, Maastricht University, Maastricht
Dept. of Consumer Research & Epidemiology, TNO Nutrition and Food Research Institute, Zeist
96 Chapter 6
Introduction
Not much attention is given to alcohol consumption as a potential risk factor for prostate
cancer in most reviews on this disease (1-5). Nevertheless, when we searched the
literature, we found at least 14 cohort studies (6-19) and 23 case-control studies (20-42) in
which alcohol consumption in relation to prostate cancer risk was investigated. In the
majority of these studies, however, no extensive evaluation was made. For example, there
were four cohort studies (6, 10, 13, 14) and 10 case-control studies (21, 22, 25-27, 33, 36,
38, 40, 41) in which some data on different types of alcoholic beverages was presented. In
some studies it was suggested that alcohol consumption might be associated with prostate
cancer etiology (11, 13, 14, 21, 22, 25, 26, 36, 40). There were only three studies in which
alcohol consumption was investigated in subgroups of aggressive or advanced prostate
tumors (21, 25, 27). Therefore, data on the hypothesis that environmental factors might be
more strongly related to advanced prostate cancer are still sparse as regards consumption
of alcohol. We further investigated this relationship in the Netherlands Cohort Study
(NLCS) on diet and cancer.
Methods
77?e cohort
The study design has been described elsewhere (43). In brief, the NLCS was initiated in
September 1986. The male cohort consists of 58,279 men who completed the
questionnaire on usual diet, alcohol consumption, personal and family history of cancer,
other risk factors for cancer, and demographic data. The case-cohort approach (44) was
used for data processing and analysis: for calculation of cancer incidence rates, the
number of cancer cases for the entire cohort was used as the numerator, while person
years at risk were estimated using a random male subcohort sample, which was sampled
directly after identification of the total cohort. The male subcohort includes 1,688 men.
Follow-up for incidence of prostate cancer was established by computerized record linkage
with all nine cancer registries in The Netherlands, and with the Dutch national data base of
pathology reports (PALGA) (45). The subcohort has been followed up biennially for vital
status information. Completeness of follow-up of cancer was at least 96 percent (46) and
no subcohort members were lost to follow-up. After a follow-up period of 6.3 years
(September 1986-December 1992), 704 incident, microscopically or histologically
confirmed, primary prostate cancer cases were detected.
The self-administered questionnaire has been described elsewhere (47). Briefly, usual
consumption of food and beverages during the year preceding the start of the study was
assessed with a 150-item semiquantitative food frequency questionnaire. Participants were
asked to report their frequency of consumption of beer, red wine, white wine, sherry and
other fortified wines, liqueurs and liquor (e.g. Dutch gin, brandy and whiskey). Categories
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ranged from 'never or less than once per month' to '6-7 days per week' and information on
the number of glasses drunk per consumption day was also requested. Daily alcohol
consumption (ethanol in g/day) was calculated using the computerized Dutch food
composition table (48). The ethanol contents (per 100 g) used were: 4 g for beer, 10 g for
red and white wine, 14 g for fortified wines, 17 g for liqueurs, and 29 g for liquor. The
questionnaire has been validated against a 9-day diet record; the Spearman correlation
coefficient for alcoholic beverages was 0.89 for all subjects and 0.85 for users of alcoholic
beverages (47).
Date ana/ys/s
Questionnaire data were key-entered twice and processed for all incident cases in the
cohort and for all subcohort members in a manner blinded with respect to case/subcohort
status. This was done in order to minimize observer bias in coding and interpretation of the
data. After excluding prevalent cancer cases other than skin cancer from the subcohort,
1630 men remained for analysis. Furthermore, subjects with incomplete alcohol data were
also excluded. Alcohol data were considered incomplete when all questions on
consumption frequency of alcoholic beverages were left blank and two questions on
alcohol consumption pattern did not indicate that the subject was a nondrinker. These two
questions concerned alcohol intake during the past week and five years previously (49, 50).
The results presented here are based on 680 incident prostate cancer cases and 1591
subcohort members for whom alcohol data were considered complete.
The associations between alcohol consumption and some potential confounding factors for
prostate cancer were evaluated among men in the subcohort, by comparing the proportion
of men with these risk factors across categories of alcohol consumption. Variables that
were considered as potential confounders were age, prostate cancer in first degree
relatives (father and brothers), and socioeconomic status. Because in previous analyses no
associations were observed between total vegetable and fruit consumption (51) and total
energy and fat intake and prostate cancer risk, these factors were not considered as
confounding factors. Rate ratios (RRs) and 95% confidence intervals (95% Cl) were
computed using the GLIM statistical package (52). Exponentially distributed survival times
were assumed in the follow-up period. Since standard software was not available, specific
macros were developed to account for the additional variance introduced by using the
subcohort instead of the entire cohort (53). Tests for trend were based on likelihood ratio
tests and two-sided P-values are used throughout this report.
Age-adjusted as well as multivariate-adjusted analyses were done for both categorized and
continuous variables; in addition to the abovementioned confounding factors, alcohol intake
from specific types of alcoholic beverages was also adjusted for total alcohol intake. Cases
detected during the first two years of follow-up were additionally excluded from analyses to
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evaluate whether preclmical symptoms might have influenced results. Analyses were also
done in case subgroups of localized (TO-2, MO) and advanced (T3-4, MO; TO-4, M1)
prostate tumors.
TaWe 7: D/sMbufibn ofpotenfta/cor/found/nc; factors forprosfate cancer /n mate subco/jorf members w/Yn
comp/ete a/cono/ consumption c/ate, Ne/her/anc/s Cotorf Sfuc/y (7 986-1992J.
Percentage with risk factor
Drinkers
Potential confounding variable Nondrinkers (n=246) <15 g/day (n=767) > 15 g/day (n=578)
Age (years)
55-59 32.9 40.2 37.5
60-64 31.7 34.6 36.0
65-69 35.4 25.3
Family history of prostate cancer
No 98.8 96.9 97.6
Yes 1.2 3.1 2.4
Socioeconomic status
Low 55.7 50.4 43.5
Medium 32.4 34.5 317
High VT9 15J 22.8
' Low is defined as primary school with/without lower vocational education, medium as secondary school or
medium level vocational education, high as university or higher level vocational education.
Results
The percentages of nondrinkers were 15.5 and 16.2, respectively, for subcohort members
and cases. Among drinking men, the mean total alcohol intake (SD) was 17.1 (16.6) g/day
for subcohort members and 17.7 (15.9) g/day for prostate cancer cases. Data on the
association between alcohol consumption and some potential confounding factors among
subcohort members are shown in Table 1. The proportion of older men was somewhat
higher among nondrinkers compared to drinkers. Nondrinkers less often had a positive
family history of prostate cancer and more often had a lower socioeconomic status than
drinkers.
In Table 2 rate ratios of prostate cancer for both categorized and continuous variables of
alcohol intake are shown. Total alcohol consumption was not related to prostate cancer risk
in the NLCS. For men consuming 30 g alcohol per day or more the RR was 1.09 (95% Cl:
0.77-1.55) compared to men who are nondrinkers. There was also no trend in risk. The RR
for intake of alcohol from beer was decreased in the highest intake category (RR for a 30
g/day vs nondrinkers was 0.47, 95% CI:0.17-1.30). In intermediate categories no
Alcohol and prostate cancer 99
TaWe 2: Rate raffos (RRsJ and 95% confidence /nterva/s f 95% C/) for prostete cancer accord/ng to /ntefce of
a/coho/, Ne(her/ands Cohort Sfudy (7986-f992J.
Alcohol intake
(g/day)
Nondrinkers*
Total alcohol'
0.1-4
5-14
15-29
Continuous, 5 g increment
Alcohol from beer
no beer
0.1-4
5-14
15-29
*30
Continuous, 5 g increment
Alcohol from wine
no wine
0.1-4
5-14
15-29
230
Continuous, 5 g increment
Alcohol from liquor
no liquor
0.1-4
5-14
15-29
^30
Continuous, 5 g increment
Age-adjusted
No of cases/
personyears in
subcohort
110/1440
143/1947
161/2637
162/2181
104/1324
213/2621
220/3376
112/1594
19/329
6/170
220/3273
199/2685
91/1421
40/575
20/135
172/2616
155/2211
109/1595
94/1149
40/518
RR (95% Cl)
1.00
1.13(0.82-1.54)
0.95(0.70-1.28)
1.08(0.79-1.46)
1.19 (0.85-1.68)
P-trend 0.37
1.01 (0.98-1.04)
1.12(0.84-1.50)
1.00(0.75-1.34)
1.16(0.83-1.62)
1.09(0.60-2.00)
0.51 (0.20-1.30)
P-trend 0.76
0.97(0.91-1.03)
1.04(0.77-1.38)
1.08(0.80-1.45)
0.97(0.69-1.38)
1.15(0.73-1.82)
2.32(1.15-4.65)
P-trend 0.12
1.06(1.00-1.12)
1.09(0.80-1.47)
1.06(0.78-1.44)
1.00(0.72-1.40)
1.08(0.76-1.54)
1.17(0.73-1.86)
P-trend 0.65
1.01(0.97-1.05)
Multivariate adjusted'
No of cases/
personyears in
subcohort
109/1428
143/1931
161/2624
161/2162
101/1324
212/2608
218/3341
111/1594
19/329
6/170
219/3239
198/2679
90/1415
39/575
20/135
172/2597
154/2208
109/1589
92/1130
39/518
RR (95% Cl)
1.00
1.11(0.81-1.53)
0.92(0.68-1.26)
1.05(0.77-1.44)
1.09(0.77-1.55)
P-trend 0.74
1.00(0.97-1.03)
1.06(0.78-1.45)
0.93(0.68-1.28)
1.07(0.74-1.56)
1.01 (0.52-1.96)
0.47(0.17-1.30)
P-trend 0.48
0.96(0.89-1.03)
1.10(0.80-1.51)
1.05(0.77-1.44)
0.94(0.64-1.39)
1.08(0.65-1.81)
2.32(1.02-5.29)
P-trend 0.67
1.05(0.97-1.12)
1.06(0.77-1.46)
1.02(0.74-1.41)
0.97(0.67-1.40)
1.07(0.69-1.64)
1.07(0.56-2.04)
P-trend 0.96
1.00(0.94-1.06)
' Adjusted for age, family history of prostate cancer, socioeconomic status, and total alcohol intake; * Reference
category;' Not adjusted for total alcohol intake.
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associations were noted. For alcohol from liquor, no clear associations with prostate cancer
risk were observed. For intake of alcohol from wine, a significant increased risk was found
for the highest vs the lowest intake category (RR=2.32, 95% Cl: 1.02-5.29). In the
intermediate intake categories no increased risk was observed. The RR for the continuous
variable was 1.05 (95% Cl: 0.97-1.12) per 5 g increment.
In Table 3 alcohol intake is evaluated separately for different types of wine: red wine, white
wine, fortified wines and liqueurs. Because of sparse data, the highest intake category
comprised men consuming 15 g alcohol or more. For liqueurs, there were only two
exposure categories. No associations with risk of prostate cancer were found for intake of
alcohol from red wine and liqueurs. For intake of alcohol from white wine, an increased risk
was observed with higher consumption, but only in the highest intake category (RR=3.25,
95% Cl: 1.15-9.21). Also for intake of alcohol from fortified wines, only in the highest intake
category an increased risk was found (RR=2.32, 95% Cl: 1.16-4.67) and no dose-response
relationship was observed. Effect estimates for continuous variables were not statistically
significant. The results shown in Tables 2 and 3 did not materially change after exclusion of
cases detected in the first two years of follow-up (data not shown).
Alcohol intake was also evaluated in subgroups of localized and advanced prostate tumors
and the results are shown in Table 4. The two highest categories of alcohol from beer (15-
29 and s30 g/day) were combined to allow for a reasonable number of cases in the
subgroup analyses. Furthermore, because the effect of alcohol from white wine and alcohol
from fortified wines was similar in the overall analysis, these two sources of alcohol intake
were combined in order to attain a reasonable number of cases. The number of cases for
alcohol from liqueurs was not sufficient to conduct meaningful subgroup analyses. Overall,
alcohol intake showed stronger associations with localized prostate tumors than with
advanced prostate tumors. In the subgroup of localized prostate tumors, all RRs for total
alcohol intake were above the null value, but only in the intake category of 0.1-4.9 g/day a
significantly increased risk was found (RR=1.65, 95% Cl: 1.04-2.62). No associations with
advanced prostate tumors were found. Alcohol from beer showed no clear associations
with risk of either localized or advanced prostate tumors. For alcohol from wine, all RRs
were increased in the subgroup of localized prostate tumors. Subjects consuming ;>30 g
alcohol per day from wine had a RR of 4.62 (95% Cl: 1.59-13.44) compared to nondrinkers.
Among advanced prostate tumors, only the RR in the highest intake category was
increased (RR=2.93, 95% Cl: 1.01-8.49). In both subgroups, however, no trend in risk was
observed. Although all RRs were increased for intake of alcohol from liquor in the localized
prostate tumors subgroup, all but one RRs were statistically nonsignificant and a dose-
response relationship was not observed (p-trend=0.08). For advanced prostate tumors no
associations with intake of alcohol from liquor were apparent. No trend in risk was found for
intake of alcohol from red wine in both subgroups. A borderline significant positive trend in
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risk was observed for the combined intake of alcohol from white wine and fortified wines
among localized prostate tumors (p-trend 0.06). Compared to nondrinkers, men with an
intake of >15 g/day had a RR of 3.60 (95% Cl: 1.54-8.44). Among the advanced prostate
tumor group, the effect estimate for the same contrast was 2.24 (95% Cl: 0.95-5.24).
fab/e 3: Rate raffos fRRsJ and 95% confidence /nfervate (95% C/j for prostete cancer according to /ntefce of
a/coho/, Atef/ier/ands Cohort S(udy (7986-J992J.
Alcohol intake
(Q/day)
Nondrinkers'
Alcohol from red wine
no red wine
0.1-4 -
5-14
s15
Continuous, 5 g increment
Alcohol from white wine
no white wine
0.1-4
5-14
a15
Continuous, 5 g increment
Alcohol from fortified wines
no fortified wines
0.1-4
5-14
a15
Continuous, 5 g increment
Alcohol from liqueur
no liqueur
0.1-4
a5
Continuous, 5 g increment
Age-adjusted
No of cases/
personyears in
subcohort
110/1440
349/5071
151/2178
55/602
15/239
362/5274
180/2551
20/226
8/38
411/5772
108/1599
27/557
24/161
511/7313
52/669
7/107
RR (95% Cl)
1.00
1.04(0.79-1.36)
1.05(0.77-1.43)
1.44(0.94-2.20)
0.95(0.49-1.84)
P-trend 0.21
1.03(0.94-1.14)
1.05(0.80-1.37)
1.06(0.78-1.43)
1.25(0.67-2.33)
3.38(1.36-8.45)
P-trend 0.13
1.24(1.04-1.47)
1.09(0.84-1.43)
0.97 (0.69-1.35)
0.74(0.44-1.22)
2.46(1.29-4.69)
P-trend 0.53
1.08(0.98-1.19)
1.06(0.81-1.37)
1.16 (0.76-1.77)
1.17(0.46-2.99)
P-trend 0.37
0.91 (0.59-1.41)
Multivariate adjusted'
No of cases/
personyears in
subcohort
109/1428
347/5030
150/2178
54/596
15/239
359/5233
180/2545
19/226
8/38
408/5731
108/1593
26/557
24/161
507/7266
52/669
7/107
RR (95% Cl)
1.00
1.04(0.78-1.40)
0.95(0.67-1.34)
1.26(0.78-2.02)
0.82(0.40-1.70)
P-trend 1.00
0.99(0.89-1.11)
1.07(0.80-1.43)
1.00(0.72-1.39)
1.15(0.60-2.24)
3.25(1.15-9.21)
P-trend 0.54
1.22(0.99-1.49)
1.10(0.82-1.47)
0.88(0.62-1.26)
0.66(0.38-1.13)
2.32(1.16-4.67)
P-trend 0.77
1.07(0.96-1.19)
1.01 (0.75-1.34)
1.13(0.74-1.74)
1.17(0.46-3.00)
P-trend 0.48
0.94(0.61-1.45)
' Adjusted for age, family history of prostate cancer, socioeconomic status, and total alcohol intake; * Reference
category.
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TaWe 4: Rate raffos ff?/?j and 95% confidence /nferva/s ("95% C/J for pros/ate cancer accord/ng to a/coto/ /ntefce
/n subgroups of/öcafeed and advancedprosfafe (umors, We/ner/ands Cotorf Sfudy (J9S6-J992J.
Alcohol intake
(g/day)
Nondrinkers'
Total alcohoP
0.1-4
5-14
15-29
230
Alcohol from beer
no beer
0.1-4
5-14
i15
Alcohol from wine
no wine
0.1-4
5-14
15-29
*30
Alcohol from liquor
no liquor
0.1-4
5-14
15-29
*30
Alcohol from red wine
no red wine
0.1-4
5-14
i15
Alcohol from white/
fortified wine
no white/ fortified wine
0.1-4
5-14
*15
Person years
in subcohort
1428
1931
2624
2162
1324
2608
3341
1594
499
3239
2679
1415
575
135
2597
2208
1589
1130
518
5030
2178
596
239
44210
2804
785
243
Localized
(T0-2,
No of
cases
28
59
55
61
33
84
82
35
7
87
69
33
11
8
57
63
41
33
14
127
60
16
5
107
70
19
12
prostate tumors
M0); n=247
RR (95% Cl)'
1.00
1.65(1.04-2.62)
1.14(0.72-1.81)
1.43(0.91-2.27)
1.28(0.76-2.18)
P-trend 0.67
1.71 (1.05-2.77)
1.43(0.88-2.34)
1.40(0.78-2.53)
0.96 (0.36-2.59)
P-trend 1.00
1.87(1.14-3.07)
1.50(0.92-2.46)
1.48(0.82-2.68)
1.37(0.60-3.12)
4.62(1.59-13.44)
P-trend 0.38
1.47(0.89-2.45)
1.72(1.05-2.84)
1.58(0.89-2.80)
1.76(0.90-3.43)
1.99(0.75-5.30)
P-trend 0.08
1.57(0.98-2.50)
1.58(0.94-2.68)
1.61 (0.77-3.36)
1.22(0.40-3.68)
P-trend 0.32
1.71 (1.06-2.76)
1.45(0.88-2.40)
1.61(0.82-3.17)
3.60(1.54-8.44)
P-trend 0.06
Advanced
(T3-4, M0;
No of
cases
34
44
63
49
35
63
81
40
7
65
72
32
14
8
58
58
35
25
15
116
46
24
5
87
73
20
11
prostate tumors
TO-4, M1); n=236
RR (95% Cl)'
1.00
0.99(0.62-1.59)
1.06(0.68-1.63)
0.93(0.59-1.48)
1.09(0.66-1.80)
P-trend 0.94
0.99(0.62-1.60)
1.07(0.67-1.71)
1.22(0.70-2.13)
0.72(0.27-1.92)
P-trend 0.65
1.03(0.63-1.67)
1.20(0.75-1.92)
1.04(0.58-1.85)
1.19(0.55-2.54)
2.93(1.01-8.49)
P-trend 0.25
1.07(0.66-1.74)
1.18(0.73-1.90)
0.94(0.53-1.64)
0.88(0.45-1.72)
1.19(0.47-3.02)
P-trend 0.78
1.13(0.72-1.75)
0.91 (0.53-1.51)
1.68(0.87-3.25)
0.84 (0.28-2.52)
P-trend 0.70
1.04(0.65-1.65)
1.13(0.70-1.81)
1.21 (0.63-2.32)
2.24 (0.95-5.24)
P-trend 0.12
' Adjusted for age, family history of prostate cancer, socioeconomic status, and total alcohol intake;' Reference
category; * Not adjusted for total alcohol intake.
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Discussion
In this study we found no evidence that total alcohol consumption is related to the risk of
developing prostate cancer. However, when specific types of alcohol were investigated,
high intakes of alcohol from white wine and fortified wines were associated with increased
risks. No clear associations existed between alcohol intake from beer, liquor, red wine, and
liqueurs and prostate cancer risk. We found no evidence that consumption of alcohol is
more related to advanced prostate tumors. On the contrary, alcohol intake showed mostly
positive associations in the subgroup of localized prostate tumors.
An important strength of our study is the prospective design, therefore, recall bias is
unlikely. Furthermore, selection bias due to loss to follow-up did not influence our results
because of the high completeness of follow-up of cases and subcohort members in the
NLCS (46, 54). Another advantage is that the assessment of alcohol consumption in the
NLCS allowed us to extensively evaluate a possible association with prostate cancer risk.
Not only overall consumption of alcohol, but also different types of alcoholic beverages
were investigated. Moreover, consumption of several types of alcoholic beverages was also
evaluated within case subgroups based on tumor characterisation. Misclassification of
exposure is a possible limitation of our study. However, if misclassification has occurred,
this is expected to be nondifferential and risk estimates are most likely biased towards the
null value. Abstainers and ex-drinkers were not separated in our study, but were included in
our reference category of nondrinkers. Ex-drinkers may differ in prostate cancer risk from
abstainers and therefore, our estimated risks might be biased in either direction. Thus far,
however, an association between alcohol and prostate cancer has not been established
definitely and it is also not known whether or how the timing of alcohol consumption might
play a role. Further studies are needed to evaluate this matter. We considered most of the
factors that have been implied in prostate cancer etiology and factors showing an
association with prostate cancer risk in the NLCS were included into the multivariate model.
Thus, total energy and fat intake were not included and also vegetable and fruit
consumption were not included. Certainly, confounding by unmeasured or other unknown
factors cannot be excluded.
In the majority of cohort (6-10, 12, 15-19) and case-control studies (20, 23, 24, 27, 29-31,
33-35, 37, 39, 41, 42) no association between total alcohol consumption and prostate
cancer risk was found and this was confirmed in the NLCS. In one cohort study in Japan,
alcohol consumption was positively associated with prostate cancer risk and when specific
alcoholic beverages were investigated, a significant positive association for consumption of
shochu was noted (14). In another cohort study alcohol abusers developed prostate cancer
more often than expected (11). In none of the cohort studies was a decreased risk
observed. In case-control studies a few positive associations (21, 25, 26) as well as one
inverse association (22) between total alcohol consumption and prostate cancer risk were
noted.
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Although a nonsignificant decreased risk was suggested in the highest intake category of
beer in our study, in the other exposure categories no association was found. Other cohort
(6, 10, 13, 14) and case-control studies (25, 27, 33, 36, 38, 41) support a conclusion of no
association between consumption of beer and risk of prostate cancer. There was one
cohort study in which ex-users of beer showed an increased risk of prostate cancer
mortality (13). In three case-control studies beer consumption increased prostate cancer
risk (21, 26, 40) and in two of these studies also a significant trend in risk was reported (21,
26). However, in one of these case-control studies other types of alcohol were also
associated with an increased prostate cancer risk and therefore it was concluded that the
association was due to alcohol and not due to some components of specific types of
beverages (21).
No association was found between red wine and prostate cancer risk within the NLCS, but
for consumption of white wine and fortified wines increased risks were observed at high
intakes. Only in two other cohort studies wine consumption was evaluated and no
associations were noted (6, 10). Also in most case-control studies no associations were
found (21, 25, 27, 32, 33, 38, 41), although some positive (26, 40) and inverse associations
(36) were indicated. Men consuming daily white wine or fortified wines might be a quite
distinctive socioeconomic group of the highest level. Therefore, residual confounding by
socioeconomic status or other factors related to socioeconomic status might be an
explanation for our observed associations regarding alcohol intake from white wine and
fortified wines. This explanation is further supported by the fact that for intake of alcohol
from beer an inverse association was observed in the highest exposure category. Among
older subjects, high intake of beer was more common in the lower than in the higher
socioeconomic classes.
Consumption of liquor was, as in the NLCS, not associated with prostate cancer risk in
most other epidemiological studies (6, 10, 13, 26-28, 33, 38, 40, 41). Nevertheless, in three
case-control studies a positive association was observed (21, 25, 36) and there was a
significant trend in risk in one of these studies (21).
The biological pathway relating alcohol consumption to prostate cancer risk is largely
unknown, but some mechanisms have been proposed to both explain an inverse as well as
a positive association between alcohol consumption and prostate cancer risk. A decreased
risk has been explained by the fact that ethanol has been found to decrease plasma
testosterone levels (55) which might decrease prostate cancer risk (25, 26). An increased
risk of prostate cancer associated with alcohol consumption has been explained by
metabolic activation of environmental nitrosamines by ethanol (21, 26). Furthermore,
alcohol contains contaminants that may be carcinogenic and the major metabolite of
alcohol, acetaldehyde, is also known to be carcinogenic and teratogenic (21).
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Immunodepression might also be a pathway through which tumor growth is stimulated by
consumption of alcohol (56). Indirect effects of alcohol consumption on prostate cancer risk
could be nutrient displacement, malabsorption, liver effects and related pathology (21, 56).
A specific hypothesis concerning beer consumption that has been proposed is that the
nitrosamine content of the beer in the past might be responsible for an increased risk of
prostate cancer (26). Finally, the observed positive associations of high white wine and
fortified wine consumption with prostate cancer may be due other unknown potential
biological pathways, or due to bias or confounding.
The hypothesis that environmental factors (alcohol consumption) are more strongly related
to advanced prostate tumors was not confirmed in this investigation. On the contrary, for
different types of alcoholic beverages, observed associations were most pronounced in the
subgroup of localized prostate tumors. The stronger associations with localized rather than
advanced prostate cancer might suggest a social class effect related to increased medical
consumption among men with a higher socioeconomic status. However, this issue was
separately investigated in the NLCS and no evidence for this explanation was found
(submitted for publication). Results from other studies are also somewhat inconsistent and
do not uniformely point into a direction of stronger associations with advanced prostate
tumors (21, 25, 27).
In summary, although total alcohol consumption seems not to be related to prostate cancer
risk, a positive effect of high intakes of specific types of alcoholic beverages, i.e. white wine
and fortified wines, cannot be excluded. Thus far, however, data from epidemiological
studies on these types of wine are sparse. Also because a possible biological pathway by
which the observed effect can be explained is unknown, this topic deserves further
investigation.
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Abstract
In the Netherlands Cohort Study we investigated whether anthropometry is associated with
prostate cancer risk. At baseline in 1986, 58,279 men aged 55-69 years completed a self-
administered questionnaire on diet, anthropometry and other risk factors for cancer. After
6.3 years of follow-up, 681 cases were available with complete data on height and weight at
baseline and 523 cases for weight at the age of 20 years. Both in age-adjusted and
multivariate case-cohort analyses (adjusted for age, family history of prostate cancer, and
socioeconomic status), height, body mass index (BMI; kg/rn^), and lean body mass (kg) at
baseline were not associated with prostate cancer risk. For BMI at age 20, the rate ratios
(RR) of prostate cancer for men with a BMI at age 20 up to 19, 21, 23, 25, and ^25 were
1.00 (ref), 1.06, 1.09, 1.39 and 1.34, respectively (p-trend = 0.02). For gain in BMI from age
20 to cohort baseline age an inverse trend in risk was found (p-trend = 0.03), which did not
persist after additional adjustment for BMI at age 20 (p-trend = 0.07). In subgroup analyses,
no clear associations between anthropometry and advanced prostate cancer were found.
Our findings suggest that body composition at the young adults age may already exert an
effect on later risk of prostate cancer.
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Introduction
Prostate cancer is one of the most frequently occurring types of cancer in western countries
but up to now very little is known about the etiology of the disease. Body composition is one
of several possible factors which might be related to prostate cancer risk (1, 2). Different
epidemiological studies have evaluated this possible relationship but with inconclusive
results. For height, weight, as well as body mass index (BMI), mostly positive or null
associations have been reported, both in cohort and case-control studies, but also inverse
associations have been observed (1, 2). A potential role of lean body mass (LBM) in
prostate cancer etiology is also still questionable (3-5). One important drawback probably
contributing to a, thus far, fairly incomplete picture of anthropometry and prostate cancer is
the fact that the majority of previous studies did not extensively evaluate this relationship.
Observed associations between anthropometry and prostate cancer are often explained by
an interaction with hormonal levels (androgens), but also mechanisms through insulin or
growth factors have been proposed (4-6). A hormonal etiology for prostate cancer seems
plausible because the normal growth and functioning of the prostate is influenced by
androgens. Increased testosterone has been implicated in prostate cancer carcinogenesis
(7) and body mass appears to influence serum androgen concentrations (8-10). Because of
the long induction period of cancer a possible effect of body composition on prostate cancer
risk might occur in an earlier stage of life. Only six studies (5, 6, 11-14) reported some
results on anthropometric measures early in life or change in anthropometric measures
during lifetime in relation to prostate cancer risk. Some findings indeed indicate an early
effect of body composition, but data are too sparse to draw strong conclusions.
Here, we report our results on anthropometry and change in anthropometric measures
during lifetime in relation to prostate cancer risk from the Netherlands Cohort Study (NLCS).
Materials and methods
T/7e cohort
Because the study design has been described before (15) we will only give a brief outline.
In September 1986 the NLCS was initiated. At baseline, 58,279 men aged 55-69 years
completed a self-administered questionnaire on usual diet, lifestyle, personal and family
history of cancer, anthropometry, demographic data, and other risk factors for cancer. The
case-cohort approach (16) was used for data processing and analysis. For calculation of
incidence rates of prostate cancer, the number of cancer cases diagnosed in the entire
cohort was used as the numerator, while person years at risk (denominator) were estimated
using a random sample of 1,688 men (subcohort). Follow-up for incident prostate cancer
was established by computerized record linkage with all nine cancer registries in The
Netherlands, and with the Dutch national data base of pathology reports (PALGA) (17). The
subcohort has been followed up biennially for vital status information which involved
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personal mailings and (for nonrespondents) additional contacts with municipal population
registries. Completeness of cancer follow-up was at least 96 percent (18) and no subcohort
members have been lost to follow-up. After a follow-up period of 6.3 years (September - .^
1986-December 1992), 704 incident, microscopically or histologically confirmed, primary
prostate cancer cases were detected.
Date co//ecf/on and ana/ys/s . : • i
Information on height (in cm), weight at baseline and weight at age 20 (both in kg) was -
obtained using a self-administered questionnaire. In order to minimize observer bias in
coding and interpretation of the data, questionnaire data of all cases and subcohort
members were key-entered twice and processed in a manner blinded with respect to
case/subcohort status. Baseline BMI and BMI at age 20 were calculated using baseline
weight and weight at age 20, respectively, divided by height at baseline squared (kg/rn^).
Change in BMI from age 20 to baseline was calculated as BMI at baseline minus BMI at age
20. LBM (kg) was calculated as [2.447 - 0.09516 age (years) + 0.1074 height (cm) + 0.3362
weight (kg)]/0.732, as described by, e.g., Willett (19). All subjects with prevalent cancer
other than skin cancer were excluded. Furthermore, all men with incomplete data on
anthropometric measures at baseline were excluded, leaving 681 cases and 1565
subcohort members for analyses. Regarding BMI at age 20, complete data were available
for 523 cases and 1249 subcohort members.
Mean values of anthropometric and potential confounding variables were compared
between cases and subcohort members. Rate ratios (RRs) of prostate cancer and 95
percent confidence intervals (95 percent Cl) were computed using the GLIM statistical
package (20). Exponentially distributed survival times were assumed in the follow-up period.
Since standard software was not available, specific macros were developed to account for
the additional variance introduced by using the subcohort instead of the entire cohort (21).
Tests for trend were based on likelihood ratio tests; two-sided P-values are used throughout
this report. Age-adjusted and multivariate-adjusted analyses were conducted for
categorized and continuous anthropometric variables. Variables included in the multivariate
analyses were age (continuous), family history of prostate cancer (no, yes), and
socioeconomic status (low, medium, high) because these variables were associated with
prostate cancer risk in our study. Energy and fat intake were not related to prostate cancer
risk in the NLCS and therefore not considered as potential confounding variables. The
same applies to vegetable and fruit consumption (22).
In order to evaluate whether results for baseline BMI were biased because of an influence
of disease occurrence, we performed analyses with exclusion of cases detected in the first
two years of follow-up. In order to investigate the hypothesis that latent and nonlatent or
aggressive prostate tumors might have a different etiology subgroup analyses were
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performed for continuous anthropometric variables within case subgroups of localized (T0-
2, MO) and advanced (T3-4, MO; TO-4, M1) prostate tumors (using the TNM classification);
well differentiated, moderately differentiated and poorly and undifferentiated prostate
tumors; and of latent and nonlatent tumors. Based on information from the pathology
reports that have been obtained from PALGA, prostate cancer cases detected during
transurethral prostate resections were coded as latent. Cases detected during surgical
procedures used in case of suspected cancer (biopsy, radical prostatectomy) were coded
as nonlatent. Cases were excluded from these subgroup analyses when this additional
information was unknown or unclear (38.8 percent).
FaWe f: Descr/pf/on ofantfiropomefric variaWes andpofenfia/confounders mprosfate cancer cases and
subco/iort members, Netfierfands Cohort S/udy (f 986- 7992J.
Variables
Anffiropomefric variaWes
Height at baseline (cm)
Weight at baseline (kg)
BMI at baseline (kg/nV)
LBM at baseline (kg)
Weight at age 20' (kg)
BMI at age 20' (kg/nf)
Pote/?//a//y confound/ng var/aWes
Age (years)
Positive family history of prostate cancer (% yes)
Highest educational leveP (%)
low
medium
high
Cases (n = 681)
mean
176.3
77.8
25.0
56.7
68.0
21.9
63.8
4.3
46.3
33.2
19.7
SD
6.7
9.2
2.5
4.9
8.3
2.4
3.8
Subcohort (n =
mean
176.6
78.0
25.0
57.1
67.9
21.8
61.4
2.6
48.1
33.8
17.4
1565)
SD
6.8
9.8
27
5.2
8.4
2.5
4.2
' Based on 523 cases and 1249 subcohort members;' There was missing information for 0.9% (cases) and 0.7%
(subcohort members); low is defined as primary school with/without lower level vocational education, medium as
secondary school or medium level vocational education, high as university or higher level vocational education.
Results
In table 1 anthropometric variables are described for cases and subcohort members. The
means of all anthropometric variables did not differ to a large extent between cases and
subcohort members. Furthermore, when subcohort members with missing information for
weight at the age of 20 were compared to subcohort members who had mentioned their
weight at the age of 20 years, no differences in mean height were found. However,
subcohort members with missing information regarding weight at age 20 had a lower weight
and BMI at baseline (76.4 kg and 24.6 kg/m*, respectively) than men with complete
information (78.4 kg and 25.1 kg/rn^, respectively). These differences in mean weight and
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BMI were statistically significant. For cases, subjects with missing information regarding
weight at age 20 did not differ on baseline height, weight and BMI from cases who had
mentioned their weight at the age of 20 years (data not shown). Also shown in table 1 are
some potentially confounding variables. The mean age is somewhat higher among cases
(63.8 years) than among controls (61.4 years). Furthermore, cases more often reported a
positive family history of prostate cancer (4.3 percent vs 2.6 percent) and are more highly
educated than subcohort members.
Faö/e 2: Rate ratfos (RR) and 95% confidence /nte/va/s fC/J forprostate cancer accord/ng to anfhropomelric
i/ariaWes, Nefnenands Conorf Sftvdy (?986-f992J.
Anthropometric
variables
Height at baseline (cm)
<170'
170-175
175-180
180-185
185-190
^190
Height continuous,
5 cm increment
BMI at baseline (kg/m')
<22'
22-24
24-26
26-28
*28
BMI continuous,
2 kg/rrf increment
LBM at baseline (kg)
<52'
52-55
55-58
58-61
*61
LBM continuous
2 kg increment
Age-adjusted
No of cases/person
years in subcohort
100/1287
155/2272
214/2703
142/1888
50/913
20/307
63/1047
167/2218
237/3012
151/1988
63/1106
108/1367
148/1959
168/2150
138/1863
119/2031
RR(95%CI)
1.00
0.92(0.67-1.27)
1.12(0.83-1.52)
1.03(0.74-1.43)
0.83(0.54-1.26)
0.97 (0.97-0.53)
P-trend 0.88
1.00(0.94-1.08)
1.00
1.21(0.85-1.74)
1.28(0.91-1.80)
1.22(0.84-1.75)
0.85(0.55-1.29)
P-trend 0.38
0.98(0.91-1.05)
1.00
0.99(0.72-1.36)
1.07(0.78-1.46)
1.05(0.76-1.44)
0.96(0.69-1.33)
P-trend 0.92
0.99(0.96-1.03)
Multivanate adjusted
No of cases/person
years in subcohort
99/1262
154/2259
210/2690
142/1879
50/907
20/307
63/1047
164/2211
236/2980
150/1976
62/1091
108/1361
145/1940
166/2131
138/1851
118/2022
RR' (95% Cl)
1.00
0.90(0.65-1.24)
1.08(0.79-1.47)
0.98(0.70-1.37)
0.78(0.51-1.19)
0.96(0.52-1.75)
P-trend 0.60
0.99(0.92-1.06)
1.00
1.20(0.84-1.73)
1.35(0.95-1.90)
1.26(0.87-1.83)
0.89(0.58-1.37)
P-trend 0.73
1.00(0.92-1.07)
1.00
0.98(0.71-1.35)
1.07(0.79-1.47)
1.05(0.76-1.45)
0.95(0.69-1.33)
P-trend 0.95
1.00(0.96-1.03)
' RRs adjusted for age, family history of prostate cancer, and socioeconomic status;' Reference category.
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In table 2 age-adjusted as well as multivariate-adjusted RRs of prostate cancer are
displayed for baseline height, BMI, and LBM. Both in the age-adjusted and multivanate
analyses height was not associated with prostate cancer risk. The RRs for BMI at baseline
were slightly (but nonsignificantly) increased in the third and fourth category, but the RR
somewhat decreased in the highest category and there was no trend in risk (p-trend =
0.73). For LBM we found no association with prostate cancer risk. Results for BMI and LBM
after exclusion of cases detected in the first two years of follow-up were essentially the
same (data not shown). We also conducted analyses in which each exposure variable was
adjusted for the other exposure variables. The estimated RRs were essentially the same as
those presented in table 2 (data not shown).
TaWe 3: Rate ratfos (RR) and 95% confidence /nterva/s fC/j for prostete cancer accord/ng to an/hropomefric
variaWes a(age 20, Nefhertands Cohort S/udy ff 986-J992J.
Anthropometric variables
BMI at age 20 (kg/m')
<19'
19-21
21-23
23-25
*25
BMI at age 20 continuous,
2 kg/rn^ increment
Change in BMI from age 20
to baseline (kg/nf)
-9.2 to <0
0 to +2>
+2 to+4
+4 to-»6
+6 to+8
Gain in BMI from age 20 to
baseline continuous,
2 kg/m' increment
Age-adjusted
No of cases/
person years
in subcohort
57/908
124/1909
178/2552
119/1521
45/598
47/668
122/1876
179/2104
113/1537
43/852
19/451
RR(95%CI)
1.00
1.10(0.75-1.62)
1.13(0.79-1.64)
1.34(0.91-1.99)
1.34(0.82-2.20)
P-trend 0.04
1.07(0.98-1.17)
1.19(0.77-1.84)
1.00
1.31 (0.97-1.76)
0.99(0.72-1.37)
0.78(0.51-1.18)
0.61 (0.35-1.08)
P-trend 0.01
0.91 (0.83-0.99)
Multivariate adjusted
No of cases/
person years
in subcohort
57/902
122/1902
176/2536
119/1496
44/598
47/668
120/1857
176/2104
113/1512
43/852
19/441
RR' (95% Cl)
1.00
1.06(0.72-1.56)
1.09(0.76-1.58)
1.39(0.93-2.06)
1.33(0.81-2.19)
P-trend 0.02
1.08(0.99-1.18)
1.19(0.74-1.90)'
1.00
1.32(0.98-1.79)'
1.04(0.74-1.47)'
0.83(0.53-1.31)'
0.67(0.36-1.23)'
P-trend 0.07'
0.93(0.84-1.03)'
' RRs adjusted for age, family history of prostate cancer, and socioeconomic status;' Reference category;'
Additional adjustment for BMI at age 20; * The test for trend applies to weight gain categories only.
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In table 3, results for BMI at age 20 and gain in BMI from age 20 to cohort baseline age are
displayed. For BMI at age 20, a significant positive trend in risk (p-trend = 0.02) was found.
Men with a BMI at age 20 of 25 or more had a RR of 1.33 (95 percent Cl 0.81-2.19)
compared to men with a BMI at age 20 of less than 19. For both subcohort members and
cases, 9 percent of all men lost weight. The mean gain in weight (standard deviation) for
subcohort members and cases was +12.1 (8.4) kg and +11.2 (7.1) kg, respectively. The
mean gain in BMI (standard deviation) was +3.9 (2.6) kg/m* for subcohort members and
+3.6 (2.2) kg/rn^ for cases. A significantly decreasing trend in risk was observed for an
increase in BMI from age 20 to cohort baseline age (p-trend = 0.03), however, after
additional adjustment for BMI at age 20 the trend test was no longer statistically significant
(p-trend = 0.07). Only in the two highest categories of gain in BMI nonsignificant decreased
RRs were observed (0.83 and 0.67, respectively).
FaWe 4: Rate ratfos (RRJ and 95% confidence /nterva/s ("C/j for prostete cancer accord/ng to anfnropomefric
variao/es /n subgroups of focafeed (TO-2, MOj and advanced f F3-4, MO; TO-4, Mf j prostete (umors,
Wefner/ands Cohort Sfudy ( 7 986-f 992|
Localized tumors Advanced tumors
(n = 239) (n = 226)
Anthropometric variables RR' (95% Cl) RR' (95% Cl)
Height at baseline continuous, 5
cm increment 0.99(0.89-1.10) 0.98(0.88-1.10)
BMI at baseline continuous,
2 kg/m' increment 0.96(0.86-1.06) 1.01(0.90-1.13)
LBM at baseline continuous,
2 kg increment 0.98(0.93-1.03) 1.00(0.94-1.06)
BMI at age 20 continuous,
2 kg/m* increment 1.18(1.04-1.35) 1.03(0.91-1.18)
Gain in BMI from age 20 to
baseline continuous, 2 kg/m*
increment 0.87(0.74-1.02)' 0.93(0.80-1.08)*
' Adjusted for age, family history of prostate cancer, and socioeconomic status;' Additional adjustment for BMI at
age 20.
In table 4 RRs are displayed for continuous anthropometric variables in case subgroups of
localized and advanced prostate tumors. No association was found between height and
localized or advanced tumors. Baseline BMI and LBM were also not associated with either
localized or advanced prostate tumors. In contrast, for BMI at age 20 a significant increase
in risk of localized prostate tumors was found (RR per increment of 2 kg/rn^ of 1.18, 95
percent Cl 1.04-1.35). No association between BMI at age 20 and advanced prostate
tumors was shown. The overall negative association between gain in BMI and prostate
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cancer risk was more pronounced for localized prostate tumors (RR = 0.86, 95 percent Cl
0.75-0.99 per increment of 2 kg/m'). Table 5 shows continuous anthropometric variables
evaluated in case subgroups by differentiation grade of the tumor. Some associations were
noted in different subgroups, however, anthropometric measures showed no consistent
association with one specific subgroup of prostate cancer tumors. For both latent and
nonlatent tumors no clear associations were observed (data not shown).
TaWe 5: Rate raftbs (RR) and 95% confidence /nterva/s fC/j for prostate cancer accorc/mg to antfiropo/nefric
varaWes /n subgroups on d/'fferenfiaf/on grade, Nefher/ands Cohort Sfudy (J986- f 992j.
Anthropometric variables
Height at baseline continuous,
5 cm increment
BMI at baseline continuous,
2 kg/m' increment
LBM at baseline continuous,
2 kg increment
BMI at age 20 continuous, 2 kg/m'
increment
Gain in BMI from age 20 to baseline
continuous, 2 kg/m' increment
Well differentiated
(n = 194)
RR' (95% Cl)
0.94(0.84-1.06)
0.92(0.82-1.04)
0.94(0.89-1.00)
1.09(0.94-1.26)
0.77 (0.65-0.92)'
Moderately
differentiated
(n = 247)
RR' (95% Cl)
0.98(0.89-1.08)
1.02(0.93-1.13)
1.00(0.95-1.06)
1.15(1.01-1.31)
0.97(0.83-1.13)'
Poorly/
undifferentiated
(n = 174)
RR' (95% Cl)
1.07(0.95-1.21)
1.01(0.89-1.14)
1.03(0.97-1.10)
0.97(0.83-1.13)
0.68(0.58-0.81)'
' Adjusted for age, family history of prostate cancer, and socioeconomic status;' Additional adjustment for BMI at
age 20.
Discussion
In our study we observed no clear associations between height, BMI, and LBM and prostate
cancer risk. For BMI at age 20 a significant positive trend in risk was observed. In contrast,
for a gain in BMI from age 20 to cohort baseline age, a significant inverse trend in risk was
found. After correction for the absolute BMI at the age of 20 the trend test was no longer
statistically significant. In subgroup analyses, these observed associations for overall
prostate cancer risk were mainly found in the subgroup of localized prostate tumors. We
found no evidence that anthropometric variables were more strongly related to advanced
prostate tumors, poorly and undifferentiated tumors or nonlatent tumors.
The results from the NLCS are not likely to be influenced by selection bias given the high
completeness of follow-up of cases and subcohort person years (18, 23). All the
anthropometric measures are self-reported and misclassification of exposure is a potential
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source of bias. Weight at age 20 was used to calculate BMI at age 20 and misclassification
of BMI at age 20 might have occurred, because weight at age 20 is difficult to remember.
However, misclassification is expected to be nondifferential and therefore a possible effect
on the risk estimates should be towards the null value. When we compared the mean self-
reported height and weight at baseline in the subcohort with the mean height and weight of
a representative sample of Dutch men aged 50 to 69 years in 1985-88 (24) these measures
were comparable. Finally, residual confounding of the effect measures cannot be excluded,
although we considered several potential confounding factors.
For 20 percent and 23 percent, respectively, of cases and subcohort members data
regarding BMI at age 20 were missing. Cases with and without information regarding BMI at
age 20 did not differ in baseline anthropometric measures, but subcohort members with
missing information had a lower weight and BMI at baseline than subcohort members with
complete information. Because of these missing data, our positive association with regard
to BMI at age 20 needs to be carefully interpreted. One case-control study reported no
association between BMI 20 years prior to the interview and prostate cancer (25). In another
case-control study risk estimates for prostate cancer were nonsignificantly increased in
association with BMI at age 25 and at age 45 (14). In contrast to these findings,
Giovannucci et al. (5) found no association between BMI at age 21 and overall prostate
cancer risk, but an inverse association between BMI at age 21 and advanced prostate
cancer risk was reported; The RR for men with a BMI >26 versus <20 at age 21 was 0.53.
For obesity at ages 5 and 10, based on self-reported assessments using pictograms of
body size, a reduced risk was also noted. An explanation that was given for this decreased
risk is that if obesity is related to the hormonal milieu, low testosterone and IGF-I levels and
higher estrogen levels may lower the risk of prostate cancer. In another cohort study (6) and
case-control study (11) no clear associations were seen for BMI at a younger age (20 or 25)
and prostate cancer risk. In general, obesity has been reported to be inversely associated
with plasma testosterone levels (5, 8-10, 26) and lower testosterone levels may be related
to a lower prostate cancer risk (7). Therefore, the suggested positive association observed
in our study is somewhat unexpected. However, obesity also shows an inverse relationship
with sex hormone-binding globuline (SHBG), and SHBG is hypothesized to have an inverse
association with prostate cancer risk (27). Because SHBG binds to testosterone and lower
levels of SHBG may lead to higher levels of bioavailable testosterone, this might be a
pathway explaining our observed positive association between BMI at age 20 and prostate
cancer risk. Our results which indicated an inverse trend in risk when evaluating gain in BMI
from age 20 to cohort baseline age (55-69 years), however, are not in concordance with this
hypothesis. Nevertheless, it might be plausible that different hormones or hormone levels
are involved at different stages in prostate cancer development. The prostate resides in a
multihormonal environment and a number of growth-regulatory pathways with complex
interactions are involved in epithelial proliferation (28). The exact role of hormones in the
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development of prostate cancer remains poorly understood (29). Therefore, studies
providing inside into possible mechanisms of action of hormones in relation to prostate
growth and prostate cancer are needed. In two cohort studies no association between
change in BMI from age 25 to cohort baseline age (65+ years) (6) or change in BMI from
college years to years following college (13) and prostate cancer risk was found. However,
in one of these cohort studies percent change in BMI from age 50 to cohort baseline age
(65+ years) showed a positive trend in risk (p-trend = 0.04), although none of the RRs were
statistically significant (6). Obviously, misclassification because of a poor memory of BMI at
earlier ages may have influenced results in different studies.
According to the results from one study, it has been suggested that lean body mass may be
associated with prostate cancer risk and not the fat tissue. In that study a positive
association was observed between the area of muscle in the arm but not with area of fat in
the arm, and prostate cancer risk (3). The authors speculated that increased muscle
development might reflect overproduction of sex hormones, this being a pathway explaining
their observed association. We found no association between estimated LBM and prostate
cancer risk and in another case-control study no association between fat-free mass and
prostate cancer was observed (30). In a retrospective cohort study among 135,006 Swedish
construction workers a significant positive trend (p-trend = 0.002) in risk was observed
between calculated LBM (using the same equation as in our study) and prostate cancer
incidence (4). The age-adjusted risk estimate for men with a LBM >62 compared to a LBM
<55 was 1.17 (95 percent Cl 1.04-1.32). A disadvantage of the calculated measure is that
the assumption of a constant water proportion in the LBM may not hold. Depending on the
state of hydration and the relative components of LBM the proportion of water varies (4, 19).
Sometimes other measures were used to estimate the distribution of fat in the body. No
clear associations were found between waist circumference and prostate cancer risk in
three studies (5, 31, 32). In the Health Professionals Follow-Up Study among 47,781 men
an inverse association was noted between hip circumference and prostate cancer. The risk
estimate for men in the fifth versus men in the first quintile was 0.85 (95 percent Cl 0.68-
1.06) and the trend test was statistically significant (p-trend = 0.04) (5). In one case-control
study no clear associations were observed with hip or thigh circumference and biacromial
breadth (31). However, in this latter case-control study significant differences between
cases and controls were found for the waist to thigh ratio (p = 0.03) with the cases having a
higher ratio than the controls. This was not confirmed in a later case-control study by the
same authors (30). In that study the only anthropometric measures that consistently differed
between cases and controls were indexes of upper body robustness, as assessed by
biacromial, bideltoid, and biacromial-to-standing height ratio measures (30). In one cohort
study the waist to hip ratio was not related to overall prostate cancer risk (5).
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Our results of no association between height and prostate cancer risk are in accordance
with results from other cohort studies (3, 6, 13, 33, 34) and case-control studies (14, 25, 30-
32, 35-42). Nevertheless, there were four cohort studies (4, 5, 43, 44) and two case-control
studies (45, 46) in which positive associations with increasing height were indicated. In
three of these studies the trend test was statistically significant (4, 43, 44). In one case-
control study the sitting to standing height ratio was significantly higher for cases than for
control subjects (31). Previous analyses from our study showed a strong positive
association between height and breast cancer risk (47). Because we do not expect the
determinants of adult height (e.g. childhood energy intake) to differ largely between men
and women in our cohort, the absence of variation in these determinants cannot explain our
finding of no association between height and prostate cancer risk. The observed positive
association between height and prostate cancer risk in some studies might be explained by
the fact that tallness could be the result of higher levels of insulin-like growth factor-l (IGF-I)
and testosterone, which might influence prostate cancer risk (4, 5). In the Health
Professionals Follow-Up Study (5), one of the prospective studies in which a positive
association between height and prostate cancer risk was found, an inverse association with
preadult obesity was observed. Both attained height and childhood obesity may be related
to the preadult hormonal milieu. Because of scarcity of data, more studies on preadult
exposures in relation to risk of prostate cancer are needed.
The vast majority of previous epidemiological studies on anthropometry and prostate cancer
reported results on indices of body mass index, as an indicator of adiposity. Like in our
study, in most cohort studies no clear associations were observed (3, 5, 13, 33, 43, 48, 49).
However, in four cohort studies positive associations were indicated (4, 6, 34, 50). Case-
control studies mostly reported null associations (25, 30-32, 36-40, 51-56), but also positive
associations were observed (12, 35, 45, 46). Because of the inverse association between
obesity and plasma testosterone levels (5, 8-10, 26) one should expect BMI to be inversely
related to risk of prostate cancer. However, the inverse association between BMI and
SHBG, as described before, might explain the positive associations observed in some
studies. Inconsistencies in reported results can partly be explained by the fact that the
evaluated range in BMI differed between the various studies. Another important drawback
of several of the published studies is that only correction for age was reported (3, 4, 12, 13,
25, 33, 34, 45, 46, 49, 51-54, 56). Also, in several case-control studies only a comparison of
mean BMI between cases and controls was reported and no risk estimates were computed
(31, 32, 36-40). Furthermore, if BMI in case-control studies was measured at the time of
diagnosis, disease may have affected this measure, leading to biased results.
Finally, we found no evidence of anthropometric measures being more strongly associated
with advanced, poorly and undifferentiated, or nonlatent prostate tumors. There were only a
few other studies (5, 6,11, 25, 43) in which case subgroups were evaluated. Results
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between these studies were not very consistent and do not permit definitive conclusions.
In conclusion, our results indicate an effect of early BMI (BMI at age 20) and change in BMI
from age 20 to baseline age. Thus far, evidence for an effect of early weight and weight
gain during lifetime is too limited to draw conclusions yet, and more research is warranted,
also to reveal potential mechanisms. Furthermore, the effect of timing of changes in
anthropometric meausures during lifetime also need attention in future studies on
anthropometry and prostate cancer risk. We found no association between height, BMI and
LBM at baseline and risk of prostate cancer.
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A case-cohort study on prostate cancer risk
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Abstract
We investigated the risk of prostate cancer in relation to a family history of prostate cancer
in 58,279 men aged 55-69 years. We found 704 incident cases after 6.3 years of follow-up.
Rate ratios and 95% confidence intervals for having an affected vs nonaffected father and
brother were, respectively 1.44 (0.80-2.58) and 5.57 (1.61-19.26). We found no evidence
for an increasing risk with an increasing percentage of affected family members. The
associations we observed were stronger for cases diagnosed before age 70 compared with
cases diagnosed after age 70 and for advanced compared with localized tumors.
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Introduction
Despite a high incidence of prostate cancer in Western countries, few risk factors are
known. A positive family history has been reported to be associated with risk (1, 2), but
limited data from prospective studies are available. With data from the Netherlands Cohort
Study we were able to investigate not only a positive family history, but also to take the
number of brothers into account as well as the age at diagnosis of brothers and fathers. We
were also able to investigate case subgroups (localized and advanced tumors) separately.
Methods
The cohort
The study design has been described in detail elsewhere (3). Briefly, in 1986, 58,279 men
aged 55-69 years who originated from 204 municipal population registries throughout the
country completed a self-administered questionnaire on personal and family history of
cancer, usual diet, and other risk factors for cancer. We used a case-cohort approach for
analyses (4): for calculation of cancer incidence rates, the number of cases for the entire
cohort was used as the numerator, while person years at risk (denominator) were estimated
using a random male sample of controls, the subcohort (n=1,630). We identified incident
prostate cancer cases using computerized record linkage with all nine cancer registries in
The Netherlands (5). The control subcohort has been followed up biennially for vital status
information. Completeness of cancer follow-up was at least 96%; no subcohort member has
been lost to follow-up (6). After 6.3 years of follow-up (September 1986-December 1992),
704 incident, primary prostate cancer cases were identified. During this period, systematic
screening for prostate cancer was not instituted in the Netherlands.
Date co//ectfon and ana/ys/s
Subjects were asked to report how many brothers they had, whether their father or
brother(s) had ever been diagnosed with prostate cancer and, if so, at what age. To take
family size into account in analyses, we computed the percentage of family members with
prostate cancer: the number of affected family members (fathers and brothers) divided by
the number of brothers plus one (father). A percentage was also computed for brothers
only.
We excluded subjects with prevalent cancer at baseline other than skin cancer and subjects
with incomplete or inconsistent dietary data according to criteria described before (7). A
total of 642 cases and 1,525 subcohort members remained for analysis. First, we examined
potential confounding factors including age, educational level, fat intake, and consumption
of vegetables and fruit. Second, we computed rate ratios (RRs) and 95% confidence
intervals (Cl). We assumed that survival times were exponentially distributed in the follow-
up period (8). We also computed RRs for subgroups of cases diagnosed before and after
age 70 and for localized (TO-2, MO) and advanced (T3-4, MO; TO-4, M1) tumors.
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Results
Of subcohort members and cases, 2.5% and 4 . 1 % , respectively, had a father or brother
with prostate cancer. Table 1 shows descriptive information on subcohort members and
cases. Subcohort members and cases with a positive family history were younger compared
with subjects without a family history. Furthermore, they less often had a lower educational
level. Fat intake and consumption of vegetables and fruit also differed between subjects
with and without a family history of prostate cancer but patterns in the distribution were less
clear.
Tab/e 7: D/s/ribufon of potenffa/ confound/ng factors among subcotort members and cases tv/fti a negafiVe and
pos/ftVe fam//y n/sfory of prosfafe cancer, Ne/ner/ands Co/iort Sfudy f7986-7992J.
Variables
Age
55-59
60-64
65-69
Educational level'
low
medium
high
Fat intake (quintiles)
1 (low)
2
3
4
5 (high)
Vegetable consumption (quintiles)
1 (low)
2
3
4
5 (high)
Fruit consumption (quintiles)
1 (low)
2
3
4
5 (high)
Person years in
subcohort (%)
No family
history
3417 (38.5)
3095 (34.9)
2355 (26.6)
4176(47.1)
3065 (34.6)
1574(17.7)
1763(19.9)
1753(19.8)
1771 (20.0)
1787(20.2)
1794 (20.2)
1800(20.3)
1702(19.2)
1760 (19.8)
1828 (20.6)
1778 (20.0)
1810(20.4)
1748(19.7)
1768(19.9)
1778(20.1)
1763(19.9)
Positive family
history
119(47.0)
100(39.1)
35(13.9)
81 (31.7)
123(48.5)
44(17.3)
43 (16.9)
54(21.3)
69 (27.2)
38 (14.8)
50 (19.8)
62 (24.3)
82 (32.1)
57 (22.2)
35(13.9)
19(7.4)
31 (12.4)
57 (22.2)
47 (18.4)
50 (19.8)
69 (27.2)
Number of
cases(%)
No family
history
92 (15.0)
217(35.3)
305 (49.7)
275 (45.2)
212(34.8)
122(20.0)
135(22.0)
130(21.2)
123 (20.0)
119(19.4)
107(17.4)
121 (19.7)
130(21.2)
122 (19.9)
141 (23.0)
100(16.3)
116(18.9)
110(17.9)
101 (16.4)
140 (22.8)
147 (23.9)
Positive family
history
6(21.4)
12(42.9)
10(35.7)
10(35.7)
10(35.7)
8 (28.6)
5(17.9)
7 (25.0)
6(21.4)
4(14.3)
6(21.4)
6(21.4)
2(7.1)
9(32.1)
6(21.4)
5(17.9)
- -
9(32.1)
5(17.9)
6(21.4)
8 (28.6)
' Because of missing information, percentages may not add up to 100%; low is defined as primary school
with/without lower level vocational education, medium as secondary school or medium level vocational education,
high as university or higher level vocational education.
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Age-adjusted and multivariate adjusted RRs for prostate cancer according to family history
were comparable (Table 2). A positive vs negative family history was associated with an
increased prostate cancer risk (RR=1.77). For an affected father the estimate was 1.38 with
a 95% Cl of 0.76-2.49, for one or more affected brothers the RR was 5.54 (1.75-17.50). The
RR for subjects with less than 50% of family members affected was 3.09 (1.60-5.98) and
0.95 (0.34-2.66) when more than 50% was affected. For subjects with less than 50% of
their brothers affected the RR was 12.26 (2.34-64.35) and 2.60 (0.51-13.26) when more
Tatte 2: Rate ratfos fRRsj and 95% confidence /nterva/s (95% C/J for prostate cancer accord/ng to /he number
and percentage of affected firs/ degree fern/Ty members and age a/ d/agnos/s of /hese fem//y members,
Nefner/ands Conor/ Sfudy (7986-J992J.
Exposure
No. of affected family members
none
i 1
Father with prostate cancer
no
yes
Brother(s) with prostate cancer
no
yes
% of affected family members
none
1-49
s50
% of affected brothers
none
1-49
250
Age (years) at diagnosis family
member'
no affected family member
i75
<75
Age (years) at diagnosis father
no affected father
i75
<75
Age-adjusted
Cases*/
Person years
in subcohort
614/8868
28/254
622/8893
20/229
634/9097
8/25
614/8868
20/125
6/86
504/7232
5/13
3/13
614/8868
11/111
13/113
622/8893
11/111
7/94
RR (95% Cl)
1.00'
1.77(1.06-2.96)
1.00'
1.36(0.75-2.45)
1.00'
6.29(1.92-20.55)
1.00'
3.00(1.83-4.89)
0.99(0.50-1.97)
1.00'
12.74(3.06-53.00)
3.50 (0.95-12.86)
1.00'
1.37(0.80-2.33)
2.38(1.41-4.03)
1.00'
1.35(0.64-2.86)
1.58(0.61-4.06)
Multivariate adjusted'
Cases*/
Person years
in subcohort
609/8814
28/248
617/8839
20/223
629/9037
8/25
609/8814
20/118
6/86
500/7175
5/13
3/13
609/8814
11/111
13/107
617/8839
11/111
7/88
RR (95% Cl)
1.00'
1.77(1.05-2.97)
1.00'
1.38(0.76-2.49)
1.00'
5.54(1.75-17.50)
1.00'
3.09(1.60-5.98)
0.95 (0.34-2.66)
1.00'
12.26 (2.34-64.35)
2.60 (0.51-13.26)
1.00'
1.36(0.64-2.89)
2.36(1.10-5.07)
1.00'
1.34(0.63-2.86)
1.64(0.63-4.23)
' Adjusted for age at baseline (continuous), educational level (low, medium, high), total fat intake (continuous),
and total vegetable and total fruit consumption (both continuous); * Because of missing information, numbers may
not add up to 642;' Reference category;' In case of more than one affected family member, the youngest age at
diagnosis was used.
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than 50% of their brothers were affected. Age at diagnosis of affected family members
before age 75 was associated with a higher relative risk (RR=2.36, 95% Cl: 1.10-5.07)
compared with age at diagnosis at age 75 years or older (RR=1.36, 95% Cl: 0.64-2.89).
In the subgroup of cases diagnosed before age 70, the RRs for a positive family history
were increased while in the subgroup of cases diagnosed after age 70, only the RR for
having a brother with prostate cancer was increased (Table 3). RRs for a family history of
prostate cancer were higher for advanced prostate tumors than for localized tumors (Table
4).
Fabte 3: Rafe raffos fRRsj and 95% confidence /nte/va/s (95% C/j for prostete cancer accord/ng to age af
d/agr/os/s and fam/V n/sfory, Netfier/ancte Coriort Sfudy (7986-f992J.
Characteristic
No. of affected family members
none'
a1
Father with prostate cancer
no'
yes
Brother(s) with prostate cancer
no'
yes
Cases diagnosed before age 70
(n=369)
Cases/
Person years
in subcohort
343/8814
21/248
350/8839
14/223
357/9037
7/25
RR' (95% Cl)
1.00
2.22(1.37-3.59)
1.00
1.61 (0.88-2.95)
1.00
6.96(2.19-22.12)
Cases diagnosed at age 70 and
older (n=273)
Cases/
Person years
in subcohort
266/8814
7/248
267/8839
6/223
272/9037
1/25
RR' (95% Cl)
1.00
0.90(0.32-2.51)
1.00
0.79 (0.27-2.32)
1.00
4.58(0.41-50.96)
' Adjusted for age at baseline (continuous), educational level (low, medium, high), total fat intake (continuous),
and total vegetable and total fruit consumption (both continuous);' Reference category.
Discussion
An important strength of our study is its prospective design, making information bias
unlikely. Another strength is that there is no loss to follow-up of cases and subcohort
members (6, 9). On the other hand, small numbers limited certain analyses. Furthermore,
family history is subject to nondifferential misclassification. Nevertheless, it has been shown
that the accuracy of reported family history of cancer (10) or prostate cancer (11, 12) in first
degree relatives is high. Another limitation is that we could not take into account the age
distribution of family members.
A positive association between family history and prostate cancer risk has been previously
reported (12-14). In several (12, 15-19), but not all (2, 11) studies, estimated risks were
higher for affected brothers (RRs varying from 1.9 to 5.3) than for affected fathers (RRs
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varying from 1.2 to 3.5). These findings support an X-linked or recessive model of
inheritance (20), but greater misclassification of the reporting of fathers' history compared
with brothers' history of prostate cancer could have influenced results. An autosomal
dominant gene has also been proposed as a model of inheritance (21, 22).
faWe 4: Rate rafos (RRsJ and 95% co/iffctence Znterva/s (95% C/J for focafeed (TO-2, MOj and advanced (T3-4,
MO; 70-4, Mtj prostete (umors accord/ng to fem/Ty n/sfcwy, Wefner/ands Cohort Sfudy ("7986-7992;.
Characteristic
No. of affected family members
none*
i1
Father with prostate cancer
no'
yes
Brother(s) with prostate cancer
no'
yes
Localized tumors
(n=226)
Cases/
Person years
in subcohort
214/8814
10/248
216/8839
8/223
222/9037
2/25
RR' (95% Cl)
1.00
1.85(0.90-3.81)
1.00
1.61 (0.72-3.56)
1.00
4.30 (0.81-22.86)
Advanced tumors
(n=213)
Cases/
Person years
in subcohort
198/8814
12/248
201/8839
9/223
207/9037
3/25
RR' (95% Cl)
1.00
2.37(1.22-4.62)
1.00
1.98(0.93-4.24)
1.00
5.33(1.36-20.85)
' Adjusted for age at baseline (continuous), educational level (low, medium, high), total fat intake (continuous),
and total vegetable and total fruit consumption (both continuous); * Reference category.
Some studies have reported an increasing risk of prostate cancer with increasing numbers
of affected first degree family members (2, 11, 12, 16). Our estimates, based on small
numbers, did not confirm this pattern. Some studies, as the NLCS, showed a higher risk
associated with a younger age at diagnosis of affected family members (12, 16), but not all
(11). We were unable to adjust for the age of family members, but controlling for the age of
the subjects might have, albeit indirectly and partially, controlled for family age. When family
members were affected, risk of developing prostate cancer before age 70 was increased
whereas risk of prostate cancer after age 70 was not. This finding comports with those in
one cohort study (23) and two case-control studies (16, 24). In one cohort (2) and one case-
control study (25), associations were not clearly different for younger and older cases. In
general, hereditary cancers are known to have earlier onset. Therefore, our findings might
indicate a hereditary component for early prostate cancer.
We found stronger associations for advanced prostate tumors than for localized tumors.
Our findings, therefore, do not support the suggestion that men with a positive family history
of prostate cancer get diagnosed at an early stage because of increased awareness.
Moreover, if men with a positive family history are at increased risk of aggressive growing
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prostate tumors, this might counteract the possibility of more early stage diagnoses and the
similar proportions in our study might be the net result of these two possibilities. In two other
studies no different association for localized and advanced tumors was reported (15, 16).
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Chapter 9
Socioeconomic status in relation to risk of
prostate cancer**
Agnes G. Schuurman*
Piet A. van den Brandt*
R. Alexandra Goldbohm*
Abstract
We studied the association between socioeconomic status and prostate cancer incidence
and the role of lifestyle factors and medical consumption pattern in explaining this
association in the Netherlands Cohort Study (NLCS). The NLCS is a prospective cohort
study that started in 1986 among 58,279 men ages 55-69 years. The cohort originates from
204 municipalities in the Netherlands. Data were collected by means of a self-administered
questionnaire. After 6.3 years of follow-up 642 incident cases were available for analysis. In
age-adjusted analyses, positive associations were observed between prostate cancer risk
and highest level of education and social standing. Rate ratios (RR) and 95% confidence
intervals (Cl) for the highest vs lowest exposure category were 1.33 (1.02-1.74) and 1.27
(0.88-1.83), respectively, and the trend tests were significant (both p-values were 0.01).
Additional adjustment was carried out for variables that have been found to be associated
with prostate cancer risk in the NLCS and that were associated with socioeconomic status.
Adjustment for family history of prostate cancer, intake of sweet peppers, mushrooms,
oranges, raisins, cured meat, milk products, linolenic acid, ß-cryptoxanthin, alcohol from
white/fortified wines and vitamin supplement use resulted in somewhat lower RRs: 1.26
(0.95-1.67) for level of education and 1.13 (0.78-1.65) for social standing (p-values trend
test 0.09 and 0.04, respectively). Analyses were repeated in subgroups of latent and
nonlatent and localized and advanced tumors. Among nonlatent and advanced tumors,
associations were positive for level of education and social standing. In the other
subgroups, no associations were observed. We conclude that lifestyle can partly explain an
association between socioeconomic status and prostate cancer risk, and not medical
consumption patterns.
^ Sutom/tfed for puW/caf/on
* Dept. of Epidemiology, Maastricht University, Maastricht
* Dept. of Consumer Research & Epidemiology, TNO Nutrition and Food Research Institute, Zeist
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Introduction
For different types of cancer (e.g. cancer of the colon, breast, lung and stomach) an
association between incidence and socioeconomic status has been observed (1). Prostate
cancer has also been subject to investigations with respect to socioeconomic status but in
reviews on socioeconomic status and prostate cancer it was concluded that, thus far, no
consistent association has been observed. Although the majority of studies showed no
clear association, positive and inverse associations have been reported too (2-4).
Socioeconomic status is not thought to be a direct risk factor but lifestyle variables related
to socioeconomic status may be responsible for observed associations. Furthermore,
socioeconomic status may be related to a specific medical consumption pattern, such that
subjects with a higher socioeconomic status more frequently visit a physician. If so, these
subjects could be diagnosed with prostate cancer more often and possibly in an earlier
stage of disease, thus resulting in a positive association between socioeconomic status
and prostate cancer risk (2). Several previous studies on socioeconomic status were limited
by small numbers of cases and mostly reported no adjustment for potential confounding
factors. In addition, an association between socioeconomic status and tumor characteristics
was only investigated in two case-control studies (2, 5). Therefore, we investigated an
association between socioeconomic status and prostate cancer incidence in the
Netherlands Cohort Study (NLCS). Moreover, we specifically examined whether other
dietary or lifestyle factors might explain a possible association and we also studied case
subgroups of latent and nonlatent and localized and advanced prostate tumors separately.
Materials and methods
The cohort s/udy
The study design has been reported in detail elsewhere (6), therefore, we will only briefly
outline the design. The NLCS was initiated in September 1986 and includes 58,279 men
aged 55-69 years at the beginning of the study who originated from 204 municipal
registries throughout the country. The cohort members completed a mailed, self-
administered questionnaire on dietary habits, education, occupation and other risk factors
for cancer. For reasons of efficiency in data processing and analysis, the case-cohort
approach (7, 8) was used. In a case-cohort approach, cases are derived from the entire
cohort (providing numerator information for calculation of cancer incidence rates), while
accumulated person years at risk in the total cohort are estimated using a random
subcohort sample (providing denominator information for the rates). In contrast to nested
case-control sampling, this subcohort can be used for multiple disease endpoints. The
subcohort (n=1,688) was sampled directly after identification of all cohort members and has
been followed up biennially for vital status information. Follow-up for incidence of prostate
cancer was established by computerized record linkage with all nine cancer registries in the
Netherlands and with the Dutch national data base of pathology reports (PALGA) (9). No
subcohort members were lost to follow-up and completeness of follow-up of cancer was at
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least 96 percent (10). After a follow-up period of 6.3 years (September 1986-December
1992), and exclusion of prevalent cancer cases other than skin cancer, 704 incident,
confirmed primary prostate cancer cases were available for analysis. In the subcohort,
prevalent cancer cases other than skin cancer were also excluded, leaving 1,630 subcohort
members for analysis. During our follow-up period, systematic screening for prostate
cancer was not instituted in the Netherlands. "
The guesfronna/re
Questions on highest attained level of education and occupational history were used to
represent socioeconomic status. Educational level was classified as low (primary school
with or without lower vocational school), medium (secondary school or medium level
vocational education), and high (university or higher level vocational school). Information
about occupational history was coded according to occupational sector and required
training (EGP) and according to social standing (U&S). For both the EGP score and the
U&S score information on the last occupation was used. The EGP coding scheme is based
on four aspects of occupation: occupational group, required training, self-support/
independence and leadership (11, 12). Each occupation is classified in (one of) 10
categories according to these aspects. The U&S score is based on an ordering of
occupational titles according to social standing (12). Information on other risk factors for
cancer, e.g. usual diet in the year preceding the baseline measurement, and alcohol
consumption was also gathered with the self-administered questionnaire.
All questionnaire data were key-entered twice and processed for all incident cases in the
cohort and for all subcohort members in a manner blinded with respect to case/subcohort
status. This was done in order to minimize observer bias in coding and interpretation of the
data.
Date ana/ys/s
Subjects with incomplete or inconsistent dietary data were excluded according to criteria
described before (13). This was done because we intended to compute multivariate
adjusted RRs with different dietary risk factors in the model and observe the effect of
inclusion of these factors. A total number of 642 cases and 1,525 subcohort members
remained for analyses.
The EGP score of the last occupation was divided into four categories: blue collar jobs
(manual workers), lower white collar jobs (nonmanual workers), upper white collar jobs
(professionals and managers) and others (farmers and self-employed people). The U&S
score of the last occupation was divided into five categories ranging from low (e.g. cleaner,
garbage collector) to high social standing (e.g. lawyer) (11, 12). Rate ratios (RRs) and 95%
confidence intervals (95% Cl) were computed using the GLIM statistical package (14).
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Exponentially distributed survival times were assumed in the follow-up period. Since
standard software was not available, specific macros were developed to account for the
additional variance introduced by using the subcohort instead of the entire cohort (15).
Tests for trend were based on likelihood ratio tests and two-sided p-values are used
throughout this report. First, analyses were only adjusted for age. Thereafter, multivariate
RRs were computed. Factors that were previously shown to be associated with prostate
cancer risk in the NLCS and that were associated with socioeconomic status such as family
history of prostate cancer (16), intake of sweet peppers, mushrooms, oranges, and raisins
(17), cured meat and milk and milk products (18), linolenic acid (19), ß-cryptoxanthin and
vitamin supplement use (20), and alcohol from white wine and fortified wines (21) were
included in the multivariate model. RRs were also computed in subgroups of latent and
nonlatent tumors, and localized and advanced tumors. Latent and nonlatent tumors were
defined based on information from the pathology reports. Prostate tumors detected
incidentally during transurethral prostate resections were coded latent. Prostate tumors
fabfe 1' Rate rafros fRRJ and 95% confidence /nferva/s ^ C/J forprosfafe cancer accord/ng to fhree d/flferevrf
soc/oeconom/c sfa/us /nd/cators, Wefher/ands Conor/ Sfudy f 7986-7 992J.
Exposure No of cases/
person years
in subcohort
RR' (95% Cl) RR' (95% Cl)
Highest level of education*
low 285/4257
medium 222/3188
high 130/1618
EGP score last profession'
blue collar 224/3181
lower white collar 66/1174
upper white collar 204/2596
other* 96/1376
U&S score last profession'
1 (low) 111/1687
2 129/2096
3 170/2278
4 100/1228
5 (high) 80/1037
1.00 1.00
1.05(0.85-1.31) 0.98(0.77-1.23)
1.33(1.02-1.74) 1.26(0.95-1.67)
P-trend 0.01 P-trend 0.09
1.00
0.81 (0.58-1.13)
1.22(0.95-1.55)
0.94(0.70-1.27)
P-trend 0.05
1.00
0.92(0.67-1.25)
1.14(0.84-1.54)
1.31(0.93-1.85)
1.27(0.88-1.83)
P-trend 0.01
1.00
0.74(0.52-1.04)
1.13(0.87-1.45)
0.90(0.67-1.23)
P-trend 0.16
1.00
0.86(0.63-1.19)
1.08(0.80-1.47)
1.24(0.87-1.78)
1.13(0.78-1.65)
P-trend 0.04
' Adjusted for age;' Adjusted for age, family history of prostate cancer, intake of sweet peppers, mushrooms,
oranges, raisins, cured meat, milk&milk products, linolenic acid, ß-cryptoxanthin, alcohol from white wine, alcohol
from fortified wines, and vitamin supplement use;' Numbers may not add up to 642 because of missing
information on last occupation; * Farmers and self-employed people, not included in the trend test.
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detected during surgical procedures used in case of suspected prostate cancer (biopsy,
radical prostatectomy) were coded nonlatent. The classification into localized tumors (TO-2,
MO) and advanced tumors (T3-4, MO; TO-4, M1) was based on the TNM staging system
(22).
Results
In table 1 the association between the three different socioeconomic status indicators and
risk of prostate cancer is shown. The highest attained level of education was positively
associated with prostate cancer risk. In the age-adjusted analyses, RRs in increasing
categories were 1.00 (ref), 1 05 and 1.33, with a statistically significant test for trend (p-
value of 0.01). Also for the U&S score a weakly positive association was noted; RRs were
1.00 (ref), 0.92, 1.14, 1.31 and 1.27. None of these RRs was statistically significant but a
positive trend in risk was observed (p-value of 0.01). No clear association for EGP score
was apparent. Overall, in the multivariate analyses the observed associations became
somewhat weaker. For the level of education, the RR in the highest category (RR of 1.26)
and the trend test (p-value of 0.09) were no longer statistically significant. Although
associations for the U&S score also largely disappeared in the multivariate models, the test
for trend remained statistically significant (p-value of 0.04).
The distribution of tumor characteristics across categories of socioeconomic status
indicators is shown in table 2. Overall, about 20 percent of all prostate tumors was
classified as latent, about 40 percent was classified as nonlatent and another 40 percent
could not be classified according to latency due to missing information. In general, subjects
with a higher socioeconomic status were slightly more often classified as having a
nonlatent prostate tumor. In the classification based on the TNM staging system, about
equal percentages were classified as localized and advanced. Some 30 percent of all
cases could not be classified into categories of localized and advanced prostate tumors
due to missing information. Also in this classification, subjects with a higher socioeconomic
status were more often classified as having an advanced prostate tumor.
Table 3 shows the multivariate adjusted associations between indicators of socioeconomic
status and prostate cancer risk separately for latent and nonlatent prostate tumors. In the
subgroup of latent tumors, no clear associations were observed. In the subgroups of
nonlatent tumors, significant positive trends in risk were observed for the highest level of
education as well as for the U&S score. RRs (95% Cl) in the highest vs lowest exposure
category were 1.46 (1.01-2.12) and 1.36 (0.83-2.23), respectively, and the p-values for the
trend test were 0.04 and 0.01, respectively.
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TaWe 2: D/s(rabuffon ofpros/afe (umor c/iaracfensftcs across cafegories of f/iree /nd/cafors of soc/oeconom/c
s/a/us, Atetfrertands Co/iort Sfudy (f 986-f 992J.
Socioeconomic status
indicator
Highest level of education
low
medium
high
EGP score last profession
blue collar
lower white collar
upper white collar
other'
U&S score last profession
1 (low)
2
3
4
5 (high)
Classification
Latent
tumors
n(%)
60(21.1)
38(17.1)
15(11.5)
44 (19.6)
18(27.3)
27(13.2)
18(18.8)
22 (19.8)
28(21.7)
34 (20.0)
12(12.0)
11(13.8)
based on TURP'
Nonlatent
tumors
n (%)
120(42.1)
98(44.1)
62 (47.7)
99 (44.2)
28 (42.4)
98 (48.0)
37 (38.5)
47 (42.3)
53(41.1)
70(41.2)
52 (52.0)
40 (50.0)
Missing
n(%)
105(36.8)
86 (38.7)
53 (40.8)
81 (36.2)
20 (30.3)
79 (38.7)
41 (42.7)
42 (37.8)
48 (37.2)
66 (38.8)
36 (36.0)
29 (36.3)
Classification
Localized
tumors
n(%)
99 (34.7)
80 (36.0)
45 (34.6)
72(32.1)
26 (39.4)
65(31.9)
41 (25.0)
41 (36.9)
49 (38.0)
57 (33.5)
32 (32.0)
25(31.3)
based on TNM*
Advanced
tumors
n (%)
92 (32.3)
66 (29.7)
52 (40.0)
78 (34.8)
16 (24.2)
74 (36.3)
31 (32.3)
30 (27.0)
38 (29.5)
66 (38.8)
34 (34.0)
31 (38.8)
Missing
n(%)
94 (33.0)
76 (34.2)
33 (25.4)
74 (33.0)
24 (36.4)
65(31.9)
24 (25.0)
40 (36.0)
42 (32.6)
47 (27.6)
34 (34.0)
24 (30.0)
' Latent tumors are those tumors that were detected as a consequence of a transurethral resection of the
prostate (TURP), nonlatent tumors are those tumors that were detected during surgical procedures used in case
of suspected prostate cancer (biopsy, radical prostatectomy);' Localized tumors: TO-2, M0 and advanced
tumors: T3-4, M0 and TO-4, M1; ' Farmers and self-employed people.
The association between socioeconomic status and localized and advanced prostate
tumors is displayed in table 4. Socioeconomic status seemed not to be strongly associated
with localized prostate tumors. Among advanced tumors, positive associations were
observed for highest level of education and for the U&S score; RRs (95% Cl) for the
highest vs lowest exposure categories were 1.55 (1.04-2.31) and 1.60 (0.91-2.80),
respectively. The trend test for level of education was of borderline significance (p-value of
0.06) and the trend test for the U&S score was statistically significant (p-value of 0.01).
Discussion
In this study, socioeconomic status was operationalized as highest attained level of
education and as occupational group and required training (EGP) and social standing
(U&S) of the last occupation. Our findings indicate that the positive associations observed
for level of education and U&S score became weaker and nonsignificant after inclusion of
family history of prostate cancer and several dietary risk factors. When subgroups of latent
and nonlatent and localized and advanced prostate tumors were investigated separately,
the highest attained level of education and the U&S score were positively associated with
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TaWe 3: Rate rafos (RRj and 95% confidence /nfe/va/s fC/j accord/ng to f/iree d/fferenf soc/oeconom/c stefus
/nd/cafors, /n subgroups of"/atenr andnon/aten(prostete /umors, We/ner/ands Cohort Sfudy (f 986-f 992|
Exposure
Highest level of education
low
medium
high
EGP score last profession
blue collar
lower white collar
upper white collar
other*
U&S score last profession
1 (low)
2
3
4
5 (high)
Person years
of follow-up
4257
3188
1618
3181
1174
2596
1376
1687
2096
2278
1228
1037
Latent tumors
(n=115)
Cases
60
38
15
44
18
27
18
22
28
34
12
11
RR' (95% Cl)
1.00
0.88(0.57-1.36)
0.84(0.46-1.54)
P-trend 0.48
1.00
1.13(0.63-2.02)
0.88(0.53-1.46)
0.88(0.50-1.56)
P-trend 0.91
1.00
0.97(0.54-1.75)
1.18(0.67-2.08)
0.91 (0.43-1.89)
0.91 (0.42-1.97)
P-trend 0.89
Nonlatent tumors
(n=282)
Cases
120
98
62
99
28
98
37
47
53
70
52
40
RR' (95% Cl)
1.00
1.02(0.75-1.39)
1.46(1.01-2.12)
P-trend 0.04
1.00
0.70(0.43-1.12)
1.22 (0.87-1.70)
0.78(0.51-1.19)
P-trend 0.11
1.00
0.83(0.54-1.29)
1.05(0.69-1.59)
1.57(0.99-2.49)
1.36(0.83-2.23)
P-trend 0.01
' Adjusted for age, family history of prostate cancer, intake of sweet peppers, mushrooms, oranges, raisins, cured
meat, milk&milk products, linolenic acid, ß-cryptoxanthin, alcohol from white wine, alcohol from fortified wines,
and vitamin supplement use; * Farmers and self-employed people, not included in the trend test.
nonlatent and advanced prostate tumors and not with latent or localized prostate tumors. In
the overall analyses as well as in the subgroup analyses, no clear associations were
observed for EGP score.
These results partially support the idea that lifestyle variables associated with
socioeconomic status are responsible for the observed positive association between
socioeconomic status and prostate cancer risk in the NLCS. In the majority of previous
studies on socioeconomic status in relation to prostate cancer characteristics between
cases and controls were compared (23-32), findings were reported without presenting risk
estimates (33-39), or unadjusted risk estimates (40-49) or only adjustment for age (50-58)
was reported. Regarding education, in several studies no clear associations were shown (5,
23-26, 28, 3 1 , 33, 34-37, 40, 43, 44, 50, 52, 59) but also inverse (32, 4 1 , 42, 47, 5 1 , 53,
55) and positive (27, 29, 30, 38, 45, 46, 54, 60-62) associations were indicated. Results
regarding occupational status and prostate cancer risk (28, 44, 47, 48, 50, 54, 56, 63) and
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regarding income as a socioeconomic status indicator (25, 26, 31, 47, 49, 57, 59) were also
diverse. In one study, the positive age-adjusted association between education and
prostate cancer disappeared after additional adjustment for urbanization and farming (5). In
three other studies positive associations between education and prostate cancer risk were
observed after correction for age, alcohol consumption and race (60), age, smoking and
alcohol consumption (61) or age, area and housing tenure (62). Besides age, race and
family history of prostate cancer, risk factors for prostate cancer are largely unknown.
Therefore, residual confounding by unknown or unmeasured factors may be responsible for
the remaining weakly positive association of level of education and U&S score in our study.
Recall bias is not likely to have taken place because of the prospective nature of our study.
Furthermore, selection bias due to loss to follow-up also is unlikely because of the high
completeness of follow-up of both cases and subcohort members (10, 64). Misclassification
of exposure, nevertheless, has to be considered in the interpretation of our results.
However, if exposure misclassification has occurred, this is expected to be nondifferential,
and estimated risks are most likely biased towards the null value. Socioeconomic status
was operationalized as highest attained level of education, EGP score (functional level)
and U&S score (social standing), the last two both based on the last occupation. It seems
reasonable to take the most recent occupation instead of the longest occupation when
occupation is used as an indicator of socioeconomic status. The highest level of education
is relatively stable over time. The level of education can mask important changes in
individual circumstances after education is finished and therefore the highest level of
education might be a less relevant socioeconomic status indicator for the older generation
(12, 65). On the other hand, at older ages the level of education is still associated with level
of knowledge which is related to lifestyle (12, 65). If the EGP score and the U&S score
could be viewed as more reflecting the recent situation, while educational level might be
viewed as reflecting a situation several years ago, it is difficult to conclude whether lifestyle
variables related to socioeconomic status are important at early stages of prostate cancer
occurrence or at later stages since we observed an association for both the level of
education and the U&S score.
It has been hypothesized that a positive association between prostate cancer and
socioeconomic status could be explained by a specific medical consumption pattern of men
with a higher socioeconomic status (2). These men might visit a physician more frequently
and therefore get diagnosed with prostate cancer more frequently and possibly at earlier
stages. If true, we would expect a positive association between socioeconomic status
indicators and latent or localized prostate tumors and no association in subgroups of
nonlatent or advanced prostate tumors. Our results, however, indicated a stronger
association between socioeconomic status and nonlatent or advanced prostate tumors
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7aWe 4: Rate rafos (RR) and 95% confidence /nterva/s fC/J for prostete cancer accord/ng to (hree d/fferenf
soc/oeconom/c ste/us /nd/cators, /n subgroups of/ocaftzed (TO-2, MOJ and advanced (73-4, MO; 7"0-4,
MfJ prostete fumors, Nerher/ands Cohort Sftjdy(7986-f992J. .
Exposure
Highest level of education
low
medium
high
EGP score last profession
blue collar
lower white collar
upper white collar
other*
U&S score last profession
1 (low)
2
3
4
5 (high)
Person years
of follow-up
4257
3188
1618
3181
1174
2596
1376
1687
2096
2278
1228
1037
Localized tumors
(n=226)
Cases
99
80
45
72
26
65
41
41
49
57
32
25
RR'(95%CI)
1.00
0.99(0.71-1.39)
1.20(0.79-1.81)
P-trend 0.42
1.00
0.89(0.54-1.48)
1.08(0.74-1.59)
1.19 (0.77-1.83)
P-trend 0.52
1.00
0.89(0.56-1.41)
0.97(0.62-1.53)
1.08(0.64-1.83)
0.95(0.54-1.67)
P-trend 0.84
Advanced tumors
(n=213)
Cases
92
66
52
78
16
74
31
30
38
66
34
31
RR'(95%CI)
1.00
0.88 (0.62-1 25)
1.55(1.04-2.31)
P-trend 0.06
1.00
0.50 (0.28-0.89)
1.16(0.81-1.67)
0.85(0.54-1.34)
P-trend 0.28
1.00
0.91 (0.54-1.52)
1.52(0.95-2.42)
1.53(0.89-2.63)
1.60(0.91-2.80)
P-trend 0.01
' Adjusted for age, family history of prostate cancer, intake of sweet peppers, mushrooms, oranges, raisins, cured
meat, milk&milk products, linolenic acid, ß-cryptoxanthin, alcohol from white wine, alcohol from fortified wines,
and vitamin supplement use; * Farmers and self-employed people, not included in the trend test.
compared with latent and localized tumors. A disadvantage of these subgroup analyses is
that a considerable proportion of cases could not be classified into the different subgroups.
However, the percentage of subjects which could not be classified due to missing
information does not differ markedly between categories of educational level and
categories of the occupation based variables. Therefore, we do not expect this missing
information to have influenced our results in any systematic way. Since population
screening of prostate cancer was not instituted in the Netherlands during our follow-up
period, we also do not expect this to have influenced our results. In one Dutch case-control
study, the percentage of incidental cases showed no clear pattern across categories of
socioeconomic status (2). In another Swedish case-control study, high level of education
was more strongly related to localized than to advanced prostate tumors but the presented
risk estimates were only age-adjusted (5).
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In summary, we observed a positive association between two socioeconomic status
indicators and risk of prostate cancer. Differences in dietary habits partially explained the
observed positive association. A different medical consumption pattern of subjects with
high and low socioeconomic status could not explain the observed associations.
Unexpectedly, high socioeconomic status was more strongly related to nonlatent and
advanced prostate tumors compared with latent and localized tumors. We conclude that
dietary risk factors or other unknown risk factors and not medical consumption patterns are
important in explaining an association between socioeconomic status and risk of prostate
cancer.
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Epilogue
The main objectives of the studies described in this thesis were to investigate whether
dietary or other environmental factors are associated with prostate cancer incidence
(hypothesis 1) and whether these factors are more strongly associated with the occurrence
of nonlatent or advanced prostate tumors than with latent tumors (hypothesis 2). The
hypotheses were stated in general words to avoid a long list of hypotheses per investigated
factor, but it is obvious that several individual hypotheses are covered by these broadly
stated ones. In chapters 2-6 results from the Netherlands Cohort Study (NLCS) on different
dietary factors as potential risk factors for prostate cancer were described and results for
some nondietary risk factors were described in chapters 7-9. A summary of the observed
associations in the NLCS is displayed in table 1. Overall, consumption of vegetables and
fruit, meat, fish, cheese, eggs and alcohol and intake of vitamins, calcium, protein, energy,
fat, and fatty acids does not seem to be strongly related to the risk of prostate cancer.
Nevertheless, for certain individual vegetables and fruits, vitamin supplements, cured meat,
milk and milk products, as well as for ß-cryptoxanthin, oleic acid and linolenic acid, alcohol
from white or fortified wines, body mass index early in life and socioeconomic status
associations were suggestive of a relationship with prostate cancer risk.
Evaluating the findings from the NLCS
If the findings from the NLCS comport with findings reported in other studies on prostate
cancer risk factors, this would support a conclusion of a certain factor being a risk factor for
prostate cancer. In the individual chapters in this thesis our findings were related to other
findings reported in the literature. The overall null associations observed in the NLCS for
consumption of vegetables and fruit, meat, fish, cheese, eggs and alcohol, and intake of
vitamins, energy and fat gain support from other studies, although it has to be mentioned
that also positive and inverse associations have been indicated for certain dietary factors.
We observed a positive association between two socioeconomic status indicators and risk
of prostate cancer and this association also gains support from previous studies, although
null associations and inverse associations have been reported too. Our null associations
observed for intake of calcium, protein and specific fatty acids gain little or no support from
other studies since these factors have not been investigated in the majority of studies on
prostate cancer risk factors. In addition, the suggested positive associations between risk of
prostate cancer and specific vegetables and fruits, cured meat, ß-cryptoxanthin, alcohol
from white or fortified wines and body mass index (BMI) at age 20 and the suggested
inverse associations for certain other vegetables and fruits, vitamin supplements and gain
in BMI during lifetime are also difficult to evaluate since these factors have been
investigated only in a few other studies. One association observed in the NLCS which is
consistent with results from other studies is the positive association for family history of
prostate cancer. Overall however, there is hardly any consistency in results from diverse
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Tabte 1' Resu/te from tfie A/e/heriands Conort Sfc/dy on d/et antfiropomefry, fem/ty n/sfory ofprosfa/e cancer
and soc/oeconom/c sfafus as potenfra/ risk factors forprosfafe cancer occurrence.
Chapter Factors not associated with prostate cancer
risk
Observed associations (+ or -)
total vegetable consumption
total fruit consumption
intake of vitamins C and E
intake of retinol, a-carotene, ß-carotene,
lycopene, lutein/zeaxanthin
total meat consumption
fish consumption
cheese consumption
consumption of eggs
intake of calcium, total protein, vegetable
protein, animal protein
total energy intake
intake of total fat, total fatty acids
intake of saturated fat, monounsaturated fat,
polyunsaturated fat
intake of palmitic acid, stearic acid, linoleic
acid, arachidonic acid, eicosapentaenoic
acid, docosahexaenoic acid
consumption of kale (-), raw endive (-),
leek (+), sweet peppers (+),
mushrooms (+)
consumption of mandarins (-), oranges (+),
apples and pears (-), raisins (-)
intake of ß-cryptoxanthin (+)
consumption of vitamin supplements (-)
interaction between vitamins and alcohol
consumption
consumption of cured meat (+),
consumption of milk and milk products (+)
intake of oleic acid (+), linolenic acid (-)
6
7
8
9
total alcohol intake
intake of alcohol from beer, red wine, liquor
height
body mass index at baseline age
lean body mass
number of brothers with prostate cancer
occupational group and required training
(functional level)
intake of alcohol from white wine (+), fortified
wines (+)
body mass index at age 20 (+)
gain in body mass index during lifetime (-)
father with prostate cancer (+)
brother(s) with prostate cancer (+)
level of education (+)
social standing (+)
studies and to a large extent this is caused by limited available data. Also, chance findings
from the NLCS or any other study cannot be excluded, thus complicating the evaluation of
consistency. Furthermore, the different methodology used in different studies is also
contributing to inconsistencies in results. One important issue in this respect is the issue of
exposure measurement. As has been described in the previous chapters, several studies
had limited exposure information or used dietary questionnaires that have not been
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validated. In the NLCS an extensive validated semi-quantitative food frequency
questionnaire was used and it was concluded that diet was reasonably well measured (1).
If misclassification has occurred in our study, this is expected to be nondifferential which
may have led to an underestimation instead of an overestimation of observed effects.
Another issue related to the different methods used in the diverse studies is the issue of
residual confounding. Several results presented in the literature were unadjusted or only
age-adjusted and residual confounding in these studies cannot be excluded. However,
since risk factors for prostate cancer are largely unknown it is also not known which
potential confounding factors should be taken into account in analyses besides age, and
family history of prostate cancer. Compared to most other studies, an advantage of the
NLCS is the extensive exposure information on e.g. diet, anthropometry, family history of
prostate cancer, and education. With this information, we were able to consider several
potential confounding factors but residual confounding in our study can also not be
excluded.
Taking all considerations into account, a straightforward answer to the first set of
hypotheses cannot be given. From our own investigations, nevertheless, we cannot
conclude that diet is not associated with risk of prostate cancer. Also for the nondietary risk
factors that were studied an association with risk of prostate cancer might exist
(anthropometry and socioeconomic status) or has more or less been established (family
history of prostate cancer).
Latent vs nonlatent or advanced prostate tumors
The second hypothesis underlying this investigation stated that environmental factors, and
perhaps specifically dietary factors, are more strongly related to the risk of nonlatent or
advanced prostate tumors than to latent tumors. Latent tumors have been defined as
incidental findings during transurethral resection of the prostate (TURP) which is performed
in case of problems associated with benign prostatic hyperplasia, or as screen-detected
tumors (2,3). Throughout this thesis, three different classifications were used to separately
investigate latent and nonlatent or advanced prostate tumors. In one classification, latent
tumors were classified as those tumors that were detected during a TURP treatment.
Nonlatent tumors were classified as those tumors that were detected during surgical
procedures used in case of suspected or diagnosed prostate cancer (biopsy, radical
prostatectomy). For this purpose, all pathology reports that were available from the national
database on pathology reports (PALGA) per prostate cancer case were used. The
pathology reports were screened for terms indicating surgical procedures in combination
with terms indicating accidental findings of adenocarcinoma of the prostate. Since
systematic screening for prostate cancer was not instituted in the Netherlands during our
follow-up period from September 1986 to December 1992, we assumed no screen-
detected tumors among our prostate cancer cases. About 38% of all cases could not be
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grouped according to latency due to lack of evidence in the pathology reports. Another
classification used in the NLCS distinguished tumors in localized and advanced cancer,
based on the TNM classification. Localized prostate cancers were defined as TO-2, MO and
advanced prostate cancers as T3-4, MO and TO-4, M1. Some 32% of all cases could not be
classified due to missing information. A third classification upon which some case subgroup
Tafate 2a: Comparison of fhe c/ass/ficafibn of /afenf and non/afenr prostete ft/mors tv/fh fne c/ass/ficaf/on of
focafeed and advanced prostete fumors, Nefheriands Cohort Sfudy.'
Latent (%)
Nonlatent (%)
Missings (%)
Total
Localized
50 (43.5)
86 (30.5)
90 (36.7)
226
Advanced
19 (16.5)
114(40.4)
80 (32.7)
213
Missing
46 (40.0)
82(29.1)
75 (30.6)
203
Total
115(100)
282(100)
245(100)
642
fab/e 2i>: Comparison of fhe c/ass/fcaf/on of /atenf and non/atenf prostete fumors vw/h fhe c/ass/fcaf/on based on
d/fferenf/ation grade of prostete fumors, Nefher/ands Cohort Sfudy.'
Latent (%)
Nonlatent (%)
Missings (%)
Total
Well
differentiated
59(51.3)
62 (22.0)
70 (28.6)
191
Moderately
differentiated
34 (29.6)
117(41.5)
78(31.8)
229
Poorly*
undifferentiated
13(11.3)
83 (29.4)
64(26.1)
160
Missing
9(7.8)
20(7.1)
33(13.5)
62
Total
115(100)
282 (100)
245(100)
642
fao/e 2c: Comparison of fhe c/ass/fcafion of focafeed and advanced prostete fc/mors w/ffi fhe c/ass/7!cafc>n
based on d/'/feren/zatfon grade of prostete fumors, Ne/her/ands Cohort Sfcydy.'
Localized (%)
Advanced (%)
Missings (%)
Total
Well
differentiated
86(38.1)
29 (13.6)
76 (37.4)
191
Moderately
differentiated
86(38.1)
86 (40.4)
57(28.1)
229
Poorly*
undifferentiated
37 (16.4)
80 (37.6)
43(21.2)
160
Missing
17(7.5)
18 (8.5)
27 (13.3)
62
Total
226 (100)
213(100)
203 (100)
642
' Numbers and percentages displayed in tables 2a-c are based on 642 cases which were used in all analyses
regarding dietary risk factors.
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analyses were based, was the classification in differentiation grade (well, moderately and
poorly and undifferentiated tumors). Only 9% of all cases could not be classified according
to differentiation grade of the tumor.
Tables 2a-c show the distribution of cases comparing the three different classifications
used in the NLCS. The majority of latent tumors were also classified as localized and well
or moderately differentiated. However, some nonlatent tumors were also classified as c
localized tumors and well or moderately differentiated tumors. Of all tumors that could not
be classified according to latency, about equal numbers were classified as localized or
advanced tumors and into categories based on differentiation grade. Comparison of the
classification of localized and advanced tumors with the classification based on
differentiation grade showed that localized prostate tumors were mostly classified as well
and moderately differentiated tumors and advanced prostate tumors were mostly classified
as moderately or poorly and undifferentiated tumors. Nevertheless, some localized tumors
were classified as poorly and undifferentiated tumors and some advanced tumors as well
differentiated. Unfortunately, there is no gold standard available for the classification of
latent and nonlatent or advanced prostate tumors. For this reason the three different
classifications were used in this thesis. It has to be mentioned, nevertheless, that the
classifications used in the NLCS as well as in other studies in which case subgroups were
separately investigated, are either a diagnostic classification (latent vs nonlatent) or a
prognostic classification (localized vs advanced; well, moderately, poorly and
undifferentiated). Whether these classifications are relevant in answering a question about
the etiology of latent and nonlatent or advanced prostate tumors remains to be proven.
A summary of the main findings of the NLCS on dietary and nondietary risk factors and
their association with localized and advanced prostate tumors is shown in table 3. Overall,
we can conclude that neither dietary nor the investigated nondietary risk factors are more
strongly related to advanced prostate tumors compared with localized prostate tumors. The
only factors related more strongly to advanced prostate tumors are two nondietary factors,
namely family history of prostate cancer in fathers and brothers and socioeconomic status.
For consumption of alcoholic beverages, observed associations were even stronger for
localized prostate tumors. In the previous chapters, our results from the subgroup analyses
were compared to results from other studies in which case subgroups were also separately
investigated. Overall, we can^conclude that there is limited data on different tumor
subgroups and results were mostly inconsistent.
Irrespective of which classification was used in our study, we observed no consistent
stronger associations for the different investigated potential risk factors with nonlatent,
advanced or poorly and undifferentiated prostate tumors compared with latent, localized
and well differentiated prostate tumors. Therefore, the second hypothesis cannot be
supported with data from the NLCS.
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Localized prostate tumors
(TO-2, MO)
no association
total vegetables
total fruit
vitamins C and E
retinol, a-carotene,
ß-carotene, ß-
cryptoxanthin,
lutein/zeaxanthin
total meat, total fish
cured meat, milk and
milk products, eggs,
calcium, protein
total fat(ty acids),
saturated fat,
monounsaturated fat,
polyunsaturated fat
height, body mass
index, lean body
mass
level of education
functional level
social standing
association (+ or -)
lycopene (+)
vitamin suppl. (-)
cheese (+)
energy (+)
total alcohol (+),
beer (+), red wine
(+), white/ fortified
wines (+), liquor (+)
body mass index at
age 20 (+), gain in
BMI (-)
prostate cancer
father (+)
prostate cancer
brother (+)
Advanced prostate tumors
(T3-4, MO; TO-4, M1)
no association
total vegetables
total fruit
vitamins C and E
retinol, a-carotene,
ß-carotene,
lycopene,
lutein/zeaxanthin
total meat, total fish
cured meat, milk and
milk products,
cheese, calcium,
protein
energy, total fat(ty
acids), saturated fat,
monounsaturated fat,
polyunsaturated fat
total alcohol, beer,
red wine, liquor
height, body mass
index, lean body
mass, body mass
index at age 20, gain
in body mass index
functional level
association (+or-)
ß-cryptoxanthin (+)
vitamin suppl. (-)
eggs (-)
white/fortified wines
M
prostate cancer
father (+)'
prostate cancer
brother (+)'
level of education (+)
social standing (+)
' Associations were stronger for advanced cases compared with localized cases.
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Further research
Thus far, several questions regarding prostate cancer etiology are still unanswered. Further
studies are warranted, which should be designed with special emphasis on exposure and
disease measurement, but also research into mechanisms is desirable.
One important issue regarding exposure measurement deals with the question which
factors might be relevant and also at what level these factors could play a role in prostate
cancer occurrence. Notwithstanding the inconsistent results, dietary risk factors for prostate
cancer seem plausible because of the large geographical variation in incidence rates and
the corresponding variation in dietary habits. Compared to Western diets, Asian diets are
generally lower in total and saturated fat and such a diet has frequently been suggested to
be associated with lower prostate cancer risk (4, 5) although it cannot be excluded that
confounding plays a role in explaining this suggested association, based on ecologic
correlation studies. Nevertheless, observations from correlational studies can be used to
identify potentially important factors which need to be thoroughly investigated in
epidemiological research. The issue of fat and prostate cancer is an example which has
frequently been investigated in cohort as well as in case-control studies, however, results
are mostly inconsistent (6, 7). Besides methodological problems, another reason for not
finding clear associations might be that the investigated consumption level in most studies
was too high. On average, the consumption level measured in the NLCS and most other
studies is of a relatively narrow range and, in general, represents a higher consumption
than the average consumption level in countries with low prostate cancer incidence rates.
The possibility that consumption of fat at lower levels is important in prostate cancer
etiology can therefore not be ruled out. From experimental research it was shown that
changing the diet of nude mice with palpable tumors (originally transplanted) into a 2.3% fat
diet or a 11.6% fat diet, resulted in a marked decrease in tumor growth rate compared with
animals on the unchanged 40.5% fat diet (8). Also in other animal studies with transplanted
prostate tumors, a fat reduction or a fat-free diet inhibited tumor growth. However, in
chemically induced carcinogenesis models in rats mostly no effect of fat was observed (9).
Results from animal studies are worthy of consideration and may be used to indicate
potentially important (levels of) risk factors, but one also has to bear in mind that animal
studies have their limitations. For example, the extrapolation of results from animal studies
to humans is hampered by the fact that experimental animals can be exposed to potential
risk factors at extreme levels which are not feasible for humans. Furthermore, animal model
systems with transplanted prostate tumors might not be useful because it does not
represent the evolutionairy stages of prostate cancer in men and only represents an end
stage (10). In fact, none of the available animal model systems is similar to human prostate
cancer in histology, biochemical properties, molecular and genetic characteristics,
embryological origin, natural history and biological behaviour (11).
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Further observations of dietary differences between countries with high and low prostate
cancer incidence rates and results from experimental or epidemiological research indicated
that soy consumption (8, 12, 13), vitamin D (14, 15), fructose (16), phosphorus (17), and
selenium (18-21) might be associated with a lower rate of prostate cancer. Results on soy
intake and prostate cancer, however, were inconsistent (12) and in some studies no
association was observed for vitamin D (22-24), and selenium (25). Because there is only
limited evidence from epidemiological studies further studies are needed to resolve these
issues. Preferably large-scale and prospective epidemiological studies should be
conducted. Extreme variation in dietary exposure variables is recommended which may be
established by including special exposure groups into the study design.
In addition to several dietary factors, also hormonal factors should be considered in the
etiology of prostate cancer. Androgens are essential for the growth and functioning of the
prostate and in experimental animals androgens can produce prostate cancer (26, 27).
Furthermore, surgical castration in men prevents prostate cancer (28). Increased levels of
dihydrotestosterone, a metabolite of testosterone, have been hypothesized to lead to
increased cell division, activation of proto-oncogenes and inactivation of tumor suppressor
genes, thus finally resulting in prostate cancer (29). However, a role for testosterone or
dihydrotestosterone in prostate cancer etiology has not been resolved yet (5, 26, 27, 30).
Other factors such as estradiol (26-28) insulin-like growth factor I (31-33) and sex hormone-
binding globulin (26-28) have also been subject to investigations, but thus far with mostly
inconsistent findings. Since the exact role of hormones in the development of prostate
cancer has not been established, hormones or other factors involved in prostate biology
should also be studied in future research.
A second issue regarding exposure measurement deals with the accuracy of
measurements. In the NLCS, a food frequency questionnaire was used to estimate usual
diet but, as with other methods of dietary assessment, the estimated intake is subject to
(random) misclassification. As a surrogate for actual dietary intake biochemical indicators
can be used, which do not rely on the memory or capacity of subjects under study. For
certain nutrients that vary widely in concentration within foods, or for which food
composition tables are inaccurate, biochemical indicators could be the only way of
estimating intake (34). However, biochemical indicators are most likely not fully
representative of dietary intake because of influences of absorption, metabolism and short-
term biologic variation (35). Nevertheless, these efects within the body give ground to
another reason for using biochemical indicators, namely, if one is concerned with the
biologic available dosis of nutrients rather than the estimated intake (34). Unfortunately,
however, for many nutrients of current interest such as total fat and fiber, biochemical
markers do not yet exist (35). Furthermore, it has to be mentioned that biochemical
measures are also subject to problems of misclassification or other biases. Although the
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use of biochemical indicators needs to be evaluated per nutrient of interest, this area of
exposure assessment may prove valuable, especially if long-term intake of specified
nutrients can be assessed.
A third issue relating to exposure measurement deals with the induction times associated
with individual exposure factors (36). Since prostate cancer exhibits a long preclinical
phase, diet or other factors may influence prostate cancer occurrence at many stages
during life. Because of the limited understanding of the pathogenesis of (prostate) cancer it
is unknown at what period of time before diagnosis diet or other factors are important (35).
In our study the usual diet in the year preceding the baseline measurement was assessed.
Five annually repeated measurements of the food frequency questionnaire were conducted
and from these measurements it was concluded that the single measurement of diet in the
NLCS can characterize dietary habits for a period of at least five years (37). Nevertheless,
diet or other risk factors early in life might be more important in explaining patterns of
prostate cancer occurrence than exposure to putative risk factors more recent in time
before diagnosis. For example, the prostate rapidly grows under stimulation of male
hormones around puberty, and this might be a critical time period for initiation of prostate
cancer. To our knowledge, only two case-control studies published results on diet during
adolescence in association with prostate cancer risk but overall found no clear associations
(38, 39). A limitation of these studies is the retrospective assessment of early diet which
may have resulted in misclassification. The hormonal environment in utero might also play
an etiologic role in the development of prostate cancer decades later (29). Some studies on
birth weight, as a marker for the hormonal environment in utero, have been conducted (40-
42) but data are too sparse for definite conclusions. Therefore in future studies, ideally,
exposure measurement should repeatedly be assessed during life to be able to determine
the induction periods for different exposure factors. Another advantage of repeated
exposure measurements during life is that retrospective assessment of exposure status
and the corresponding methodological problems may be prevented.
A fourth issue relating to exposure measurement deals with component causes (36).
Disease may not be produced by one specific event, condition or characteristic, but by a
set of conditions and events (component causes) which are all necessary to produce
disease. Therefore, it may be important not to investigate separate factors, but to
investigate combinations of different exposure variables. For example, we found no clear
overall effect of the intake of several vitamins, but in the absence of alcohol consumption,
for certain vitamins a protective effect was observed (43). Although there is no
straightforward explanation for our finding, biological interaction needs to be considered
and investigated in other studies. Calcium, phosphorus and vitamin D have also been
proposed to be interacting components in prostate growth, differentiation and cancer risk
(17). It seems very likely that other dietary or nondietary potential risk factors for prostate
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cancer also biologically interact. In addition, genetic polymorphisms controlling hormone
synthesis, metabolism, and bioactivity may be involved in different pathways (17) but this
also needs to be explored in future studies. The issue of component causes is very
complex since most of the component causes for prostate cancer are still unknown.
Furthermore, each component cause of a sufficient cause may act at a different point in
time but the relevant induction periods for component causes are also largely unknown.
Regarding disease measurement, there is still the complicating factor that the natural
history of prostate cancer is unknown. Based on the observation of similar prevalence of
latent prostate tumors, it has been proposed that additonal malignant events and not solely
tumor growth is required for a latent tumor to progress to a clinically evident one (44, 45); if
only tumor growth was required the prevalence of clinical prostate cancer would be similar
worldwide, which is not the case. With current histopathologic techniques, however,
prostate tumors that remain clinically silent cannot be distinguished from tumors that will
become clinically apparent and finally progress into metastatic disease (17, 46). Therefore,
research into etiology is needed which may elucidate the pathway by which prostate cancer
develops. If prostate tumors could be characterized by their biological potential, or
molecular markers could be used, this may guide research and risk factors could be studied
separately by type of prostate tumor.
One final point to give direction to future research regarding prostate cancer etiology deals
with research on biologic mechanisms. Most proposed mechanisms to explain an observed
association between a certain risk factor and prostate cancer incidence involve the male
endocrine system, as was discussed in several of the previous chapters. Androgens may
be a mediator of dietary or nondietary influences on prostate carcinogenesis. For example,
fat intake may increase sex hormone levels finally resulting in activation of proto-
oncogenes and deactivation of tumor suppressor genes (7, 29). Also, anthropometric
measures may be related to prostate cancer risk by modulating endogenous hormone
levels or growth factors (47-49). Since the exact role of hormones in the development of
prostate cancer remains poorly understood, as well as the mediating role of hormones for
non-hormonal risk factors, this may very well be one of the most promising research topics.
Concluding remarks
From the investigations described in this thesis no strong dietary risk factors for prostate
cancer were identified. Nevertheless, we cannot conclude that diet is not important in
prostate cancer occurrence. Our results do also not support the hypothesis that dietary
factors are more strongly related to nonlatent or advanced prostate tumors than to latent
tumors. Future epidemiological studies on prostate cancer risk factors should preferably
collect exposure data prospectively at different points in time. In addition, to allow for large
variation in exposure variables and a reasonable number of cases for analyses these
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studies should be large-scale. Important research issues are dietary or other environmental
factors as well as potential endogenous risk factors, for which there is still limited evidence.
Furthermore, biological interaction between putative risk factors needs to be considered.
Most certainly, not only epidemiologists but also other disciplines like biochemistry,
pathology, endocrinology, urology, molecular biology and toxicology should participate. A
multidisciplinairy cooperation which makes use of the different skills and perspectives of
researchers from different disciplines will be needed to unravel the multifactonal etiology of
prostate cancer.
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Summary
Although the incidence of prostate cancer is high in Western countries, possible risk factors
for prostate cancer are largely unknown. Environmental factors are thought to be important
in the etiology of prostate cancer, for example because of the large differences in incidence
rates worldwide. A role for environmental factors in the occurrence of prostate cancer is
further supported by the observation that migrants tend to acquire the prostate cancer
pattern of their new home. Prostate cancer is often distinguished in latent and nonlatent
prostate cancer. Latent prostate tumors are usually defined as those tumors that have been
detected incidentally; Nonlatent tumors are detected because of clinical symptoms of
prostate cancer. The observation of similar prevalence of latent prostate cancer across
countries with high and low rates of prostate cancer incidence might also implicate that
environmental factors are important in the occurrence of prostate cancer.
The assocation between several dietary factors but also some nondietary factors and
prostate cancer incidence is described in this thesis. Broadly stated, the hypotheses
underlying these investigations are as follows: 1) environmental factors, specifically dietary
factors, are associated with prostate cancer risk, and 2) these factors are more strongly
related to nonlatent or advanced prostate tumors than to latent tumors.
The analyses regarding associations between dietary factors (vegetables and fruit,
vitamins, animal products, energy, fat and alcohol) and some nondietary factors (family
history of prostate cancer, anthropometry, and socioeconomic status) and the incidence of
prostate cancer (first hypothesis) were carried out within the context of the Netherlands
Cohort Study (NLCS) on diet and cancer. The NLCS is a prospective cohort study, which
started in 1986 with a total of 58,279 men aged 55-69 years. All men completed a self-
administered questionnaire on dietary habits and other risk factors for cancer. For the
analyses presented in this thesis, all incident prostate cancer cases detected during a
follow-up period of 6.3 years (September 1986- December 1992) were included with a total
of 704 cases. To investigate the second hypothesis, analyses were repeated in subgroups
in which prostate tumors were classified on certain characteristics (latent and nonlatent;
well, moderately and poorly differentiated tumors; localized and advanced tumors).
In chapter 1 of this thesis the literature on previous prospective studies on diet and
prostate cancer is reviewed. Overall, this review shows that previous studies only briefly
investigated diet in relation to risk of prostate cancer. The majority of studies had limited
exposure measurements and a limited number of prostate cancer cases. For almost all
investigated dietary exposures, it can be concluded that, thus far, results from previous
studies are inconsistent.
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The results of the analyses from the NLCS regarding different dietary factors and their
association with risk of prostate cancer are described in chapters two to six. Per
investigated dietary factor we investigated whether a higher intake was associated with the
occurrence of prostate cancer. For the following dietary risk factors no association with
prostate cancer risk was observed: intake of total vegetables and fruit (chapter 2); intake of
retinol, vitamins C and E, a-carotene, ß-carotene, lycopene and lutein+zeaxanthin (chapter
3); intake of meat, fish, eggs, calcium and protein (chapter 4); the total energy and fat
intake, and the intake of saturated fat, mono and polyunsaturated fat and different
individual fatty acids (chapter 5); the total alcohol consumption and the intake of alcohol
from beer and liquor such as brandy and whiskey (chapter 6). For increasing intake of leek,
oranges, sweet pepper, and mushrooms (chapter 2); ß-cryptoxanthin (chapter 3); cured
meat and milk and milk products (chapter 4); oleic acid (chapter 5); and alcohol from white
wine and fortified wines (chapter 6) we observed an increased prostate cancer risk. Results
for some other dietary factors indicated that a higher consumption was associated with a
decrease in prostate cancer risk: intake of pulses, kale, raw endive, mandarins and raisins
(chapter 2); intake of supplements containing vitamin A, C, or E (chapter 3); and linolenic
acid intake (chapter 5).
In chapters seven to nine results from the analyses of several nondietary risk factors and
their association with prostate cancer incidence are described. The height of a subject, as
well as the body mass index and the lean body mass were not related to risk of prostate
cancer in the NLCS. These anthropometric measures referred to the age of a subject at
baseline (55-69 years). For a high body mass index at age 20 vs a lower body mass index,
a positive association with later risk of prostate cancer was observed (chapter 7). Our
analyses also showed that having a father or brother(s) with prostate cancer is related to an
increased prostate cancer risk. The association was stronger for affected brothers than for
an affected father. No evidence for an increasing risk with increasing numbers of affected
family members was found (chapter 8). The highest attained level of education and the last
occupation of a subject were used as measures for the socioeconomic status. Occupation
was classified according to occupational sector and required training (EGP score) and
social standing (U&S score). A higher vs a lower education and U&S score were associated
with an increased prostate cancer risk. For the EGP score no associations were found
(chapter 9).
All analyses were repeated in subgroups to investigate whether certain potential risk factors
are differently associated with different subgroups of prostate cancer. Overall, we can
conclude that the investigated factors are not differently associated with latent and
nonlatent prostate tumors, or with well, moderately and poorly differentiated tumors, or with
localized and advanced prostate tumors. The only factors related more strongly to
advanced prostate tumors compared to localized tumors are two nondietary factors, namely
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family history of prostate cancer in the father and/or brothers and socioeconomic status.
In the individual chapters our results are discussed and also compared with results from
other studies on risk factors for prostate cancer. Only the positive association between
family history of prostate cancer and risk of prostate cancer has consistently been reported
from other studies. All other results are inconsistent between the different studies. The
NLCS is one of the few studies that extensively investigated different (dietary) factors in
relation to risk of prostate cancer. Other advantages of the NLCS compared to other
studies are the large number of cases upon which the analyses are based and the
availability of data on several potential risk factors for prostate cancer so that confounding
could be extensively investigated. In addition, our study offered the possibility to separately
investigate subgroups of prostate cancer. Misclassification could have influenced the
results from the NLCS. Misclassification, nevertheless, is expected to be nondifferential
thus leading to an underestimation instead of an overestimation of the strength of
association. Although different risk factors have been evaluated as potential confounding
factors, residual confounding cannot totally be excluded. Finally, some of our results may
have been chance findings.
From the results of the NLCS we cannot conclude that diet or the other investigated
environmental factors are not associated with risk of prostate cancer. Specific factors
involved in prostate cancer etiology, however, cannot yet be specified. The second
hypothesis which stated that environmental factors are more strongly related to nonlatent or
advanced prostate tumors than to latent tumors cannot be supported with data from the
NLCS. Few other studies also investigated this issue, and the results are all inconsistent.
The epilogue of this thesis ends with several suggestions for further research. Future
research on risk factors for prostate cancer is still important and should be aimed at factors
for which there is limited evidence yet. Because the exact role of hormones in the etiology
of prostate cancer is unknown, this issue also deserves attention. To be able to determine
if different factors play a role at different points in time in prostate cancer etiology, exposure
measurements per subject should repeatedly be assessed during life. For example, it
cannot be excluded that certain factors are imporant early in life and not in the recent years
before diagnosis. Biological interaction between different putative risk factors seems
plausible, and this also deserves further investigation. Besides research on risk factors for
prostate cancer, research on the natural history of prostate cancer as well as on biological
mechanisms explaining prostate cancer etiology is needed.

Samenvatting
Hoewel prostaatkanker een hoge incidentie heeft in Westerse landen, is er omtrent
mogelijke oorzaken nog weinig bekend. Van omgevingsfactoren wordt gedacht dat ze
belangrijk zijn in de etiologie van prostaatkanker, ondermeer vanwege de grate
internationale variatie in het voorkomen van prostaatkanker. Ook is het zo dat onder
migranten die verhuizen van een gebied met een läge prostaatkankehncidentie naar een
gebied met een hoge incidentie, een stijging van de incidentie wordt gezien. Bij
prostaatkanker wordt vaak een onderscheid gemaakt tussen latente prostaattumoren, die
gezien nun aard en grootte min of meer per toeval worden ontdekt,en niet-latente vormen
van prostaatkanker waarbij (duidelijke) klinische Symptomen wijzen op het bestaan ervan.
Uit onderzoek blijkt dat het voorkomen van latente tumoren ongeveer gelijk is verdeeld over
de wereld, in tegenstelling tot niet-latente prostaatkanker. Ook dit verschil in voorkomen
van latente en niet-latente prostaatkanker zou er op kunnen wijzen dat omgevingsfactoren
belangrijk zijn bij het ontstaan van prostaatkanker.
In dit proefschrift wordt de relatie beschreven tussen verschillende voedingsfactoren en
een aantal factoren buiten de voeding en de incidentie van prostaatkanker. De algemene
hypotheses die aan het onderzoek ten grondslag liggen zijn de volgende: 1) omgevings-
factoren, met name voedingsfactoren, zijn geassocieerd met het risico op prostaatkanker,
en 2) deze factoren zijn sterker gerelateerd aan niet-latente of meer agressieve vormen
van prostaatkanker dan aan latente tumoren.
De analyses betreffende de associaties tussen voedingsfactoren (inname van groente en
fruit, vitamines, dierlijke produkten, energie, vet, en alcoholconsumptie) en een aantal niet-
voedingsfactoren (voorkomen van prostaatkanker in de familie, antropometrische factoren,
en sociaal economische status) en de incidentie van prostaatkanker (eerste hypothese)
werden uitgevoerd met gegevens van de Nederlandse Cohort Studie (NLCS) naar voeding
en kanker. De NLCS is een prospectief cohortonderzoek, gestart in 1986 onder 58.279
mannen in de leeftijd van 55-69 jaar. Alle personen vulden een uitgebreide schriftelijke
voedingsvragenlijst in en tevens werd informatie over andere mogelijke risicofactoren voor
kanker verzameld. Voor de in dit proefschrift beschreven analyses werd gebruik gemaakt
van een follow-up periode van 6,3 jaar (September 1986 - december 1992). Gedurende
deze periode ontwikkelden 704 mannen prostaatkanker. Om de tweede hypothese te
onderzoeken werden analyses herhaald in subgroepen waarbij de tumoren werden
ingedeeld op bepaalde karakteristieken (latent en niet-latent; goed, matig en siecht
gedifferentieerde tumoren; gelokaliseerde en niet-gelokaliseerde tumoren).
In hoofdstuk 1 van dit proefschrift wordt een literatuuroverzicht gegeven van andere
cohortstudies waarin voeding in relatie tot prostaatkanker werd onderzocht. Hieruit blijkt dat
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de uitgevoerde studies tot nu toe weinig uitgebreid zijn geweest. De meeste studies
hebben een beperkte meting van voedingsfactoren gehanteerd. Verder waren in de
analyses meestal slechts een beperkt aantal mannen met prostaatkanker betrokken. Voor
vrijwel alle onderzochte voedingsfactoren kan worden geconcludeerd dat resultaten uit de
diverse onderzoeken tot dusverre inconsistent zijn.
In de hoofdstukken twee tot en met zes worden de resultaten besproken van de analyses
binnen de NLCS naar de relatie tussen diverse voedingsfactoren en het risico op
prostaatkanker. Voor de verschillende voedingsfactoren werd steeds gekeken of een
toenemend gebruik verband hield met het ontstaan van prostaatkanker. Voor de volgende
voedingsfactoren werd geen duidelijk verband gevonden met het risico op prostaatkanker:
de totale inname van groenten en fruit (hoofdstuk 2); inname van retinol, vitamines C en E,
a-caroteen, ß-caroteen, lycopeen en luteine+zeaxanthine (hoofdstuk 3); consumptie van
vlees, vis, kaas, eieren, calcium en eiwit (hoofdstuk 4); de totale energie- en vetinname, en
de inname van verzadigd vet en enkel- en meervoudig onverzadigd vet en een aantal
individuele vetzuren (hoofdstuk 5); de totale alcoholconsumptie alsmede de inname van
alcohol uit bier en uit sterke drank zoals jenever en whiskey (hoofdstuk 6). Voor bepaalde
voedingsfactoren was er een aanwijzing dat een hogere inname gepaard ging met een
verhoogd risico op prostaatkanker. Dit geldt voor factoren zoals: prei, sinaasappels, paprika
en champignons (hoofdstuk 2); ß-cryptoxanthine (hoofdstuk 3); vleeswaren, melk en
melkprodukten (hoofdstuk 4); oliezuur (hoofdstuk 5); alcohol uit witte wijn en alcohol uit
wijnen zoals port en sherry (hoofdstuk 6). De resultaten voor sommige andere
voedingsfactoren gaven een aanwijzing dat een hogere consumptie ervan mogelijk een
beschermende werking zou hebben op het ontstaan van prostaatkanker: de inname van
peulvruchten, boerenkool, rauwe andijvie, mandarijnen en rozijnen (hoofdstuk 2);
Supplementen met vitamine A, C of E (hoofdstuk 3); de inname van linoleenzuur (hoofdstuk
5).
In de hoofdstukken zeven tot en met negen worden de resultaten beschreven van de
analyses naar een aantal factoren buiten de voeding en hun relatie met het ontstaan van
prostaatkanker. Zowel de lengte van een persoon alsmede de Quetelet Index en de vetvrije
massa bleken in onze Studie niet gerelateerd te zijn aan het risico op prostaatkanker. Het
betraf hier de antropometrische gegevens ten tijde van de beginmeting van de NLCS. Een
hoge ten opzichte van een lagere Quetelet Index van een persoon op 20-jarige leeftijd leek
het risico op prostaatkanker op latere leeftijd te verhogen (hoofdstuk 7). Het voorkomen
van prostaatkanker bij de vader en/of broer(s) van een persoon bleek ook het risico op
prostaatkanker voor die persoon te verhogen. Dit verband was sterker voor het voorkomen
bij broers dan bij de vader. Er kon niet worden aangetoond dat het risico toeneemt bij een
toenemend aantal familieleden met prostaatkanker (hoofdstuk 8). De hoogst behaalde
opleiding en het laatst uitgeoefende beroep van een persoon werden gebruikt als maten
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voor sociaal economische status. Beroep werd ingedeeld naar beroepssector en
benodigde opleiding (EGP-score) en naar aanzien (U&S-score). Een hogere ten opzichte
van een lagere opleiding en U&S-score waren gerelateerd aan een verhoogd
prostaatkankerrisico. Voor de EGP-score werd geen associatie aangetoond (hoofdstuk 9).
Alle analyses werden herhaald in subgroepen om te onderzoeken of bepaalde potentiate
risicofactoren verschillend zijn geassocieerd met verschillende subgroepen van
prostaatkanker. Over het algemeen kan gesteld worden dat de door ons onderzochte
factoren niet verschillend zijn geassocieerd met latente en niet-latente prostaatkanker, of
met goed, matig of siecht gediffentieerde tumoren, of met gelokaliseerde en niet-
gelokaliseerde tumoren. Alleen de gevonden associaties voor het voorkomen van
prostaatkanker in de familie en de sociaal economische status bleken sterker te zijn voor
niet-latente of niet-gelokaliseerde tumoren in vergelijking met de associaties in de subgroep
van latente of gelokaliseerde tumoren.
In de individuele hoofdstukken worden de gevonden resultaten bediscussieerd en tevens
vergeleken met resultaten uit andere onderzoeken naar prostaatkanker. Slechts het
positieve verband tussen het voorkomen van prostaatkanker in de familie en het risico op
prostaatkanker wordt consistent in de literatuur gerapporteerd. Alle andere resultaten zijn
inconsistent tussen de verschillende studies. De NLCS is een van de weinige onderzoeken
waarin uitgebreid verschillende (voedings)factoren in relatie tot prostaatkanker zijn
onderzocht. Andere voordelen van de NLCS ten opzichte van andere studies zijn de grate
aantallen waarop de analyses zijn gebaseerd en de grote beschikbaarheid van gegevens
waardoor ook confounding uitgebreid kon worden onderzocht. Tevens bood de NLCS de
mogelijkheid om subgroepen van prostaatkanker apart te onderzoeken. Misclassificatie zou
de resultaten uit de NLCS kunnen hebben beinvloed. De verwachting is echter dat
eventuele misclassificatie nondifferentieel is waardoor de gevonden resultaten een
onderschatting, maar geen overschatting van het werkelijke verband kunnen geven.
Hoewel verschillende factoren als mogelijke confounder zijn onderzocht, kan residuele
confounding niet worden uitgesloten. Verder is het uiteraard mogelijk dat sommige
bevindingen op basis van toeval zijn ontstaan.
Uit de resultaten van de NLCS kan niet worden geconcludeerd dat voeding of enkele
andere onderzochte omgevingsfactoren niet met het risico op prostaatkanker zijn
geassocieerd. Specifieke (voedings)factoren kunnen echter nog niet worden aangeduid,
daarvoor is eerst verder onderzoek noodzakelijk. De tweede hypothese die stelde dat
omgevingsfactoren sterker aan niet-latente of agressievere vormen van prostaatkanker zijn
geassocieerd, kon met de resultaten uit de NLCS niet worden bevestigd. Slechts in enkele
andere onderzoeken werden ook subgroepen apart bestudeerd, en de resultaten waren
wederom inconsistent.
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De epiloog van dit proefschrift wordt afgesloten met een aantal suggesties voor verder
onderzoek naar mogelijke oorzaken van prostaatkanker. Toekomstig onderzoek blijft
relevant en zou zieh moeten richten op factoren waarover nog weinig bekend is. Ook de rol
van hormonen in het ontstaan van prostaatkanker verdient aandacht. Om te kunnen
bepalen op welk moment in de tijd bepaalde factoren een rol kunnen spelen zouden
meerdere expositiemetingen per persoon moeten worden uitgevoerd over längere
tijdsperioden. Het is immers niet uit te sluiten dat bepaalde factoren al vroeg in het leven
van belang zijn, en niet in de recente jaren voordat de diagnose wordt gesteld. Een
biologische interactie tussen potentiele risicofactoren lijkt plausibel en hiervoor is ook nader
onderzoek nodig. Behalve onderzoek naar risicofactoren is ook onderzoek nodig naar de
natuurlijke ontwikkeling van prostaatkanker, alsmede naar de biologische mechanismen die
de etiologie van prostaatkanker kunnen verklaren.
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